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Abstract 
 
Leveraging Native Mass Spectrometry and 193 nm Ultraviolet 
Photodissociation as Structural Biology Tools 
 
Megan Rachel Mehaffey, Ph.D. 
The University of Texas at Austin, 2020 
 
Supervisor:  Jennifer S. Brodbelt 
 
Structural biology studies aimed at the elucidation of protein-dependent disease 
mechanisms have traditionally relied on high-resolution techniques, including X-ray 
crystallography, nuclear magnetic resonance, and cryogenic electron microscopy. While 
such methodologies remain standard for gaining information on the core structure of 
proteins, specific drawbacks including time or large sample quantities associated with these 
approaches have spawned the development of other pipelines. Mass spectrometry (MS) is 
one such tool that has gained traction as a rapid and sensitive low-resolution structural 
biology technique. Routinely protein complexes of interest are reacted in solution with 
covalent chemical probes to preserve structural information prior to enzymatic digestion 
and mass spectrometric read-out. However, with the advent of native MS, protein 
complexes can now be efficiently transferred intact into the gas phase using high ionic 
strength solutions while retaining structures reminiscent of their solution conformations, 
and directly interrogated using MS/MS methods. Ultraviolet photodissociation (UVPD) is 
one such ion activation method that has been extensively developed to break apart protein 
complexes in a manner that allows conclusions about structure to be drawn based on the 
 viii 
fragmentation behavior. The work presented here leverages native mass spectrometry in 
conjunction with 193 nm UVPD to probe a variety of biologically important protein-ligand 
and protein-protein complexes. 
The utility in a native UVPD-MS approach for structural examination of protein-
ligand complexes is demonstrated through characterization of conformational changes 
associated with the catalytic cycle of a phosphotransferase enzyme as well as elucidation 
of structural changes resulting from mutation or inhibition of an enzyme responsible for 
conferring antibiotic resistance to bacteria. An oncogenic protein and several clinical 
variants bound to a downstream effector protein provides an example of the capabilities of 
native MS and UVPD to characterize the structure of a protein-protein complex. Native 
UVPD-MS is also used for epitope mapping of the main antigenic determinant of the 
influenza virus. Aimed at improving analysis of larger complexes, multistage native 
UVPD-MS is developed to probe the structure of a protein implicated in chemotherapeutic 
resistance in glioblastoma tumors. Lastly, uniting on-line capillary electrophoresis (CE) 
with multistage native UVPD-MS offers a high-throughput workflow for structural 
characterization of ribosomal protein complexes. 
 ix 
Table of Contents 
Chapter 1: Introduction ........................................................................................................1 
1.1 Motivation and Scope of Research .......................................................................1 
1.2 Mass Spectrometry as a Structural Biology Tool .................................................2 
1.2.1 Covalent Labeling ..................................................................................3 
1.2.2 Native MS ..............................................................................................6 
1.2.3 Ion Mobility-MS ..................................................................................10 
1.3 Tandem Mass Spectrometry of Intact Protein Complexes .................................12 
1.3.1 Polypeptide Fragmentation Nomenclature ..........................................12 
1.3.2 Collisional Dissociation .......................................................................14 
1.3.3 Electron-based Dissociation ................................................................16 
1.3.4 Surface-Induced Dissociation ..............................................................18 
1.3.5 Ultraviolet Photodissociation ...............................................................18 
1.4 High-Throughput Analysis of Native Protein Complexes ..................................21 
1.4.1 On-line Separation Methods Compatible with Native MS ..................22 
1.4.2 Multistage MS/MS Approach ..............................................................24 
1.5 Overview of Chapters .........................................................................................26 
1.6 References ...........................................................................................................29 
Chapter 2: Experimental Methods .....................................................................................40 
2.1 Overview .............................................................................................................40 
2.2 Mass Spectrometry .............................................................................................40 
2.2.1 Native Electrospray Ionization ............................................................40 
2.2.2 Mass Analyzers ....................................................................................42 
 x 
2.3 Ion Activation .....................................................................................................45 
2.3.1 In-Source Trapping ..............................................................................45 
2.3.2 Higher-energy Collisional Dissociation...............................................46 
2.3.3 Ultraviolet Photodissociation ...............................................................46 
2.4 On-line Separation Methods ...............................................................................47 
2.4.1 Size-Exclusion Chromatography .........................................................47 
2.4.2 Capillary Zone Electrophoresis ...........................................................48 
2.5 Data Analysis ......................................................................................................49 
2.5.1 ProSight Lite and ProSight Native.......................................................49 
2.5.2 Identifying Holo Fragment Ions ..........................................................50 
2.5.3 UV-POSIT ...........................................................................................51 
2.5.4 Statistical Analysis ...............................................................................52 
2.6 References ...........................................................................................................52 
Chapter 3: Tracking the Catalytic Cycle of Adenylate Kinase by Ultraviolet 
Photodissociation Mass Spectrometry .........................................................................54 
3.1 Overview .............................................................................................................54 
3.2 Introduction .........................................................................................................55 
3.3 Experimental .......................................................................................................58 
3.3.1 Materials and Reagents ........................................................................58 
3.3.2 Mass Spectrometry ..............................................................................59 
3.3.3 Data Analysis .......................................................................................59 
3.4 Results and Discussion .......................................................................................67 
3.4.1 Native MS and UVPD of AK-Ligand Complexes...............................67 
 xi 
3.4.2 Mapping UVPD Holo Fragment Ions to Examine Ligand Binding 
Sites .........................................................................................................72 
3.4.3 Conformational Changes throughout the Catalytic Cycle ...................77 
3.4.4 Examining the Impact of the Mg2+ Cofactor .......................................84 
3.4.5 Tracking Conserved Residue R138 during the Catalytic Cycle ..........87 
3.5 Conclusion ..........................................................................................................88 
3.6 References ...........................................................................................................90 
Chapter 4: Elusive Structural Changes of New Delhi Metallo-β-Lactamase Revealed 
by Ultraviolet Photodissociation Mass Spectrometry ..................................................95 
4.1 Overview .............................................................................................................95 
4.2 Introduction .........................................................................................................96 
4.3 Experimental .....................................................................................................100 
4.3.1 Sample Preparation ............................................................................100 
4.3.2 Mass Spectrometry ............................................................................102 
4.3.3 Data Analysis .....................................................................................102 
4.4 Results and Discussion .....................................................................................106 
4.4.1 Inhibitor Selection..............................................................................106 
4.4.2 UVPD-MS to Localize a Lysine-Selective Covalent Inhibitor of 
NDM-1 ..................................................................................................108 
4.4.3 Tracking Closure of an Active Site Loop over a Lysine-Modifying 
Covalent NDM-1 Inhibitor ...................................................................115 
4.4.4 Detecting Displacement of Zn2 by a Cysteine-Modifying Covalent 
NDM-1 Inhibitor ...................................................................................122 
4.4.5 Examining Structural Changes in NDM Clinical Variants 
Associated with Zn(II) Binding Residues .............................................131 
4.5 Conclusion ........................................................................................................140 
 xii 
4.6 References .........................................................................................................143 
Chapter 5: Investigation of GTP-Dependent Dimerization of G12X K-Ras Variants 
Using Ultraviolet Photodissociation Mass Spectrometry ..........................................148 
5.1 Overview ...........................................................................................................148 
5.2 Introduction .......................................................................................................149 
5.3 Experimental .....................................................................................................153 
5.3.1 Sample Preparation ............................................................................153 
5.3.2 Mass Spectrometry ............................................................................156 
5.3.3 Data Analysis .....................................................................................157 
5.4 Results and Discussion .....................................................................................161 
5.4.1 Native MS to Detect GTP-Dependent Formation of K-Ras 
Homodimers..........................................................................................161 
5.4.2 Impact of G12X Mutations on K-Ras:Raf Heterodimer Formation ..168 
5.4.3 Analysis of UVPD Holo Fragment Ions to Examine K-Ras:Raf 
Heterodimer Interface ...........................................................................172 
5.4.4 Variations in UVPD Cleavage Efficiency for G12X K-Ras:Raf 
Heterodimers .........................................................................................181 
5.5 Conclusion ........................................................................................................188 
5.6 References .........................................................................................................189 
Chapter 6: Mapping a Conformational Epitope of Hemagglutinin A Using Native MS 
and Ultraviolet Photodissociation ..............................................................................195 
6.1 Overview ...........................................................................................................195 
6.2 Introduction .......................................................................................................196 
6.3 Experimental .....................................................................................................200 
6.3.1 Sample Preparation ............................................................................200 
6.3.2 Mass Spectrometry & Data Analysis .................................................202 
 xiii 
6.4 Results and Discussion .....................................................................................205 
6.4.1 Deglycosylation of HA1 Antigen for Improved MS Analysis ..........205 
6.4.2 Formation and MS Characterization of the Antibody-Antigen 
Complex ................................................................................................212 
6.4.3 UVPD-MS for Epitope Mapping .......................................................219 
6.4.4 Approach for Elucidation of an Unknown Epitope using UVPD-
MS .........................................................................................................225 
6.5 Conclusion ........................................................................................................232 
6.6 References .........................................................................................................233 
Chapter 7: Multistage Ultraviolet Photodissociation Mass Spectrometry to 
Characterize Single Amino Acid Variants of Human Mitochondrial BCAT2 ..........240 
7.1 Overview ...........................................................................................................240 
7.2 Introduction .......................................................................................................241 
7.3 Experimental .....................................................................................................244 
7.3.1 Sample Preparation ............................................................................244 
7.3.2 Mass Spectrometry ............................................................................245 
7.3.3 Data Analysis .....................................................................................250 
7.4 Results and Discussion .....................................................................................251 
7.4.1 Multistage Native UVPD-MS for Complete Protein Complex 
Characterization ....................................................................................251 
7.4.2 Native MS1 and Size-Exclusion Chromatography of BCAT2 ..........256 
7.4.3 In-Source Trapping and UVPD for Improved Localization of 
T186R Mutation in BCAT2 ..................................................................259 
7.4.4 Mapping UVPD Holo Fragment Ions to Examine the Cofactor 
Binding Site along BCAT2 ...................................................................266 
7.5 Conclusion ........................................................................................................269 
 xiv 
7.6 References .........................................................................................................270 
Chapter 8: Uniting Native Capillary Electrophoresis and Multistage Ultraviolet 
Photodissociation Mass Spectrometry for On-line Separation and Characterization 
of E. Coli Ribosomal Proteins and Protein Complexes .............................................275 
8.1 Overview ...........................................................................................................275 
8.2 Introduction .......................................................................................................276 
8.3 Experimental .....................................................................................................281 
8.3.1 Ribosomal Sample Preparation ..........................................................281 
8.3.2 Native Capillary Electrophoresis .......................................................281 
8.3.3 Mass Spectrometry ............................................................................282 
8.3.4 Data Analysis .....................................................................................283 
8.4 Results and Discussion .....................................................................................286 
8.4.1 Separation of Ribosomal Proteins by Native CE using Various 
Mg2+ Concentrations .............................................................................286 
8.4.2 MS/MS Methods for the Analysis of Ribosomal Proteins ................289 
8.4.3 Multistage MS/MS Approach for the Improved Characterization of 
Ribosomal Protein Complexes..............................................................297 
8.4.4 Mapping UVPD Holo Fragment Ions to Examine Metal Cofactor 
Binding to Ribosomal Proteins .............................................................303 
8.5 Conclusion ........................................................................................................307 
8.6 References .........................................................................................................308 
Chapter 9: Conclusions ....................................................................................................314 
9.1 Summary of Chapters .......................................................................................314 
9.2 Future Directions ..............................................................................................317 
References ........................................................................................................................320 
Vita ...................................................................................................................................363 
 1 
Chapter 1: Introduction 
1.1 MOTIVATION AND SCOPE OF RESEARCH 
Structural biology, or the study of the molecular structures of proteins and nucleic 
acids, relies on the key principle that structure determines function. As such, studies are 
aimed at mapping the dynamic movements and noncovalent interactions of such biological 
macromolecules to gain insight into their complex interplay that sustains life.1 Arguably 
even more important is understanding the mechanisms by which these processes go awry, 
leading to dysfunction or disease. Although molecular modelling is useful for refining and 
visualizing certain aspects of biomolecular assemblies,2 the foundation of the structural 
biology toolbox used to probe macromolecular structures is comprised of high-resolution 
experimental methods including X-ray crystallography (XRC),3,4 nuclear magnetic 
resonance (NMR),5,6 and more recently, cryogenic electron microscopy (cryo-EM).7 These 
“gold standard” techniques provide information on the structures of macromolecules with 
single amino acid residue resolution that translate directly into three-dimensional 
representations of side chain positions from which specific function can be inferred. 
However, each of these approaches is not without specific drawbacks. XRC and NMR both 
require relatively large sample quantities (up to milligram amounts or millimolar 
concentrations) that are often not representative of biologically relevant concentrations. 
This can result in packing artifacts of important loops during crystallization or protein 
precipitation during NMR analysis.8–10 Additionally, both of these methods require 
complex and time-consuming data interpretation approaches, hampering them from being 
amenable to high-throughput screening of small molecule drugs or interacting partners. 
Although cryo-EM addresses these issues while still delivering high-resolution data, low 
signal-to-noise ratios can complicate data acquisition.11 These specific shortcomings have 
 2 
spawned the development of alternative structural biology tools more fitting for certain 
tasks.  
Mass spectrometry (MS) is one such method that has solidified a spot in the 
structural biology toolbox with its unparalleled sensitivity and speed making it an attractive 
option for analyzing protein architectures.12–14 Typically, sub-microgram quantities of 
proteins are enough for structural characterization by MS. Additionally, in conjunction 
with on-line sample introduction or separation methods, many combinations of protein 
sequences and ligands can be quickly screened with the resulting data comparatively easy 
to interpret. Although the structural information gained by MS is typically low-resolution, 
these attributes often counterbalance the lack of position information on the single amino 
acid level. The work presented in this dissertation focuses on the application of native MS 
in conjunction with ultraviolet photodissociation (UVPD) to characterize the structure of 
increasingly large proteins and complex biological samples. However, a brief review of the 
advent and development of MS for structural biology applications is first necessary to 
appreciate recent advancements.  
1.2 MASS SPECTROMETRY AS A STRUCTURAL BIOLOGY TOOL 
Over the past two decades, MS has come of age as a structural biology method 
capable of informing on all levels of protein organization and tracking dynamic 
interactions.12,15,16 The first applications of MS to probe macromolecular structures 
involved the attachment of covalent modifications or chemical probes to preserve structural 
information during proteolytic digestion and MS detection.17 A shift to transferring intact 
protein assemblies into the gas phase for direct analysis was enabled with the arrival of 
native MS.18,19 Coupling ion-mobility spectrometry (IMS) with native MS (termed IM-
MS) can provide further information on the topology of protein complexes.20 
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1.2.1 Covalent Labeling 
Building on classical MS-based proteomics approaches utilizing proteolytic 
digestion and on-line liquid chromatography with tandem MS (LC-MS/MS) to identify and 
quantify proteins and their interaction partners, the introduction of covalent labeling to the 
general workflow added “structural biology tool” to the MS resume. Specifically, covalent 
labeling refers to the covalent addition of chemical probes to reactive and accessible amino 
acids on the surfaces of proteins.17 The position of attachment of such tags can be localized 
by tracking the resulting mass shift after subsequent proteolytic digestion of the protein 
and LC-MS/MS analysis of resulting peptides. Low-resolution structural information is 
then inferred from a map of the modified residues. Although MS involves detection of 
analytes in the gas phase, the modification reactions typically occur in buffered solutions, 
as such the native solution behavior is probed.17 Commonly used covalent labeling 
techniques fall into three main categories that are each described below: solvent 
accessibility, hydrogen/deuterium exchange (HDX), and chemical cross-linking. 
Taking advantage of a variety of specific side chain chemistries, solvent 
accessibility labeling refers to the decoration exclusively of exposed amino acid side chains 
along the protein surface by small, reactive molecules.21 The extent to which each amino 
acid is labelled can be determined from the number of unmodified and modified sites along 
constituent peptides resulting from digestion and LC-MS/MS analysis. By far the most 
common target for solvent accessibility studies are primary amines, present on side chain 
lysine residues and the N-terminus of the protein.21 Typically found on the outer surfaces 
of folded proteins and acting as strong nucleophiles, solvent accessible free amines are 
easily targeted by N-hydroxysuccinimidyl (NHS) leaving group chemistries.22 Other side 
chain groups that have been successfully targeted include arginine, cysteine, histidine, 
tyrosine, tryptophan, aspartic acid, and glutamic acid.21 Additionally, less specific labels 
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have been developed (i.e. ones that target multiple side chain groups at once) to increase 
the number of sites probed per experiment but this results in more complex samples and 
data analysis.23 Emerging covalent labeling approaches typically rely on laser activation to 
attach photoreactive groups with minimal side chain identity bias of solvent accessible 
residues. One such method, termed fast photochemical oxidation for proteins (FPOP) 
involves addition of millimolar concentrations of peroxide and exposure to laser irradiation 
(250 nm – 270 nm) resulting in the creation of radical OH species that can oxidize most 
amino acid side chain moieties (excluding alanine, asparagine, aspartic acid, glycine, 
glutamine, and glutamic acid).24 Similarly, carbene footprinting utilizes a sterically 
strained, UV photoreactive diazirine ring. Exposure to 355 nm laser light activates the 
reagent to covalently attach at any surface accessible amino acids and even the protein 
backbone itself.25 Not only do these solvent accessibility approaches maximize the 
information gained on exposed sites, the reactions occur on rapid timescales, preventing 
any structural disruption to the protein that can result from slower labeling techniques.26 
While solvent accessibility approaches offer insight into the surface exposure of 
individual side chain residues, hydrogen/deuterium exchange (HDX) instead monitors 
protein structure by probing the dynamic reactivity of amide sites along the protein 
backbone.17 Exposure of proteins to deuterium oxide-containing solvents induces the 
replacement of backbone hydrogen with deuterium. Exchange events can then be tracked 
using the multiple resulting ~1 Da mass shifts in resulting peptides by LC-MS/MS.27 
Typically deuterium uptake per residue is compared for different HDX reaction times or 
across different solution conditions to track dynamic movements of the protein backbone. 
Although HDX-MS offers the highest resolution of any covalent labeling MS technique, 
the main challenge with this type of experiment is preventing back exchange during 
proteolysis and MS analysis.27 Owing to the reversibility of the HDX process, returning 
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the protein to a non-deuterated solvent causes the loss of some structural information as 
hydrogen exchanges back into the backbone. Back-exchange of side chain heteroatoms (O-
H, N-H, S-H) is so rapid that HDX events at these sites are not measured.17 Nevertheless, 
several precautions can be taken to mitigate this process along the backbone including acid 
quenching and freezing after D2O exposure, digestion with pepsin, a rapid and non-specific 
protease that cleaves under conditions ideal for preventing back-exchange (0 °C, pH 2), 
and shortened reversed-phase LC gradients, often using cryogenically-cooled systems.27 
Despite these challenges, HDX-MS has been fully developed and even commercialized as 
a robust method28 routinely used in academia and industry alike to characterize protein 
structures such as studying conformational changes in amyloid beta peptides during 
aggregation29 and mapping epitopes of antibody-antigen complexes.30  
As opposed to probing the surface accessibility of side chains or the backbone, 
chemical cross-linkers instead act as molecular rulers that covalently attach residues within 
a specified distance constraint of each other in space.31 Such information aids in structural 
modeling of complexes32 as well as in identifying interaction networks of individual 
proteins.33 Similar to solvent accessibility probes, the reactivity of cross-linking reagents 
can be tuned to target specific side chain moieties.31 Primary amines are again the most 
attractive target for cross-linking reagents containing NHS leaving groups at each end with 
a carbon chain in between to set the distance constrain of the linker (typically in the range 
of 10 – 30 Å). Such reagents with identical reactive groups on each side are referred to as 
homobifunctional. However, heterobifunctional cross-linkers have also been developed for 
applications in which targeting two different side chain groups is desirable.31 Photoreactive 
cross-linkers containing diazirine or benzophenone groups represent a specific class of 
heterobifunctional reagents that allow for promiscuity in the residues targeted by one side 
of the linker.34 Aimed at identifying residues that are spatially close or directly interacting, 
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zero-length cross-linkers utilize 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
coupling reactions to form a new peptide bond between acidic and basic side chains.35 
Other classes of chemical cross-linking reagents continue to be developed to address the 
two main challenges with this approach: low reaction yields and complex fragmentation 
patterns resulting from MS/MS of cross-linked peptides.31 Including groups along the 
cross-linker structure susceptible to enrichment procedures after the reaction can improve 
the signal of desired cross-link products orders of magnitude during LC-MS/MS analysis.36 
Similarly, using cross-linking reagents whose structure has been modified to dissociate in 
a more predictable, simplified manner during MS/MS streamlines data analysis.37 Other 
recent advancements have centered on skipping the digestion step and directly probing 
intact cross-linked protein complexes by MS/MS, referred to as top-down cross-linking 
MS,38,39 but this approach has numerous other technical hurdles which has limited 
widespread adoption. 
1.2.2 Native MS 
A significant shift in the paradigm of MS for structural biology analysis occurred 
with the introduction of native MS.14,18,19 This approach negates the need for protein 
labeling and subsequent digestion through the use of high ionic strength solution (i.e. 
“salty” solutions) during the electrospray ionization (ESI) process to gently transfer intact 
protein complexes into the gas phase while maintaining noncovalent interactions with 
metal cofactors, ligands, or other proteins.19,40 Thus, protein architectures can now be 
directly probed within the mass spectrometer instead of relying on the preservation of 
structural information through covalent tags. In addition to conserving noncovalent 
interactions into the gas phase, native MS solution conditions also alter the ESI charging 
process.41 In contrast to denaturing MS conditions (typically defined as > 50% organic 
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solvent and up to 2% acid) which yield a wide range of high charge states, native MS 
solutions lead to a narrow range of low charge states as proteins are ionized from nearly 
100% aqueous solvents with high concentrations (5 mM up to 2 M) of volatile salts, most 
commonly ammonium acetate but ammonium formate and ammonium bicarbonate are also 
options.41,42 Figure 1.1 demonstrates this observed principle for two standard protein 
complexes: myoglobin and concanavalin A. Native MS conditions allow the retention of a 
noncovalent heme ligand for myoglobin (Figure 1.1A) and preserves the preferred 
homotetrameric oligomeric state of concanavalin A (Figure 1.1B). Conversely, denaturing 
MS conditions cause ejection of the ligand (evident in Figure 1.1A as a separate peak at 
m/z 616) and monomerization of concanavalin A as well as the observation a wider 
distribution of higher charge states (relative to the mass of the species) for both proteins.  
The observed differences in resulting charge states for denaturing and native MS 
are thought to the be result of divergent ionization mechanisms termed the chain ejection 
model (CEM) and charge residue model (CRM).41 The former describes the ionization of 
proteins under denaturing conditions while the latter details the proposed mechanism of 
gas phase transfer for native MS conditions. Following the CEM, unfolding protein 
structures reveals hydrophobic side chains typically buried deep in the folded structure that 
cause the proteins to arrange around the outer edge of a charged, hydrophilic ESI droplet. 
As coulombic explosions and solvent evaporation lead the droplet to shrink, the 
hydrophobic groups further drive the protein to extrude from the outer barrier of the droplet 
and pick up many of the charges that reside along the outer surface of the relatively large 
ESI droplet as it exits.41 Alternatively, the CRM proposes for native MS conditions that 
owing to the conservation of a folded protein structure, the hydrophobic effect no longer 
pushes the protein to the outskirts of the droplet and instead it remains near the center for 
the duration of ionization. Continuous evaporation of the droplet leads to the deposition of 
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what little charge remains on the surface of the evaporated droplet along the outside of the 
folded protein.41  
 
 
Figure 1.1: ESI-MS of (A) myoglobin and (B) concanavalin A each sprayed under 
denaturing (50:50 acetonitrile:water) and native (20 mM ammonium acetate, 
pH 6.8) MS conditions. The heme ligand in myoglobin is represented as a 
black pentagon. Select charge states are labelled. 
The preservation of noncovalent interactions and production of lower charge states 
observed with native MS initially presented limitations in instrumentation that prohibited 
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widespread adoption of this technique. Not only are the analytes typically larger, the ESI 
process imparts less charge meaning even small proteins and protein-ligand complexes 
show up above the normal scan range maximum of m/z 2000. Until recent years, a limited 
number of mass spectrometers were capable of guiding such large ions through the 
instrument optics and scanning up to the higher m/z regions in which native protein 
complexes are observed (typically 2500 – 8000 m/z).43 Mass spectrometers utilizing time-
of-flight (TOF) mass analyzers were among the first used for native MS studies owing to 
their mid-range resolving powers and high m/z scan ranges.43,44 Fourier-transform ion 
cyclotron resonance (FT-ICR) instruments afford the highest resolutions for native MS 
experiments, but prohibitively expensive maintenance continues to make them the least 
commonly used.43,45,46 Instead, Orbitrap mass analyzers introduced in the early 2000’s offer 
relatively high resolving powers and the ability to scan high m/z regions, making them the 
top choice for native mass spectrometrists.43,47,48 Recently a commercial Orbitrap 
instrument was developed aimed specifically at extending the scannable mass range for 
improving native MS capabilities.48 
The application of native MS to elucidate subunit stoichiometry and connectivity 
has become increasingly routine for ever larger protein complexes.49 Ranging in size from 
kDa protein oligomers such as ATP-synthase,50 to MDa assemblies including intact 
ribosomal particles51 and virus capsids,52,53 the speed and sensitivity of native MS make it 
an attractive technique for such analysis. Additionally, native MS has demonstrated utility 
in monitoring a wide range of protein-ligand interactions54 including screening small 
molecule drug candidates,55 determining optimal lipid compositions for membrane protein 
analysis,56,57 measuring dissociation constants,58 and defining kinetic and thermodynamic 
binding parameters.59,60 Although native MS itself can provide some structural 
information, it is far more powerful for gaining detailed structural biology insight when 
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used in conjunction with other gas phase techniques, particularly ion mobility spectrometry 
(IMS) or tandem MS (MS/MS) methods. 
1.2.3 Ion Mobility-MS 
In short, ion mobility spectrometry (IMS) involves the separation of gas-phase ions 
by size and shape based on their differential mobility through a buffer gas.61 For proteins 
this drift time is represented as a rotationally averaged cross-sectional area, referred to as 
a collision cross section (CCS) value, that can be used to correlate structures and 
conformations.20,62–64 Depending on the desired resolution or information, in practice three 
primary IM-MS techniques are used: drift-time (DT) IMS, travelling-wave ion mobility 
spectrometry (TWIMS), and field-asymmetric ion mobility spectrometry (FAIMS).61 DT-
IMS represents the oldest and conceptually simple version of IMS utilizing a uniform static 
electric field across drift tube filled with a buffer gas.61 Owing to the higher number of 
interactions with the drift gas, elongated structures travel the length of the tube slower than 
more compact ions. TWIMS removes the need for a high drift voltage across the entire 
tube by instead successively applying a direct current (DC) voltage to a series of stacked 
rings that outline the drift region to propel the ions axially and create a “travelling wave”. 
Opposite phase radio-frequency (RF) potentials applied to adjacent electrodes confine the 
ions radially.61 This method has been commercialized in the popular Waters Synapt Q-TOF 
platform. FAIMS devices utilize two electrodes with a voltage across them that deflects 
ions introduced perpendicular towards the walls. A second voltage is manipulated to 
selectively permit ions of interest to pass through the electrodes while removing ions of 
differing mobility. While FAIMS does not measure CCS values, it can filter out unwanted 
species and improve the signal of desired species up to several orders of magnitude.61 As 
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such, FAIMS devices are typically integrated to the front end of a mass spectrometer, prior 
to mass analysis. 
Coupling IMS with native MS (referred to as native IM-MS) provides an avenue 
for more detailed structural analysis of large or heterogenous protein assemblies by 
providing a type of shape/size-based sieving. Measurement of the CCS values of the 
individual m/z values related to these complexes and their composite subunits offers a new 
dimension of information on the flexibility and conformational dynamics of a system, in 
addition to the stoichiometry and topology.20,61,62,65 Such characteristics make IMS a 
complementary tool to native MS in the context of structural biology.66 One particular area 
in which native IM-MS has provided critical insight is defining protein folding/unfolding, 
in which changes in ion mobility as a function of gentle collisional activation or partial 
solvent denaturation serve as an indicator of conformational disruption.61,62 In fact, IM-MS 
experiments offer the most compelling evidence that proteins ionized by native MS do 
retain architectures in the gas phase reminiscent of their solution phase structures, a topic 
still hotly debated.67–69 Additionally, native IM-MS has been applied to study a wide 
variety of biologically important topics including the structural impact of single point 
mutants of human hemoglobin,70 disorders related to glycosylation state that alter protein 
conformation,71 and diseases caused by protein conformers or aggregates.72,73 Databases of 
CCS values help to calibrate drift time measurements and maintain uniformity across IM-
MS platforms, especially following the commercialization of TWIMS and subsequent 
increase in widespread application to studying structural biology questions.74 Also 
common is the use of native IM-MS in conjunction with tandem MS (MS/MS) approaches 
to further probe secondary and tertiary structures of single protein subunits within 
complexes.75,76  
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1.3 TANDEM MASS SPECTROMETRY OF INTACT PROTEIN COMPLEXES 
Tandem MS (MS/MS) in basic terms refers to the addition of energy to gas phase 
ions of interest to cause dissociation into smaller fragment ions. Activation of intact 
proteins or protein complexes is referred to as top-down MS in contrast to the bottom-up 
MS approach which must include a proteolytic step yielding peptides for MS/MS 
analysis.77 Upon ion activation of a protein-ligand or protein-protein complex several 
dissociation pathways are possible, the most common of which include ejection or 
unfolding of the ligand/single subunits, disassembly of the oligomeric assembly into 
smaller sub-complexes, or cleavage of the covalent bonds comprising the protein 
backbone.78,79 The amount of energy and timescale of deposition both impact which of 
these outcomes are favored.78,79 As such, traditional collisional activation typically falls 
short in producing fragment ions that provide structural information so several alternative 
MS/MS approaches have been tested. Following is a brief review of the merits and specific 
applications of common MS/MS activation methods (collisional dissociation, electron-
based dissociation, surface-induced dissociation, and ultraviolet photodissociation) with 
regards to dissociating the intact protein-ligand and protein-protein complexes resulting 
from native MS. 
1.3.1 Polypeptide Fragmentation Nomenclature 
Disassembly of the noncovalent bonds within a protein complex after ion activation 
yields intact protein subunits or ligands whose m/z values are easily labelled as such in the 
resulting MS/MS spectra.78 Conversely, cleavage of the covalent bonds along the 
polypeptide backbone within a single subunit, herein referred to as sequence ions, requires 
its own systematic nomenclature to categorize the resulting fragments.80 Together the 
location of the bond cleavage within the repeating unit of the protein backbone and the 
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terminus which is retained (N- or C-) define the type of sequence ion, while the number 
denotes the position in the overall sequence. Sequence ions containing the N-terminus are 
classified as a-, b-, or c-type ions depending on whether the cleavage occurs across the Cα-
C bond, C-N amide bond, or N-Cα bond, respectively. The corresponding ion types 
containing instead the C-terminal end of the protein are x-, y-, and z-type ions.81 As such, 
a/x, b/y, and c/z ions make complementary pairs resulting from cleavage of the same bond 
along the backbone (although both partners in the pairs are not necessarily detected). A 
graphical illustration representing this sequence ion nomenclature is shown in Figure 1.2. 
Owing to the differences in energy and timescale of depositions, each ion activation 
method favors the production of certain ion types.78,79 Briefly, threshold-based methods, 
including collisional dissociation and infrared wavelength photodissociation, result in 
predominantly b- and y-type ions following cleavage of the lowest energy peptide bond. 
Electron-based dissociation methods that rely on radical-directed mechanisms typically 
yield c- and z-type ions. Ultraviolet photodissociation (UVPD), a higher energy activation 
method, produces all six ion types with a slight preference for a/x-type ions for intact 
proteins or b/y-type ions for peptides.78,79 
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Figure 1.2: Representation of the nomenclature proposed by Roepstorff et al. to classify 
sequence ions resulting from fragmentation of the polypeptide backbone of 
a protein subunit, illustrated for a peptide containing four amino acids. 
1.3.2 Collisional Dissociation 
Collisional dissociation refers to low-energy collision-induced dissociation (CID) 
or collisionally activated dissociation (CAD) involving the acceleration of ions to low 
kinetic energies (< 1 keV) causing inelastic collisions with an inert gas, typically helium 
or nitrogen, and converting kinetic energy into internal vibrational energy. Owing to the 
low energy deposition of this process, multiple collisions are typically required to reach 
the dissociation threshold of the precursor ion and cause fragmentation (i.e. referred to as 
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slow heating), resulting in preferential cleavage of only the most labile bonds.82 On modern 
mass spectrometers, collisional dissociation is implemented either within an ion trap 
through resonant excitation using a supplemental RF waveform at the secular frequency of 
the precursor ion, or by acceleration of precursor ions through a higher-pressure collision 
cell, referred to as beam-type activation.82 The latter is termed higher-energy collisional 
dissociation (HCD) on Thermo Scientific commercial MS platforms, not be confused with 
true high-energy collisional dissociation (> 1 keV collision energies on TOF or sector 
instruments). Collisional dissociation remains the most established and widely utilized ion 
activation method due to its robust performance and implementation on virtually all 
commercially available mass spectrometers. 
 In regards to collisional activation of protein-ligand or protein-protein complexes 
introduced by native MS, it predominantly results in disruption of labile noncovalent 
interactions.78,79,83 For protein-ligand complexes, this corresponds to ejection of the ligand 
as the protein unfolds during the inelastic collisions before reaching the threshold of 
backbone fragmentation and producing sequence ions.78,79 As such, information on the 
binding site is not reflected in observed fragment ions. Although there have been a limited 
number of studies in which collisional dissociation was used to determine binding sites of 
adenosine phosphate ligands through the retention of one or two phosphate groups 
noncovalently bound to the protein during dissociation (i.e. likely due to the enhanced 
strength of electrostatic interactions in the gas phase) or the entire ligand when 
supercharging reagents were added.84,85 Similarly, collisional activation of protein-protein 
complexes primarily results in unfolding of a single subunit that sequesters a 
disproportionately high amount of the charge as it is ejected.78,79 A typical MS/MS 
spectrum then contains, in addition to a limited number of sequence ions, a highly charged 
monomer in the lower m/z region and the remaining low charge (n-1)-mer in the higher m/z 
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region. To gain structural information from this type of favored dissociation pathway, 
typically MS/MS spectra are collected over a range of collision energies. Briefly, collision 
energy refers to the amount of kinetic energy added to the precursor during collisional 
activation. Tracking the production of subunits and eventually sequence ions across 
activation energies allows relative gas-phase stabilities to be established and offers some 
insights on protein structure with regards to salt bridges, charge density, or subunit 
flexibility.83 This approach is even more powerful when combined with IMS measurement, 
termed collision-induced unfolding (CIU) footprinting. Measuring the CCS value of a 
protein or protein complex as a function of collision energy creates an unfolding 
“footprint”, allows visualization of unfolding intermediates, and enables rapid 
differentiation of protein isoforms with subtle differences based on their unfolding 
patterns.86 Despite the widespread availably of collisional dissociation methods, its 
limitations in providing structural information on proteins make alternative approaches 
worthwhile for structural biology applications. 
1.3.3 Electron-based Dissociation 
Electron-based ion activation methods rely on the gas phase interaction of electrons 
or radical reagents with ions of interest to promote fragmentation. The energy range of 
such electrons defines the fundamental difference between the variety of electron-based 
dissociation methods. Electron capture dissociation (ECD) induces fragmentation of 
multiply charged protein cations by exothermic capture of low energy electrons (< 1 
eV).87,88 This technique was originally limited to FT-ICR instrument platforms on which a 
magnetic field facilitates the simultaneous trapping of electrons and analyte cations, but 
ECD has more recently been implemented on other platforms via a modular drop-in 
electron filament device from eMSion. Electron transfer dissociation (ETD), the ion trap 
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instrument analogue of ECD, instead transfers an electron to a multiply charged 
polypeptide cation via reaction with a radical anion reagent (i.e. fluoranthene or 
anthracene).89 Higher energy electrons (~30 kV) have also been used to activate protein 
complexes, termed electron ionization dissociation (EID).90 The formation of odd-electron 
radical species represents a primary advantage of electron-based ion activation methods as 
fragmentation occurs through hydrogen radical migration prior to energy redistribution 
through vibrational relaxation. This presumed non-ergodic dissociation behavior allows 
certain challenges associated with collisional activation to be overcome including 
preferential cleavages and loss of labile modifications.91–93 
Although originally aimed at improving the sequence characterization of denatured 
peptides and proteins for proteomics applications, ECD and ETD have been widely applied 
for structural analysis of protein-protein complexes. In stark contrast to collisional 
activation of protein complexes, electron-based methods result predominantly in the 
production of sequence ions and limited disassembly of noncovalent higher order structure. 
The resulting sequence ions typically originate exclusively from surface exposed regions 
of a folded protein structure.94 Maps of sequence ions by residue resulting from ECD/ETD 
of proteins introduced by native MS have been correlated with crystallographic B-factors, 
a measure of flexibility in XRC experiments. As such, electron-based dissociation 
approaches can be used to directly probe secondary and tertiary structure of proteins.94 To 
date, the higher order structures of increasingly large multimeric protein complexes 
including hemoglobin (64 kDa),95 alcohol dehydrogenase (147 kDa),95–97 and GroEL (802 
kDa)46 have been probed using ECD or ETD. Additionally, the extra electron energy 
imparted during EID can yield significantly more informative sequence ions compared to 
ECD while retaining sensitivity to higher order protein structure.90 
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1.3.4 Surface-Induced Dissociation 
As the name suggests, surface-induced dissociation (SID) involves the fast, 
energetic collision of protein ions with a surface. The rapid and high deposition of energy 
results in disassembly of noncovalent protein complexes into constituent subcomplexes 
with little to no backbone cleavage nor unfolding of individual subunits, as evidenced by 
symmetric partitioning of charge during dissociation (i.e. the precursor charge splits evenly 
by mass among the observed subcomplexes).98 As such, SID is exceptionally useful for 
probing the quaternary structure of protein-protein complexes. Specifically, tracking 
observed subcomplexes as the SID energy is increased offers insight into the relative 
strength of protein interfaces. IMS separation of complexes before SID allows different 
protein conformations to be activated individually while IMS of subcomplexes resulting 
from SID greatly improves the resolving power of this approach by eliminating 
overlapping m/z peaks (e.g. a 10+ dimer and 5+ monomer).98  The SID-IM-MS 
methodology has been used to study a variety of protein complexes including rapidly 
screening 48 computationally designed heterocomplexes to confirm stoichiometry, 
intersubunit connectivity, and complex topology.99 Also, recently the capability of SID to 
localize small ligand binding for multimeric protein-ligand complexes to either within a 
subunit or between adjacent subunits was demonstrated.100 
1.3.5 Ultraviolet Photodissociation 
Although a laser was first coupled to a mass spectrometer for the purpose of 
photoactivation of gas phase ions almost 50 years ago,101,102 only within the last decade 
have photodissociation methods evolved into powerful and versatile tools for identification 
and structural characterization of various classes of biomolecules.78,79 Continuous wave 
CO2 lasers have been used to probe protein complexes with IR wavelength photons, 
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referred to as infrared multiphoton photodissociation (IRMPD), but the low energy 
deposition yields similar fragmentation trends as collisional activation.46 Instead, 
irradiation of proteins with photons in the ultraviolet range, termed ultraviolet 
photodissociation (UVPD), has proven highly effective for the structural characterization 
of protein-ligand and protein-protein complexes. Coordinating commercially available 
laser technology with specific wavelengths strongly absorbed by the polypeptide backbone 
make coupling excimer lasers operated at 157 nm or 193 nm to mass spectrometers the 
optimal choice for UVPD applications.78,79 While the general utility of UVPD as a frontier 
strategy for generating informative fragmentation patterns of proteins, nucleic acids, lipids, 
and carbohydrates alike has been showcased, the work presented in this dissertation focuses 
specifically on using 193 nm photons to characterize protein-ligand and protein-protein 
complexes introduced by native MS. 
Despite the lack of a detailed understanding of the complex mechanisms governing 
photodissociation of intact protein complexes, several specific attributes posit UVPD as an 
all-inclusive approach for the analysis of protein complexes across all structural levels. 
Regarding primary structure, UVPD of intact proteins under denaturing or native 
conditions yields the full array of backbone cleavages (a-, b-, c-, x-, y-, and z-type ions).103–
105 Absorption of photons by the protein backbone is a fast, high energy process thought to 
result in both electronic excitation as well as intermolecular vibrational redistribution 
allowing access to both higher energy direct dissociation and lower energy internal 
conversion pathways.106–108 The observation of a diverse set of ion types and access to 
higher energy dissociation pathways translates to sequence coverages of intact proteins 
unsurpassed by other ion activation methods.104,105 For example, UVPD of model 
membrane protein complexes sprayed by native MS resulted in significantly improved 
sequence coverages compared to collisional activation.109 Sequence coverage is defined as 
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the percentage of residues for which backbone cleavage is observed adjacent to that residue 
in a given protein sequence. 
Additionally, direct dissociation pathways allow significant retention of labile 
covalent and noncovalent modifications along UVPD sequence ions (i.e. covalent bonds 
along the polypeptide backbone break before vibrational redistribution occurs to instead 
dissociate lower energy covalent or noncovalent bonds).105,110–112 For peptides or denatured 
intact proteins, this has allowed improved localization of biologically relevant covalent 
post-translational modifications, including phosphorylation and sulfation sites.110–112 In the 
context of native MS, small molecule ligand or metal cofactor binding sites can be 
determined from UVPD spectra of protein-ligand complexes.105 Specifically, the location 
within the protein sequence of fragment ions noncovalently bound to the ligand/metal 
(referred to as holo ions) are mapped based on the corresponding mass shift of these ions 
from sequence ions that do not retain the ligand/metal (termed apo ions). Such analysis has 
allowed confirmation of the putative binding sites for a wide variety of protein-ligand 
complexes including: the heme group bound to myoglobin,105 an NADPH cofactor and 
inhibitor methotrexate bound to dihydrofolate reductase (DHFR),113 and GDP or a GTP-
analogue bound to the oncogenic rat sarcoma protein K-Ras.114 
Information on the secondary and tertiary structure of protein complexes is gained 
from examination of the abundances of observed sequence ions as well as the sequence 
position.115,116 Subtraction of the intensities of backbone cleavages upon UVPD for a 
protein in different conformational states creates a difference plot that highlights regions 
of enhancement or suppression.115 Observed variations in UVPD behavior reflect changes 
in stabilizing noncovalent interactions and protein flexibility. Specifically, enhancement of 
backbone fragmentation signifies fewer interactions and more flexibility, which in turn 
leads to the greater production of sequence ions; whereas suppression indicates 
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engagement in more extensive interactions, which limits the separation and detection of 
fragment ions.115,117 This native UVPD-MS approach has been applied to probe the 
structure of myoglobin across several ESI charge states,115 detect loop movements induced 
by ligand binding to DHFR,113 define conformational changes upon ligand exchange for 
sequence variants of K-Ras and DHFR,114,118 and evaluate metal binding regions of 
calmodulin and azurin.119 In addition to a variety of protein-ligand complexes, UVPD-MS 
has also been used to analyze protein-protein complexes.116,120–123 Favored dissociation 
pathways resulting from UV photoactivation of multimeric proteins include both subunit 
disassembly (with limited subunit unfolding during ejection) and sequence ion production. 
As such, information on the quaternary structure of protein-protein complexes can be 
gained by tracking resulting subcomplexes as a function of pulse energy or the number of 
pulses, in addition to the primary, secondary, and tertiary structural insight available from 
sequence ion identification.120,121 Much of the work presented in this dissertation builds on 
these previous studies and further develops native UVPD-MS for structural analysis of 
biologically important protein-ligand complexes as well as scales it up to increasingly large 
protein-protein complexes. However, other technical developments with regards to on-line 
separations and multistage MS/MS approaches are first necessary to make possible the 
analysis of the higher order structures within more biologically complex samples. 
1.4 HIGH-THROUGHPUT ANALYSIS OF NATIVE PROTEIN COMPLEXES 
A logical step towards the overarching goal of analyzing increasingly complex 
mixtures by native MS approaches is enabling higher-throughput analysis of native protein 
complexes. Such developments are aimed at facilitating the idea of “native” proteomics 
which would entail structural characterization of every protein within a cell, identification 
of its interacting partners, and quantitative analysis of the dynamics of the states in which 
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it exists.124,125 This type of detailed information is necessary to paint the complete picture 
of processes governing most disease mechanisms owing to their reliance on non-covalent 
interactions and networks of binding partners.126 In practice, much work remains to 
optimize a reliable on-line separation method that is compatible with native MS conditions, 
as well as improve MS/MS approaches with regards to when and how energy is deposited 
into proteins of interest.  
1.4.1 On-line Separation Methods Compatible with Native MS 
While the large majority of native MS studies to date involve the direct infusion of 
a single purified protein, efforts to analyze more complex mixtures rely on coupling 
separation techniques to allow sequential detailed analysis of all species present.127 For 
bottom-up and top-down proteomics applications reverse-phase liquid chromatography 
(RPLC) acts as a robust and high-resolution separation approach that is easily coupled with 
MS. However, the denaturing solvents required by the separation principles governing 
RPLC make this method incompatible with native MS. Among conventional separation 
techniques that can be adapted to native conditions and act as possible alternatives are size 
exclusion chromatography (SEC),128,129 ion exchange chromatography (IEX),99,130 
hydrophobic interaction chromatography (HIC),131 and capillary zone electrophoresis 
(CZE).127,132–134 SEC allows separation of proteins and protein complexes based on 
decreasing size as larger analytes are excluded from pores and travel faster than smaller 
analytes that can fit within the particle cavities. As such, the pore size can be tuned to 
separate a desired mass range. An isocratic mobile phase is used to introduce analytes and 
SEC columns are notoriously tolerant of salts or detergents making it relatively easy to 
maintain native conditions during separation and couple on-line with MS. However, the 
simplicity in principle and implementation of SEC result in relatively low-resolution 
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separations insufficient for the distinction of species with subtle differences. IEX and HIC 
have each afforded slightly higher resolving power but IEX can require several columns 
(i.e. separate columns are necessary for cation and anion exchange), and both of these 
approaches require high salt concentrations (up to 1 M) which can disrupt weak 
noncovalent interactions and foul MS interfaces. Additionally, these separation methods 
(SEC, IEX, HIC) are not particularly amenable to nanoscale flow rates (< 1 μL/min) and 
instead are more routinely carried out at microbore (10 – 500 μL/min) or capillary (1 – 10 
μL/min) flow rates, thus requiring significantly larger sample quantities. The improved 
sensitivity characteristic of nanoflow rates is highly desirable for native analysis of protein 
structures due to the division of the MS signal into multiple channels corresponding to 
different oligomeric, modification, or ESI charge states.127 
In contrast to the above techniques, electrophoresis approaches that rely on an 
electric field instead of solution phase interactions with a solid phase to separate analytes 
based on charge and size (i.e. electrophoretic mobilities which are dependent on analyte 
charge and hydrodynamic volume) have become exciting avenues for native 
separations.134,135 Capillary isoelectric focusing (cIEF) and native gel-eluted liquid fraction 
entrapment electrophoresis (GELFrEE) have both been used for separation of native 
protein complexes.136,137 However, so far cIEF is limited to relatively stable complexes due 
to concerns of unfolding at a given protein’s isoelectric point and the need for denaturing 
sheath flow buffers to maintain stable ESI. Additionally, native GELFrEE is limited to off-
line separations as it has yet to be coupled on-line to a mass spectrometer owing to the use 
of non-MS compatible detergents and salts. Instead recently capillary zone electrophoresis 
(abbreviated as CE in this dissertation) has become the front-runner as an MS compatible 
separation method (under both denaturing and native conditions) based on its ability to 
achieve high-resolution separations in 0-30 kV electric fields using negligible sample and 
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buffer quantities.134,135 Native MS-friendly salts are easily substituted for more harsh 
buffers typically used in CE as the background electrolyte (BGE). Initial challenges with 
coupling CE on-line with MS stemmed from the difficulty in completing the electrical 
circuit for separation while simultaneously providing voltage for ESI. However, several 
commercial solutions for interfacing CE on-line to MS exist including sheath flow, 
sheathless, and liquid junction.134,135 A sheath flow interface involves directing BGE flow 
into a sheath liquid junction at which a separate ESI voltage is applied allowing ionization 
of eluting analytes from the sheath liquid. In practice this entails coupling the CE capillary 
coaxially with a glass emitter, similar to that used for direct infusion experiments. Another 
important advance in the application of CE-MS was the introduction of neutral capillary 
coatings, particularly linear polyacrylamide (LPA).134,135 Coating procedures cover the 
inner walls of the capillary, eliminating the electroosmotic flow (EOF) to afford wider 
separation windows and suppress protein adsorption to the bare silica. Both sheath flow 
and sheathless interfaces have been used along with LPA-coated capillaries for the 
separation of fractionated lysate samples under native MS conditions.127,133 Similar CE 
conditions using a sheath flow interface are employed in this dissertation for the separation 
of ribosomal proteins. Advances in CE interfaces now offer the possibility of separating 
proteins based on injections containing as little as 50 nL, albeit at higher concentrations 
(10-30 μM) than typically used with nanoscale LC separations (typically using 1-5 μL 
injections at 1 μM concentrations). 
1.4.2 Multistage MS/MS Approach 
As separations technologies inch closer to full compatibility with native MS, 
simultaneous development of MS/MS approaches is still necessary to enable 
comprehensive structural characterization of protein complexes on a high-throughput 
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timescale. Alternative ion activation methods, in particular ECD/ETD and UVPD, have 
demonstrated great utility in probing the higher order structures of relatively large protein 
complexes. However, with increasing protein size, these techniques require more scans to 
acquire quality MS/MS spectra. As such, amenability to the structural analysis of large 
protein complexes introduced by on-line separation methods is questionable. Instead, 
multistage MS/MS approaches have been introduced that involve the introduction of intact 
protein complexes into the gas phase by native MS, subunit disassembly of the protein 
complexes into monomers using front-end collisional activation, isolation of a specific 
monomeric subunit for subsequent activation by higher-energy collisional dissociation 
(HCD), and detection of the resulting sequence ions.138 A schematic outlining the 
multistage MS/MS approach is shown in Figure 1.3. The main benefit of this method lies 
in simplification of the species being probed during the MS/MS event (i.e. monomer 
instead of oligomer) without sacrificing information on the quaternary structure of the 
protein complex, which is still obtained from the full MS scan. The benefits of employing 
a multistage MS/MS approach for the analysis of several model protein complexes,138 a 
biologically important metabolic enzyme,139 and off-line separated endogenous protein 
complexes124 have already been demonstrated. In this dissertation, the multistage approach 
is further developed in this for improved structural characterization protein complexes by 
utilizing UVPD instead of HCD as the MS/MS step. 
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Figure 1.3: Schematic illustrating a typical multistage MS/MS approach for the 
improved analysis of intact protein complexes. 
1.5 OVERVIEW OF CHAPTERS 
As increasingly complex disease mechanisms remain to be unraveled and new ones 
arise, MS has already solidified its place in the structural biology toolbox owing to the 
speed and sensitivity it offers as an analytical technique. Although a solid groundwork for 
applying native MS with 193 nm UVPD to probe the structure of proteins has previously 
been laid, further development is still necessary to scale up this approach to larger and 
more complex protein samples. The work presented here is aimed at applying native 
UVPD-MS to characterize increasingly larger protein complexes, as well as at employing 
an on-line separation method in conjunction with a multistage MS/MS approach to improve 
the throughput of the analysis. 
In Chapter 3, the utility of UVPD-MS for providing structural information on 
several different scales from large loop movements down to fluctuations of single residues 
is demonstrated by tracking the conformation of the phosphate transferase enzyme 
adenylate kinase during its entire catalytic cycle. Each step in the reaction is probed 
including binding one each of a monophosphate and triphosphate ligand, addition of a Mg2+ 
cofactor, and production of two diphosphate ligands. Variations in the efficiencies of 
UVPD backbone cleavage efficiencies for each protein-ligand complex provide snapshots 
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highlighting specific regions that undergo local fluctuations to facilitate the global 
transitions responsible for the catalytic function of the enzyme.  
Chapter 4 details the application of UVPD-MS to characterize structural variations 
due to the inhibition or mutation of New Delhi metallo-β-lactamase (NDM), an enzyme 
responsible for conferring antibiotic resistance to bacteria. Native MS of the protein bound 
separately to three different covalent inhibitors provides information on the enzyme 
metalation state, while mapping the differences in UVPD fragment ion distributions for the 
three protein-ligand complexes allows closure of a beta hairpin loop to be tracked. 
Similarly probing the metal affinity of three clinical variants for two active site zinc ions 
provides insight on how zinc scarcity is driving evolution of this antibiotic resistance 
determinant.  
The first application of UVPD-MS to investigate conformational changes in a 
protein-protein complex is described in Chapter 5. Native MS offers insight into the 
guanosine-ligand dependent homodimerization of the GTP-ase rat sarcoma (K-Ras), an 
important oncogene in human cancers, and three G12X clinical mutants. Additionally, 
heterodimerization with the downstream effector kinase rapidly accelerated fibrosarcoma 
(Raf) was monitored for each K-Ras variant by UVPD-MS. The stabilization of two 
different heterodimer interfaces were related to each of the specific variants, offering 
insight on how different G12X mutations impact downstream signaling and cause 
oncogenic upregulation. 
In Chapter 6, UVPD-MS shows promise as a rapid and sensitive method to map the 
epitope regions of an intact model antibody-antigen complex. The workflow involves 
comparison of sequence coverage afforded by UV photoactivation of hemagglutinin A 
(HA), the main immunogenic antigen of the influenza virus, to that of HA in complex with 
the D1 H1-17/H3-14 antibody which has shown to confer potent protection to infection. 
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Specifically, the presence of the antibody results in a suppression of UVPD backbone 
cleavages exclusively along the putative antigenic determinant regions of HA. Plotting the 
number and type of sequence ions observed per residue highlights the epitope regions as 
stretches of HA in which fewer and less diverse sequence ions are observed for the 
HA:antibody complex compared to HA. 
Chapter 7 introduces a multistage UVPD-MS approach aimed at more thorough 
structural characterization of increasingly larger noncovalent protein assemblies. Front-end 
collisional activation is used to break apart multimeric protein complexes into monomeric 
subunits that can be subsequently interrogated individually with UVPD-MS. Using this 
approach, two single amino acid variants of human mitochondrial enzyme branched-chain 
amino acid transferase 2 (BCAT2), a protein implicated in chemotherapeutic resistance in 
glioblastoma tumors, are each characterized from the higher-order structure down to 
specific interactions with a small molecule cofactor in a single experiment. 
Uniting capillary electrophoresis (CE) on-line with multistage UVPD-MS allows 
for the high-throughput analysis of proteins comprising the E. coli ribosome in Chapter 8. 
Lowering the magnesium concentration in solution and removing the RNA that holds the 
ribosome unit together allows subcomplexes and individual ribosomal proteins to be 
observed, even under native CE-MS conditions. Implementing a multistage UVPD-MS 
approach for the analysis of ribosomal protein complexes separated by CE affords higher 
sequence coverages and improved structural characterization of protein-metal, protein-
ligand, and protein-protein complexes alike. This strategy represents a significant advance 
towards the structural characterization of complex endogenous protein samples using 
UVPD-MS. 
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Chapter 2: Experimental Methods 
2.1 OVERVIEW 
Exploiting the methods described below allows significant improvements in the 
versatility and throughput for the structural characterization of protein-ligand and protein-
protein complexes by MS. Key developments include coupling native MS compatible 
separation methods with existing UVPD technology in a multistage tandem MS approach 
as well as streamlining the data analysis workflow by utilizing several MS/MS 
interpretation pipelines.  
2.2 MASS SPECTROMETRY 
Either a Fourier transform (FT) hybrid linear quadrupole ion trap-Orbitrap mass 
spectrometer or an ultra-high mass range Orbitrap mass spectrometer were used for all 
experiments detailed in this dissertation. Each of these instruments was equipped with an 
electrospray ionization (ESI) source to ionize proteins under native conditions and 
modified to perform UVPD in the HCD collision cell. 
2.2.1 Native Electrospray Ionization 
A basic requirement of any MS-based approach is the creation of gas-phase ions 
from analytes of interest. As such, an alphabet soup of ionization techniques already exists 
(e.g. EI, MALDI, APCI, DESI, etc.) while more are still being developed for specialized 
applications. Nevertheless, the field of biological MS has specifically relied on those 
methods capable of maintaining the integrity of biomolecules as they are charged and 
transferred to the gas phase. Among such soft ionization techniques, electrospray ionization 
(ESI) remains the most widely used owing to the deposition of multiple charges and 
orthogonality in on-line coupling of solution-phase separations. First reported in 1984 by 
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Fenn and Yamishita, ESI is best depicted as a controlled current electrolytic cell (Figure 
2.1).1,2 Under the influence of an electric field, charge accumulates at the surface of a 
solution containing the analytes of interest. For denaturing MS conditions (> 50% organic 
solvent, typically acetonitrile or methanol) low percentages of formic or acetic acid (< 1%) 
are added to aid in this process. However, for native MS conditions, spray solvents only 
contain volatile salts (ammonium acetate, ammonium bicarbonate, or ammonium formate) 
at near-neutral pH values to mimic physiological conditions. With sufficiently high voltage 
conditions, a Taylor cone is formed at the tip of the spray needle from which highly charged 
droplets are ejected. As these droplets travel towards the mass spectrometer inlet, they 
undergo rapid evaporation of the surrounding solvent. As coulombic repulsion forces of 
the ions surpass the surface tension of the shrinking droplets, referred to as the Rayleigh 
stability limit, numerous fission events occur and eventually yield completely desolvated, 
gas-phase ions that can enter the mass spectrometer for analysis.  
 
 
Figure 2.1: The electrospray ionization process as a schematic representation with values 
corresponding to nESI conditions (adapted from Cech and Enke).2 
 42 
For native MS applications, typically this process is scaled down to nano ESI 
(nESI) in which, instead of introducing the sample with an ESI source and syringe pump, 
metal-coated borosilicate emitters (20-50 μm inner diameter) are filled with ~5 μL of 
solution for offline ionization. A ring electrode acts to hold the emitter tip in proximity to 
the mass spectrometer inlet and apply a voltage along the metal coating (20:80 Au:Pd), 
which in turn induces electroosmotic flow of the nESI solution. In addition to lower sample 
volumes, nESI requires lower spray voltages compared to standard ESI (1-2 kV vs. 3-5 kV, 
respectively). This is advantageous for lowering the internal energy imparted to analytes 
during ionization and minimizing protein unfolding. In the same vein, the mass 
spectrometer inlet temperature is typically lowered from 275 °C to 50-200 °C for native 
MS experiments. In general, native MS ionization parameters are tuned to be as “gentle” 
as possible, often at the expense of sensitivity compared to denaturing MS. 
2.2.2 Mass Analyzers 
Schematic representations of the two mass spectrometric platforms used for all 
work detailed in this dissertation are shown in Figure 2.2. The Orbitrap Elite (Thermo 
Fisher Scientific, Bremen Germany) is a hybrid ion trap-Orbitrap mass spectrometer. 
Following ionization in the nESI source region, several optics are used to guide ions to the 
dual linear ion traps (LITs). Composed of two pairs of hyperbolic rods arranged 
orthogonally and radially equidistant from each other (referred to as a quadrupole) as well 
as static lens elements at both terminal ends of the rods, LITs can be used for low-resolution 
mass analysis, ion isolation, and collisional ion activation.3 RF voltages applied to each 
pair of rods 180 degrees out of phase confine ion motion radially while DC offset voltages 
on the static lens elements at the front and back control the ions axially and gate flow of 
the ions into the trap. Broadband waveforms and auxiliary RF voltages are applied to one 
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pair of rods to enable ion isolation and activation in a secular frequency-dependent manner. 
For mass analysis, instead an RF amplitude ramp causes sequential, mass-selective ejection 
of ions through slits in the center electrodes. Typically, dual LITs are present, allowing the 
first to be maintained at a higher pressure (~5 mTorr) of helium bath gas for improved ion 
trapping and collisional activation efficiency, while the second is kept at a lower pressure 
(0.3 mTorr) and used exclusively for mass analysis scans. For native MS experiments, LITs 
are useful for ion isolation, but activation by beam-type collisional activation in the HCD 
cell and high-resolution mass analysis in the Orbitrap are more informative. 
First introduced almost 20 years ago by Makarov, Orbitraps provide high resolving 
power, part per million mass accuracies, and short acquisition times without the need for 
the expensive superconducting magnets required by FT-ICR instruments.4,5 Instead an 
Orbitrap is composed of a barrel-shaped electrode with two different segments that enclose 
an inner spindle-like electrode. Packets of ions are pulsed into the analyzer and undergo 
harmonic oscillations along the axis of the inner electrode under the influence of a quadro-
logarithmic field. The frequency of this motion, which is proportional to (m/z)-1/2 for a 
given ion, is detected as an image current between the two segments comprising the outer 
electrode. In the context of native MS, Orbitrap mass analyzers can scan high m/z regions 
(currently up to m/z 80,000 on some instruments) but still fail to routinely provide isotopic 
resolution for complexes larger than ~30 kDa. As such, native MS spectra of large 
complexes are typically collected at lower resolving powers (< 25K) as the overall signal 
decreases quickly at higher resolving power values. 
While the other mass spectrometer in Figure 2.2 similarly contains an Orbitrap for 
mass analysis, several modifications were made to the ion optics at the front-end to improve 
the transfer of higher m/z ions (these modifications are detailed in Chapter 7). As such it is 
referred to as a Q Exactive UHMR (ultra-high mass range) mass spectrometer (Thermo 
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Fisher Scientific, Bremen, Germany). Additionally, a quadrupole mass filter is used for ion 
isolation instead of a LIT. Consisting of two pairs of hyperbolic rods with RF voltages 180 
degrees out of phase applied to opposite pairs (similar to the middle section of a LIT), 
quadrupoles can operate as RF-only ion guides allowing all ions to pass or as narrow 
isolation width filters for specific m/z values by application of DC offset voltages to each 
pair of electrodes. Both instrument platforms contain an HCD collision cell for ion 
activation by HCD or UVPD prior to Orbitrap mass analysis. The specific values of all MS 
parameters used to acquire data are detailed in each Chapter. 
 
 
Figure 2.2: Schematic representations of a Thermo Fisher Scientific (A) Orbitrap Elite 
and (B) Q Exactive UHMR mass spectrometer with important regions 
labelled. Modifications to enable UVPD in the HCD cell of each instrument 
are detailed in section 2.3.3. 
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2.3 ION ACTIVATION 
For the protein-ligand and protein-protein complexes probed herein, either HCD or 
UVPD were employed for ion activation. Additionally, in-source trapping (IST) provided 
front-end collisional activation during the analysis of some complexes. Subsequent 
sections detail relevant acquisition parameters and any modifications necessary to 
implement these MS/MS approaches.  
2.3.1 In-Source Trapping 
Exclusive to the Q Exactive UHMR is a type of broadband front-end collisional 
activation enabled in the ion optics region of the instrument (specifically in the injection 
flatapole) and termed in-source trapping (IST).6 Since there is no precursor isolation of a 
specific m/z value, this type of activation is not technically considered an MS/MS 
technique. Increasing the positive potential on the lens following this multipole while 
simultaneously dropping the injection flatapole bias to a negative voltage, referred to as 
the desolvation voltage (up to -250 V), blocks ions from exiting and traps them in a 
potential well for a set amount of desolvation time (4 – 10 msec). This process is depicted 
in Figure 2.3. While trapped, ions collide with background gas in the injection flatapole 
causing collisional activation. A 200 µs release event returns the injection flatapole and 
following lens biases to their previous operating values and allows the resulting ions to 
proceed through the instrument. The makeup of the resulting ion population following IST 
is dependent on the desolvation voltage as well as protein size and flexibility, with lower 
desolvation voltage values (-50 to -150 V) simply aiding in desolvation and maintaining 
intact complexes, while higher desolvation voltages (> -150 V) typically causing 
disassembly of complexes into constituent subunits or even production of sequence ions. 
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Figure 2.3: Graph schematically representing the injection flatapole bias as a function of 
time during an IST event. The depth of the potential well is determined by the 
desolvation voltage while the width is controlled by the desolvation time. 
2.3.2 Higher-energy Collisional Dissociation 
Throughout this dissertation, beam-type higher-energy collisional dissociation 
(HCD) is used as a collisional activation method for protein-ligand and protein-protein 
complexes. The metrics (sequence coverage, localization of modifications, etc.) of HCD 
provide a baseline to which UVPD can be compared, making evident specific advantages 
of using an alternative ion activation method. Both instrument platforms used in this work 
have an HCD cell so no instrument modifications were necessary. On the Orbitrap Elite, 
HCD is controlled as a % normalized collision energy (% NCE) that is normalized to the 
charge state of the precursor while on the Q Exactive UHMR, instead the collision energy 
is set as a direct value in electronvolts. 
2.3.3 Ultraviolet Photodissociation 
As depicted in Figure 2.2, both mass spectrometers required modifications to 
enable ultraviolet photodissociation (UVPD) in the HCD cell via coupling Coherent 
ExciStar XS 500 (Santa Clara, CA) pulsed excimer lasers using ArF to operate at 193 nm. 
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For the Orbitrap Elite, these changes have been previously described.7 Briefly, a CaF2 
optical window was added coaxially to the vacuum manifold of the HCD collision cell to 
allow transmission of the laser beam. Firmware modifications allowed the creation of a 
custom UVPD flag that sends an external trigger to the laser using a Berkeley Nucleonics 
Corp. pulse generator (San Rafael, CA) as ions are transferred into the HCD cell using 1% 
NCE. The laser was similarly incorporated through the HCD cell on the Q Exactive 
UHMR. Further detailed in Chapter 7, a fused silica window was incorporated using a 
stainless-steel tube, allowing the laser beam to pass coaxially through the HCD cell. An 
Arduino Uno microcontroller controlled by a custom script creates transistor-transistor 
logic (TTL) signals to trigger emission of the laser based on a rise in the HCD multipole 
DC offset. On both instruments, the laser is operated at the maximum repetition rate (500 
Hz) to generate one 5 nsec pulse every 2 msec. Unless otherwise noted, UVPD spectra are 
the result of 1 pulse at 3 mJ. 
2.4 ON-LINE SEPARATION METHODS 
Two separation methods were coupled on-line with MS in this dissertation to enable 
another dimension of analysis. The first, size-exclusion chromatography (SEC), was used 
to gain information on the solution phase oligomeric states of protein-protein complexes. 
The second, capillary zone electrophoresis (CE), allowed separation of a more complex 
biological mixture for high-throughput analysis by UVPD-MS. 
2.4.1 Size-Exclusion Chromatography 
A Dionex LC system (Thermo Fisher Scientific) interfaced on-line with the mass 
spectrometers in Figure 2.2 was used to carry out size-exclusion chromatography (SEC) 
experiments. Owing to the higher flow rates (80 – 100 μL/min) required for SEC, an ESI 
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source with spray voltages of 3-4 kV and nitrogen sweep gas was used to ionize proteins. 
Unless otherwise stated, samples were prepared at 1 μg/μL for 5 μL injections. Isocratic 
mobile phases of 20-50 mM ammonium acetate (pH 6.8) pushed proteins along a 2.1 mm 
× 300 mm ACQUITY UPLC Protein BEH SEC column with a 200 Å pore size and 1.7 µm 
particle size (Waters, Milford, MA), or a 2.1 mm × 300 mm Zenix-C column with an 80 Å 
pore size and 3 µm particle size (Sepax Technologies, Newark, DE). ESI-MS spectra were 
collected at a resolving power of 240K (Orbitrap Elite) or 12500 (Q Exactive UHMR) as 
proteins eluted. 
2.4.2 Capillary Zone Electrophoresis 
For the CE-MS analysis described in Chapter 8, a CMP Scientific (Brooklyn, NY) 
ECE-001 capillary electrophoresis autosampler and electrokinetically pumped sheath flow 
interface were coupled on-line to the Q Exactive UHMR mass spectrometer. Samples were 
prepared at ~30 μg/μL and hydrodynamically injected (using 5 psi for 45 sec) into a 100 
cm LPA-coated capillary (50 µm inner diameter). Briefly, as previously described,8 the 
capillary coating process involved successively flushing a bare fused silica capillary with 
1 M hydrochloric acid, water, 1 M sodium hydroxide, water, and methanol. Subsequent 
exposure to 3-(trimethoxysilyl) propyl methacrylate introduced carbon-carbon double 
bonds along the inner wall of the capillary. The treated capillary was filled with an 
acrylamide solution in water containing ammonium persulfate and incubated at 50 ˚C for 
1 hour. Unreacted reagents were flushed with water. The background electrolyte (BGE) for 
CE was 25 mM ammonium acetate (pH 6.8) containing up to 100 μM magnesium acetate, 
and the sheath liquid used for ESI was 10 mM ammonium acetate (pH 6.8). CE separation 
was achieved using a +30 kV separation voltage and 0.5 psi pressure was applied for the 
duration of the separation. A Sutter Instrument (Novato, CA) P-1000 micropipette puller 
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was used to fabricate ESI emitters (~20 μm tip opening, 4 cm length) for the CE-MS 
interface from borosilicate capillaries (1.0 mm outer dimeter, 0.75 mm inner diameter). 
ESI spray voltages of 2.4-2.6 kV were used for on-line ionization of proteins following CE 
separation. 
2.5 DATA ANALYSIS 
Several MS data analysis programs are used in conjunction throughout this 
dissertation to aid in the interpretation of MS/MS spectra. Specifically, ProSight Lite and 
ProSight Native are used to identify sequence ions or monomeric subunits resulting from 
HCD or UVPD of protein-ligand or protein-protein complexes. Adding expected mass 
shifts to the search parameters in these programs allows for the identification of ligand-
bound holo fragment ions. For UVPD spectra, UV-POSIT streamlines summation of 
sequence ion intensities by residue. Statistical analysis is performed for measured 
differences in UVPD fragment ion intensities to establish a confidence threshold for claims 
about structural changes. 
2.5.1 ProSight Lite and ProSight Native 
Obtaining structural information from MS/MS spectra requires identifying up to 
hundreds of sequence ions from a single spectrum. As this would be a tedious and time-
consuming task to carry out by hand, programs exist to generate a theoretical mass list 
resulting from cleavage along every single backbone site. The experimental mass list can 
then be cross-referenced and identifications of sequence ions made within a mass tolerance. 
ProSight Lite is one such program that matches experimental fragment ions to the list of 
theoretical sequence ion masses and visualizes the results along the entered protein 
sequence.9 Specifically, all HCD and UVPD MS/MS spectra in this dissertation were first 
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deconvoluted using the Xtract algorithm (Thermo Fisher Scientific) using a signal-to-noise 
ratio of 3, fit factor of 44%, and remainder of 25% to create a list of monoisotopic fragment 
ion masses. Based on the protein sequence input into ProSight Lite, sequence ion matches 
were made within a ±10 ppm mass tolerance. For HCD spectra, only b- and y-type ions 
were considered while for UVPD spectra, nine possible ion types (a, a + 1, b, c, x, x + 1, 
y, y – 1, z) were searched. More recently developed, ProSight Native facilitates 
deconvolution and sequence ion identification for MS/MS spectra of protein-protein 
complexes collected in a high-throughput manner. This software helps assign peaks that 
correspond to intact subunits resulting from disassembly of oligomeric complexes in 
addition to backbone cleavages. ProSight Native was used to identify ribosomal protein 
complexes analyzed by CE-MS/MS in Chapter 8. 
2.5.2 Identifying Holo Fragment Ions 
UVPD of a protein non-covalently bound to a ligand typically yields a significant 
number of backbone fragment ions that retain the ligand. Termed holo fragment ions, 
identification of these mass shifted sequence ions facilitates the localization of ligand 
binding sites and improves sequence coverages. Figure 2.4 shows an example of a holo 
fragment ion in the UVPD MS/MS spectrum of holo myoglobin (non-covalently bound to 
a heme ligand). In addition to the heme-free, apo x120
6+ sequence ion, also observed is the 
heme-bound, holo x120
6+ sequence ion that is shifted by the corresponding mass of the heme 
group (+615.1695 Da). Throughout this dissertation, holo fragment identifications are 
made by adding expected mass shift values at the N- and C-termini in ProSight Lite search. 
Once identified, holo fragment ions contribute to reported sequence coverages and can be 
mapped along the sequence to gain structural insights or highlight binding sites. 
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Figure 2.4: UVPD MS/MS spectrum (1 pulse at 3 mJ) of the 8+ charge state of holo 
myoglobin sprayed by native MS. The apo (heme-free) and holo (heme-
bound) versions of the x120
6+ fragment ion are both labelled, separated by a 
mass shift corresponding to the heme group (+615.1695 Da). 
2.5.3 UV-POSIT 
Information on the structure of protein-ligand and protein-protein complexes is 
gleaned through comparison of the relative abundances of UVPD fragment ions for 
different conformational states. As such, fragment ion intensities must be summed in a 
manner that accurately represents the propensity for cleavage adjacent to each residue in a 
protein sequence. The fragment ion abundance utility of the web-based program UV-
POSIT automates this process based on the exported list of deconvoluted masses and 
intensities that comprise a given UVPD spectrum.10 The program reports a UVPD 
backbone cleavage yield normalized to the total ion current of the spectrum for each amino 
acid. Specifically, for a given residue n in a protein containing R amino acids numbered 1 
(N-terminus) to R (C-terminus), UV-POSIT collectively sums the intensities of N-terminal 
apo and holo sequence ions (an, bn, cn) arising from backbone cleavage C-terminal to 
position n with C-terminal fragment ions (xR-n+1, yR-n+1, zR-n+1) resulting from cleavage N-
terminal to residue n. These calculated values were used to represent UVPD backbone 
cleavage efficiency adjacent to each amino acid in the protein sequence and compared 
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between different conformational states for a given protein to highlight regions exhibiting 
suppression or enhancement. 
2.5.4 Statistical Analysis 
Owing to the reliance of UVPD-MS on measuring differences in backbone cleavage 
efficiencies to gain structural information, statistical analysis is necessary to ensure 
significance and establish a confidence threshold. UVPD MS/MS spectra were collected 
in triplicate which allowed calculation of standard deviations for all backbone cleavage 
efficiency values. For comparison of the cleavage yield at a given residue for two different 
protein states, Student’s t-test was used to ensure that the variation in the measurements 
(i.e. standard deviation) was significantly smaller than the difference between the two 
values. Briefly, pooled standard deviations were used to calculate t-values which were 
converted to p-values, assuming a two-tailed test. Only those residues with values 
exceeding the confidence threshold 99% (corresponding to a p-value < 0.01) were 
considered statistically significant and discussed as structural changes in the protein. 
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Chapter 3: Tracking the Catalytic Cycle of Adenylate Kinase by 
Ultraviolet Photodissociation Mass Spectrometry* 
3.1 OVERVIEW 
The complex interplay of dynamic protein plasticity and specific side-chain 
interactions with substrate molecules that allows enzymes to catalyze reactions has yet to 
be fully unraveled. Herein the phosphotransferase adenylate kinase (AK) provides a 
tractable framework for development of native mass spectrometry and top-down ultraviolet 
photodissociation (UVPD) as a new tool for tracking conformational fluctuations of active 
enzymes throughout a given reaction cycle. Complexes containing AK and one of four 
adenosine phosphate ligands were transferred to the gas-phase using nano-electrospray 
ionization and subsequently characterized with UVPD-MS. Ligand-containing holo 
fragment ions were mapped to establish the locations of the substrates in their respective 
binding pockets. Variations in efficiencies of UVPD backbone cleavages were consistently 
observed for three α-helices and the adenosine binding regions for AK complexes 
representing different steps of the catalytic cycle, implying that these stretches of the 
protein sample various structural microstates as the enzyme undergoes global open-to-
closed transitions. Focusing on the conformational impact of recruiting or releasing the 
Mg2+ cofactor highlights two loop regions for which fragmentation increases upon UVPD, 
signaling an increase in loop flexibility as the metal cation disrupts the loop interactions 
with the substrate ligands. Additionally, the observation of holo ions and variations in 
UVPD backbone cleavage efficiency at R138 implicate this conserved active site residue 
in stabilizing the donor phosphoryl group during catalysis. This study establishes the utility 
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of UVPD-MS for providing information on several different scales ranging from global 
movements down to conformational fluctuations of single residues for active enzymes. 
3.2 INTRODUCTION 
Enzymes are powerful catalysts capable of accelerating chemical reaction rates 
several orders of magnitude allowing biochemical processes to take place on biologically 
relevant timescales. Despite the enormous headway in deciphering the interplay of side-
chain residues, cofactors, and overall protein plasticity that contributes to a suitable 
electrostatic environment amenable for promoting a given chemical reaction, a 
comprehensive understanding of enzymatic catalysis is still lacking.1–4 One well-studied 
enzyme known to undergo a large conformational change from an open inactive state to a 
closed active state is adenylate kinase (AK).5 Acting to maintain the energy balance in 
cells, this protein catalyzes the reversible phosphoryl transfer reaction starting with 
adenosine 5’-monophosphate (AMP) and adenosine 5’-triphosphate (ATP) which results 
in production of two adenosine 5’-diphosphate (ADP) molecules.6 Strategies involving 
elaborate computer simulations and ultrafast laser spectroscopy have complemented the 
static three-dimensional structures provided by crystallography and NMR studies to 
identify the specific residues of AK, in concert with a divalent Mg cofactor, which play 
key roles in the acceleration of phosphoryl transfer.7–22 However, controversy still remains 
over whether individual high-frequency local fluctuations in the enzyme’s structure 
facilitate large conformational transitions on the timescale of catalytic turnover and 
significantly contribute to an increase in efficiency of transferring the phosphoryl 
moiety.2,3,12,14,15,22–24 Given that catalytic mechanisms often involve several microscopic 
steps occurring over a hierarchy of time and distance, development of novel tools for 
unraveling these complex processes would represent a compelling advance.3,22 
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Mass spectrometry (MS) has shown promise in recent years for the development of 
sensitive, higher-throughput approaches to addressing structural biology questions.25 
Bottom-up strategies involving covalent chemical probes, including hydrogen/deuterium 
exchange (HDX) and cross-linking of reactive residues, have cemented the pivotal role of 
tandem mass spectrometry (MS/MS) in examining the native structures of proteins.26–29 
Although these covalent labeling techniques have been successfully applied to evaluate 
solvent accessibilities, reveal distance restraints, and determine transient protein-protein 
interactions, the development of less chemically intensive top-down MS methods has 
provided an alternative non-proteolytic strategy.29 Native MS methods allow the efficient 
transfer of proteins and protein complexes into the gas phase in low charge states via 
electrospray ionization of buffered solutions that contain volatile salts, most commonly 
ammonium acetate.30,31 Despite the questions that still remain concerning the specific 
mechanism of native electrospray ionization (ESI), measurements of collisional cross 
sections by ion mobility MS suggest the charged proteins and protein complexes maintain 
to a large extent the folded tertiary and quaternary structures adopted in solution.32–34 
Applications of native MS to determination of stoichiometries and binding/dissociation 
constants of protein-ligand and protein-protein complexes continue to grow.  Moreover, 
even the ability to elucidate conformational changes occurring during ligand interactions 
and/or unfolding has been demonstrated.30,31,35–41 Time-resolved electrospray ionization 
(ESI) and HDX MS experiments have been previously used to directly monitor enzymatic 
reactions on millisecond time scales and detect transient covalent intermediates.42–44 
The development of MS/MS methods sensitive to protein structure has further 
advanced the utility of native MS. Electron-based activation techniques, including electron 
transfer dissociation (ETD)45 and electron capture dissociation (ECD),46–50 yield significant 
sequence coverage with abundances of the resulting fragments correlating with 
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crystallographic B-factors.49,50 Fragments reflecting the degree of flexibility of certain 
regions are thought to arise from salt bridges in proteins that may be strong enough in the 
gas phase to survive exothermic electron-transfer reactions.45 Surface-induced dissociation 
(SID) is another activation method that has found great utility for decoding the quaternary 
structures of protein-protein complexes.51 A third activation method, ultraviolet 
photodissociation (UVPD), offers unsurpassed levels of diagnostic backbone 
fragmentation for both denatured and natively sprayed proteins via fast high-energy 
excitation caused by absorption of 193 nm photons.38–41,52–54 UVPD yields both holo 
(ligand-bound) and apo (free of ligand) product ions with ion abundances that reflect 
secondary or tertiary protein structure, thus offering both localization of non-covalent 
protein-ligand interaction sites and structural characterization of complexes.38–41 
Suppression or enhancement in UVPD cleavage efficiencies at certain positions along the 
protein backbone may result from variations in secondary or tertiary features occurring in 
other regions of the protein structure.40 Furthermore, ion mobility MS measurements of 
ubiquitin have demonstrated that UVPD fragmentation patterns vary for different gas-
phase conformers, a particularly interesting outcome that demonstrates the sensitivity of 
UVPD to protein structure.55,56 Most recently UVPD fragmentation patterns were used to 
monitor stepwise loop movements of dihydrofolate reductase (DHFR) upon binding of co-
factor NADPH and inhibitor methotrexate, and to delineate conformational changes caused 
by clinically relevant single point G12X mutants of K-Ras bound to guanosine phosphate 
ligands.40,41 These previous studies have demonstrated the versatility of UVPD-MS for 
monitoring conformational changes in proteins arising from binding different ligands or 
from subtle mutations in protein sequence. The aim of the present work is to evaluate the 
utility of UVPD for tracking the conformational dynamics of an active enzyme throughout 
its catalytic cycle. 
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Here we present native MS and top-down UVPD of binary and ternary complexes 
of AK with AMP, ADP, ATP, and P1, P4-di(adenosine-5’)tetraphosphate (AP4A) inhibitor, 
mirroring the steps of its enzymatic cycle. Previously native MS has been used to screen 
metal-chelating to AKs and quantify association constants with various noncovalent 
inhibitors.57,58 More recently, phosphate-bound fragment ions observed upon ECD and 
collision-induced dissociation (CID) were used to elucidate ATP binding sites of the 
enzyme sequence.59 Comprehensive studies of the AK energy landscape along the reaction 
pathway at the molecular level point to the precise placement of a divalent Mg cofactor, 
conserved Arg residue, and conformational fluctuations in the protein as possible 
explanations for the efficient phosphoryl transfer and suppression of detrimental 
hydrolysis.2,3,12,16,19,22 These studies using traditional structural biology methods provide a 
comparative framework for the gas-phase UVPD approach used in the present work. 
Building on these results, we track variations in UVPD of AK throughout its catalytic cycle 
to shed light on the roles of local unfolding during a global open-to-closed transition, a 
divalent metal cofactor, and interactions of the ligands with a conserved residue in 
assembling the pre-organized active site essential for catalysis. Our work highlights the 
utility in developing novel approaches that may provide a deeper understanding of the 
general mechanism of enzyme catalysis. 
3.3 EXPERIMENTAL 
3.3.1 Materials and Reagents 
Adenosine 5’-monophosphate (AMP) monohydrate, adenosine 5’-diphosphate 
(ADP), adenosine 5’-triphosphate (ATP) disodium salt hydrate, P1, P4-di(adenosine-
5’)tetraphosphate (AP4A) ammonium salt, ammonium acetate, magnesium acetate 
tetrahydrate, and adenylate kinase (AK) (myokinase from chicken muscle) were purchased 
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from Sigma-Aldrich (St. Louis, MO). Protein samples were desalted and concentrated to 
10 µM at pH 6.5 buffered with 10 mM ammonium acetate containing 10 µM magnesium 
acetate using 10 kDa molecular weight cutoff filter devices (Millipore, Billerica, MA). 
Adenosine phosphate ligands were added to the protein solution at a 1:1 ratio after 
desalting. 
3.3.2 Mass Spectrometry 
Equimolar protein-ligand solutions were infused with a gold-coated static tip 
electrospray setup operated at an applied voltage of 1.0-1.2 kV. A heated capillary set at 
200°C aided in desolvation of protein-ligand complexes. All experiments were performed 
on a Thermo Scientific Orbitrap Elite mass spectrometer (Bremen, Germany) modified as 
previously described52 with a Coherent Excistar 193 nm ArF excimer laser (Santa Cruz, 
CA) to perform photodissociation in the HCD cell. All spectra were collected with a 
resolving power of 240 K at m/z 400. For MS1 spectra, sixty scans were averaged with an 
automatic gain control (AGC) set to achieve a signal level of 1E6. MS/MS analysis 
involved selection of the 9+ charge state of each protein-ligand complex using an isolation 
width of 15-20 m/z and activation by exposure to a single 3 mJ pulse. For UVPD 
experiments, the AGC value was set to 5E5 with a maximum ion time of 2 s. Each UVPD 
mass spectrum represents the average of 500 scans of the Orbitrap mass analyzer over a 
range from m/z 220-4000. Three replicates of MS/MS spectra were collected for each 
protein-ligand complex. 
3.3.3 Data Analysis 
Xtract was used to de-charge and de-isotope UVPD MS/MS spectra with a signal-
to-noise ratio of 2, fit factor of 44%, and remainder of 25%.  Monoisotopic fragment ions 
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were then searched against the AK amino acid sequence using a version of ProSight PC 
3.0 modified to account for the nine ion types observed with UVPD (a, a•, b, c, x, x•, y, y-
1, z). Figure 3.1 gives the sequence of AK (Gallus gallus) and the structures of the 
adenosine phosphate ligands. Residues are numbered from the first serine (S) in subsequent 
figures and all N-terminal fragment ions were identified containing an N-terminal 
acetylation (+42.0106 Da).  
 
 
 
Figure 3.1: (A) Sequence of adenylate kinase (AK) isoenzyme 1 (Gallus gallus). 
Residues are numbered from the first serine (S) in subsequent figures. All N-
terminal fragment ions were identified containing an N-terminal acetylation 
(+42.0106 Da). (B) Structures of the adenosine phosphate ligands: (1) AMP, 
(2) ADP, (3) ATP, and (4) AP4A. 
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Holo ions were also considered by searching the spectra for fragment ions with a mass shift 
corresponding to the mass of the bound adenosine phosphate ligand and coordinating Mg2+. 
Plots of the number of holo fragment ions identified versus the mass shift searched relative 
to the apo fragment ions for each of the AK•ligand complexes examined are given in 
Figure 3.2. Specifically, mass shifts included in the searches are: 345.0474-347.0631 Da 
for AMP, 425.0138-427.0294 Da for ADP, 504.9800-506.9957 Da for ATP, 834.0326-
836.0483 Da for AP4A, and 852.0432-854.0588 Da for AMP + ATP/ADP + ADP. A 
+21.9694 Da shift was used to account for the presence of the Mg2+ cofactor (e.g., addition 
of one Mg atom and loss of two hydrogen atoms).  
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Figure 3.2: Number of holo (ligand-containing) fragment ions identified plotted versus 
the mass shift searched relative to the apo fragment ions for each of the (A) 
binary and (B) ternary (with and without the Mg2+ cofactor) AK•ligand 
complexes examined. The mass shifts specifically included in the searches 
are: 345.0474-347.0631 Da for AMP, 425.0138-427.0294 Da for ADP, 
504.9800-506.9957 Da for ATP, 834.0326-836.0483 Da for AP4A, and 
852.0432-854.0588 Da for AMP + ATP/ADP + ADP. A +21.9694 Da shift 
was used to account for the presence of the Mg2+ cofactor. 
To determine cleavage yields at each backbone position upon UVPD, the abundances of 
identified holo and corresponding apo ions were normalized to the total ion current of the 
spectrum and summed per residue along the protein backbone as previously described.40,41 
Briefly, N-terminal fragment ions (an, bn, cn) resulting from cleavage of the backbone C-
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terminal to a given amino acid were collectively summed with C-terminal product ions (xR-
n+1, yR-n+1, zR-n+1) arising from fragmentation N-terminal to that same amino acid to 
represent the UVPD cleavage efficiency for a specific residue, n, in a protein sequence with 
R amino acids. Figure 3.3 gives the normalized TIC abundances of summed holo and apo 
product ions plotted per residue for the AK•ligand complexes examined. Statistical 
significance of a change in backbone cleavage efficiency upon UVPD between steps of the 
catalytic cycle was determined using student’s t-test with pooled standard deviations. P-
values were determined from calculated t-values assuming a two-tailed test. Consequently, 
for a given residue, a p-value smaller than 0.01 indicates that the average measured UVPD 
intensity within a triplicate measurement is statistically different from the measured 
average in the subsequent step of the catalytic cycle at the 99% confidence level. Calculated 
p-values per residue corresponding to the differences in UVPD cleavage efficiency 
throughout the catalytic cycle are given in Figure 3.4. A histogram of calculated p-values 
over the entire data set reveals that over 32% of all measured differences in backbone 
cleavage efficiency are significant at the 99% confidence level (Figure 3.4B). An overlay 
of the UVPD cleavage efficiency plot for each of five separate replicates collected for the 
AK•ATP complex demonstrates the high reproducibility of the measurements (Figure 3.5).  
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Figure 3.3: Normalized TIC abundance of summed holo and apo product ions plotted per 
residue for the (A) binary and (B) ternary AK•ligand complexes examined. 
These plots were used to create the difference plots shown in Figure 3.15. For 
each binary complex in (A), the UVPD data for apo AK is shown as a 
reference. For each ternary complex in (B), the UVPD data for a second 
binary or ternary complex of interest is shown as a reference. 
 
 
 65 
 
Figure 3.4: (A) Calculated p-values per residue corresponding to the differences plotted 
in Figure 3.15 with a confidence threshold at 99% shown as a gray dotted line. 
(B) Histogram of calculated p-values over the entire data set with the 
cumulative percentage shown in blue. Student’s t-test was performed for each 
comparison of UVPD between the steps of the catalytic cycle using pooled 
standard deviations. P-values were determined from calculated t-values 
assuming a two-tailed hypothesis. Consequently, for a given residue, a p-
value smaller than 0.01 indicates that the average measured UVPD intensity 
within a triplicate measurement is statistically different from the measured 
average in the subsequent step of the catalytic cycle at the 99% confidence 
level. 
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Figure 3.5: Overlay of the normalized TIC abundances of summed holo and apo product 
ions plotted per residue for five separate replicates of UVPD activation of the 
AK•ATP complex. The average of the five replicates is given as a gray dotted 
line with the error bars corresponding to the standard deviation. Inset shows 
an expanded view for residues 74-108. 
A diagram of the crystal structure of AK•AP4A (PDB ID: 2C95)60 used as a model is given 
in Figure 3.6 with the three domains (CORE, AMP binding domain (bd), and ATP lid) 
color coded and the conserved residue R138 shown in stick format closing over the active 
site. 
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Figure 3.6: The three domains of AK (CORE, AMP binding domain, and ATP lid) color 
coded on the crystal structure of the protein bound to AP4A (PDB ID: 2C95). 
The bound ligand is represented as sticks with the AMP portion shown in 
purple and ATP portion in orange. Conserved residue R138 is also shown as 
sticks closing over the active site. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Native MS and UVPD of AK-Ligand Complexes 
Mirroring the steps of the catalytic cycle, native MS conditions were used to 
transfer complexes containing AK non-covalently bound to AMP, ADP, ATP, or AP4A 
into the gas phase by electrospray ionization. Low charge states (8+, 9+, 10+) characteristic 
of native-like proteins were observed for each protein-ligand complex (Figure 3.7A-F, 
including AK, AK•AMP, AK•ADP, AK•ATP, AK•AP4A, AK•AMP•ATP, 
AK•AMP•ATP-Mg, AK•ADP•ADP, and AK•ADP•ADP-Mg). Although present in each 
solution, the divalent Mg cofactor only bound to the ternary complexes (Figure 3.7G-I). 
Catalytic products (AMP, ADP, ATP-Mg) were observed in the ESI mass spectra for the 
ternary complexes containing Mg but not when bound to the AP4A inhibitor, thus 
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indicating that the protein adopted an enzymatically active conformation during analysis 
(Figure 3.8).  
 
 
Figure 3.7: ESI mass spectra (2000-3000 m/z) of natively sprayed (A) apo AK with a 1:1 
ratio of (B) AMP, (C) ATP, (D) AMP + ATP, (E) ADP, and (F) AP4A present 
in solution. The colored circles identify the species observed in each spectrum 
for the 9+ charge state. An expanded view of mass range 2380-2530 m/z 
demonstrates that only Na+ adducts were observed for (G) apo AK and binary 
complexes including (H) AK•ATP while one Mg2+ was bound to the ternary 
complexes as shown for (I) AK•AMP•ATP (and also for AK•ADP•ADP, 
spectrum not shown). Mg2+ was present in each solution at a 1:1 ratio with 
AK. 
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Figure 3.8: Mass range 300-600 m/z of ESI mass spectra for complexes of AK sprayed 
with Mg and (A) AMP:ATP (1:1:1), (B) ADP (2:1), or (C) AP4A (1:1) 
demonstrating that the enzyme was catalytically active during analysis except 
when bound to the AP4A inhibitor. 
For each complex examined, the most abundant charge state (9+) was subsequently isolated 
and subjected to 193 nm UVPD to yield the informative fragmentation patterns in Figure 
3.9. Although the spectra appear congested, expansions of specific segments of the m/z 
range show isotopically resolvable fragment ions that are readily assigned as diagnostic 
sequence ions (Figure 3.9J).  
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Figure 3.9: (A-I) UVPD mass spectra of the 9+ charge state of AK•ligand complexes 
activated using a single 3 mJ pulse. (J) Expanded view (1700-1750 m/z) of 
panel (A) with selected fragment ions labelled. The sequence coverage 
obtained was between 74-83% for all complexes examined. The red diamond 
(B, F-I) indicates loss of intact AMP during activation. 
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Deconvoluted spectra were created from raw UVPD spectra using Xtract to decharge the 
fragment ions (Figure 3.10). High sequence coverage (74-83%) was obtained for all nine 
complexes examined. More extensive details on assignment of apo (without ligand) and 
holo (ligand-containing) fragment ions, and data interpretation are given in the 
Experimental section. 
 
 
Figure 3.10: (A-I) Deconvoluted UVPD mass spectra (corresponding to the spectra in 
Figure 3.9) of all AK•ligand complexes examined (9+ charge state) 
performed using one 193 nm pulse at 3 mJ. Several abundant fragment ions 
are labelled in (A). The asterisks (G-I) represent surviving precursor that 
resulted as an artifact during deconvolution. 
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3.4.2 Mapping UVPD Holo Fragment Ions to Examine Ligand Binding Sites 
Previously it was reported that the intrinsic stability of electrostatic interactions 
governing the binding of adenosine phosphate ligands allowed the survival and detection 
of protein fragment ions containing mono- and diphosphate groups and release of the 
truncated adenosine monophosphate upon CAD or ECD of AK•ATP complexes in the gas 
phase.59 A subsequent study found that using supercharging reagents, such as m-
nitrobenzyl alcohol and sulfolane, to increase the charge state of the precursor allowed 
production of AK fragment ions bound non-covalently to intact ATP upon ECD.61 
Interestingly, UVPD has been shown to produce fragment ions retaining intact nucleotide 
phosphate ligands without the need for supercharging reagents for eIF4E•m7GTP, 
DHFR•NADPH, and K-Ras•GDP/GTP complexes.38,40,41 The retention of entire nucleotide 
phosphate ligands upon UVPD rather than retention of individual phosphate groups upon 
CAD or ECD59 is attributed to the higher energy deposition upon absorption of 193 nm 
photons which presumably favor cleavage of backbone bonds of the protein rather than 
cleavage of labile phosphate bonds.38,40,41 Classifications of the patterns and relative 
abundances of the extensive array of N- and C-terminal holo (ligand-containing) sequence 
ions resulting from UVPD as a function of backbone cleavage site has shown to be 
predictive for ligand binding sites.38,40,41 In particular regions with overlapping N- and C-
terminal holo fragment ions are anticipated to be directly involved in non-covalent 
interactions with the bound ligand.40,41 In the present study, holo fragment ions containing 
the intact adenosine phosphate ligands were observed for each of the complexes examined. 
Figure 3.11 displays the distribution of holo fragment ions for the binary and ternary AK 
complexes with the specific residues containing bidirectional holo ions (e.g., bidirectional 
holo ions are those for which both N-terminal and C-terminal fragment ions retain the 
ligands and share overlapping residues) highlighted in red. These regions demarcated by 
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the holo fragment ions are represented as red spheres on space-filled models on the crystal 
structure of the protein (PDB ID: 2C95)60 in Figure 3.12 to aid in visualization of the 
putative binding locations of the adenosine phosphate ligands. 
 
 
Figure 3.11: Plots of the normalized abundances of N-terminal (blue) and C-terminal 
(green) holo fragment ions produced upon UVPD per residue for the (A) 
binary and (B) ternary AK•ligand complexes examined. For the ternary 
complexes, the plots reflect product ions that retain only a single ligand (either 
AMP in B(1), ADP in B(2), or ATP in B(3)). The complementary plots 
showing retention of both ligands upon UVPD of the ternary complexes are 
displayed in Figure 3.13. Residues with overlapping N- and C-terminal holo 
ions are shaded in red. 
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Figure 3.12: Potential adenosine phosphate ligand binding residues derived from 
overlapping N- and C-terminal holo fragment ions produced by UVPD of (A) 
binary and (B) ternary AK•ligand complexes represented as red spheres in 
space-filling models of the crystal structure of the protein bound to AP4A 
(PDB ID: 2C95). 
For the binary complexes, ATP was retained preferentially compared to either AMP 
or ADP as evidenced by the overall greater number and higher abundance of holo ions (88, 
71, and 164 unique holo fragment ions for AK•AMP, AK•ADP, and AK•ATP respectively) 
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(Figure 3.11A). This outcome correlates well with crystallographic data and molecular 
modelling that suggest the phosphate groups of ATP are more strongly bound to the 
enzyme than the adenosine moiety while the converse is true for AMP.11,62 In essence, the 
hydrogen bonding network established between protein side-chains and the adenosine ring 
of AMP, a network that allows high nucleotide monophosphate specificity in the binding 
pocket, is less stable in the gas phase and more likely to disassemble during photoactivation 
than the strong electrostatic interactions formed between the phosphate portion of ATP and 
positively polarized side-chains of the protein.  
For two of the ternary complexes (AK•AMP•ATP and AK•ADP•ADP), the 
majority of holo fragment ions contained both ligands (e.g., 93 unique fragment ions 
contained both AMP and ATP for AK•AMP•ATP and 79 unique fragment ions contained 
both ADP molecules for AK•ADP•ADP) (Figure 3.13).  
 
 
Figure 3.13: Plots of the normalized abundances of N-terminal (blue) and C-terminal 
(green) holo fragment ions retaining both ligands upon UVPD for the (A) 
AK•AMP•ATP and (B) AK•ADP•ADP ternary complexes. Residues with 
overlapping N- and C-terminal holo ions are shaded in red. 
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To streamline deciphering the location of each ligand within the binding pocket, it is most 
informative to search for holo fragment ions originating from the ternary complex but only 
retaining one of the ligands (Figure 3.11B). AMP and ATP were traced back to their 
respective binding sites in AK while evidence of ADP binding was found for both regions. 
As an example, analysis of the AK•AMP complex yielded overlapping holo fragment ions 
from both the N- and C- terminus for residues in the AMPbd (L57, Q58) and ATPlid (D140) 
regions suggesting that this ligand is promiscuous in the absence of ATP (Figure 3.12A(1) 
AK•AMP). However in the presence of ATP, only residues in the AMP adenosine binding 
region (L57, E65) yielded bidirectional AMP-bound holo fragment ions for the ternary 
complex (Figure 3.12B(1) AK•AMP•ATP). Evidence of ADP interactions were only 
found involving residues in the ATP adenosine binding region (S19, G20) for the binary 
AK•ADP complex, further supporting the high monophosphate nucleotide specificity of 
the AMP binding pocket (Figure 3.12A(2) AK•ADP).11,62–64 For the ternary complex 
containing two ADP molecules, N- and C-terminal holo fragment ions incorporating 
residues in the adenosine binding regions of both AMP (E65) and ATP (P17, S19) were 
identified (Figure 3.12B(2) AK•ADP•ADP). For both the binary and ternary complexes 
involving ATP, both N- and C-terminal fragment ions retaining ATP spanned residues 
from the ATP adenosine binding (S19, G22, T23) and ATPlid (K131, R132, R138) regions 
(Figure 3.12A(3) AK•ATP, and 3.12B(3) AK•AMP•ATP). This finding correlates well 
with previous top-down MS data that identified amino acids G121-D140 in the ATPlid 
region as the primary binding site of ATP as well as an additional minor site at residues 
D141-D180.59 Prior data supported the role of several conserved arginines (R44, R97, 
R132, R138, R149) in binding ATP; however, the Gly-loop making up the ATP adenosine 
binding region (G18-T23) was not previously implicated59 but is identified in the current 
study. Even though these interactions were too labile to survive collisional activation, in 
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the present study UVPD did not disrupt these interactions and key ATP-bound holo ions 
were observed from this region for both the binary and ternary complexes. 
3.4.3 Conformational Changes throughout the Catalytic Cycle 
Enzymatic activity is often governed by a dynamic interplay between structure and 
stability but understanding this linkage between plasticity and activity is still in its infancy. 
For AK, which is known to undergo a large conformational transition from an open inactive 
to a closed active state, it has been established that dynamic sampling of several structural 
microstates limits the rate of substrate molecule turnover.10,12,14–19 Unlike other protein 
kinases that require specific protein-protein interactions or covalent modifications to 
enable catalytic activity, the presence of two adenosine phosphate substrates is all that is 
necessary for AK to catalyze a reversible reaction; thus making it amenable to experimental 
and theoretical studies aimed at identifying specific residues that contribute to opening and 
closing, and the timescale of these events. Based on these previous studies, almost 
exclusively focused on AK from E. coli, the AMPbd and ATPlid regions are implicated as 
undergoing the largest conformational changes and the rate of catalytic turnover is limited 
by opening of these regions after phosphoryl transfer to release product molecules.12,14,16–
19,22 One aim of the current study is to assess the sensitivity of UVPD-MS to some of the 
more subtle structural changes AK undergoes during its catalytic cycle. In an effort to 
identify these we focused on AK from Gallus gallus (PDB ID: 2C95)60 which has 
abbreviated AMPbd and ATPlid regions compared to AK from E. coli (PDB ID: 1AKE)
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(Figure 3.14). These two regions still close over the active site to align the substrates for 
phosphoryl transfer and prevent hydrolysis, but owing to the shortened active site loops, 
dynamic fluctuations throughout the remainder of the enzyme during catalysis have a more 
significant impact.  
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Figure 3.14: Overlay of the crystal structures of AK from Homo sapiens (gray; PDB ID: 
2C95) and E. coli (blue; PDB ID: 1AKE) bound to AP4A (92% and 55% 
sequence homology, respectively, with AK from Gallus gallus). The bound 
ligand is represented as sticks with the AMP portion shown in purple and ATP 
portion in orange. The most significant differences in structure are highlighted 
with ovals and occur in the ATPlid and AMPbd regions that are abbreviated in 
AK from Homo sapiens and Gallus gallus. As such, AK from Gallus gallus 
is smaller in size (21.5 kDa, 193 amino acids) than AK from E. coli (23.4 
kDa, 213 amino acids). 
Conformational information was inferred from backbone cleavage efficiencies 
across the protein determined by analysis of both holo and apo fragment ions upon 
UVPD.39–41 In particular, we are interested in the changes in UVPD backbone cleavage 
efficiencies that occur during each step of the reaction cycle. Enhancement or suppression 
of backbone cleavages upon UVPD depend on the flexibility, e.g., the extent to which a 
given region is involved in stabilizing intramolecular interactions.39–41 Cumulative 
evidence suggests that regions where UVPD fragmentation of a protein or protein complex 
is suppressed (relative to an analogous protein or protein complex in another state) 
indicates enhanced stabilization owing to conformational changes, variations in 
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intramolecular interactions, or other factors.39–41 The efficiency of backbone cleavage upon 
UVPD relative to each amino acid for each AK•ligand complex is represented graphically 
in Figure 3.3. To visualize these changes in backbone cleavage efficiency for each of the 
eight steps of the AK catalytic cycle, difference plots were constructed by subtraction of 
the summed holo and apo fragment ion abundances for a given step in the cycle from the 
previous step (Figure 3.15). As shown in Figure 3.15, values that fall below the zero axis 
indicate a decrease or suppression of UVPD, whereas values that lie above the zero axis 
indicate an increase or enhancement of fragmentation. Considering all of the steps of the 
reaction cycle, most of the significant variations in backbone cleavage efficiency upon 
UVPD occur in the adenosine binding region of ATP and α-helices of the AMPbd. Those 
amino acids (representing backbone cleavage sites along the sequence of AK) for which 
reproducible and statistically significant variations were observed are highlighted on the 
structure of AK•AP4A in Figure 3.16 for each step of the catalytic cycle. Red-colored 
residues designate an increase in backbone cleavage upon UVPD compared to the previous 
step in the cycle, thus implying weakened or reduced intramolecular interactions. 
Conversely blue-colored residues denote a decrease in cleavage efficiency suggesting 
engagement in new intramolecular interactions that stabilize the structure. Figure 3.17 
showcases five regions of the enzyme (α1, α2, α3 helices, AMP and ATP adenosine binding 
regions) found to consistently undergo significant conformational changes throughout the 
enzymatic cycle (based on the UVPD data) highlighted on the crystal structure of AK 
bound to AP4A. 
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Figure 3.15: Difference plots showing the change in summed abundances of holo and apo 
fragment ions produced upon UVPD of each AK•ligand complex throughout 
the entire catalytic cycle of the enzyme. The UVPD fragmentation plot for 
each individual complex is shown in Figure 3.3. The dotted line indicates the 
position of R138. Relevant helices (α1, α2, α3) and regions (adenosine 
binding regions of AMP and ATP, AMPbd, ATPlid) are labelled underneath 
the x-axis using colors corresponding to Figure 3.16. 
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Figure 3.16: Tracking the enhancement (red) and suppression (blue) of UVPD throughout 
the entire catalytic cycle impressed on a crystal structure of AK bound to 
AP4A (PDB ID: 2C95): apo AK binding to form binary complexes (step 1 to 
2A,B), each transitioning to the ternary complex (step 2A,B to 3), recruiting 
the Mg2+ cofactor (step 3 to 4), closing into the transition state (step 4 to 5), 
producing two ADP molecules (step 5 to 6), losing the cofactor (step 6 to 7), 
and releasing ADP (step 8 to 1). The colored regions reflect statistically 
significant changes in UVPD backbone cleavage efficiency for the difference 
plots shown in Figure 3.15. Three key helices are labelled in step 1 to 2A. 
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Figure 3.17: Five regions of the protein consistently undergoing significant fragmentation 
changes based on UVPD, indicative of conformational changes throughout 
the enzymatic cycle highlighted on the crystal structure of AK bound to AP4A 
(PDB ID: 2C95). 
In detail, following a random bi-bi mechanism during catalysis (i.e., two substrates 
on, two substrates off), either AMP or ATP can bind apo AK and cause suppression of 
backbone cleavage in the AMPbd and AMP adenosine binding region (Figure 3.16(step 1 
to 2A)) or K21 of the ATP adenosine binding region (Figure 3.16(step 1 to 2B)). 
Enhancement in the degree of fragmentation of the α1 helix for both states suggests a global 
opening of the protein during binary complex formation. Addition of the second cognate 
ligand to each of the binary complexes to form the ternary AK•AMP•ATP complex results 
in similar changes in UVPD cleavage efficiencies: most notably significant enhancement 
of fragmentation in the α1, α2, and α3 helices (Figure 3.16(steps 2A, 2B to 3)). This 
outcome is consistent with further opening of AK to accommodate a second ligand as well 
as local conformational fluctuations of these three helices to align the reactive atoms of the 
substrate ligands during catalysis. Recruitment of the Mg2+ cofactor leads to further 
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enhancement of fragmentation in these helical regions, a result that parallels the increased 
catalytic efficiency of AK as these regions dynamically sample different microstates to 
carry out the enzymatic function (Figure 3.16(step 3 to 4)). Locking the protein in the 
transition state with inhibitor AP4A causes significant suppression of UVPD backbone 
cleavage efficiency in the α1 and α3 helices. As expected this supports that the protein is 
trapped in a closed but catalytically inactive conformation (Figure 3.16(step 4 to 5)). 
Fragmentation throughout the α1 and α3 helices is again enhanced transitioning to the 
catalytically active ternary complex containing two ADP products and the Mg2+ cofactor 
(Figure 3.16(step 5 to 6)). Removal of the cofactor causes significant suppression of 
fragmentation throughout the entire protein, especially in the α1 and α3 helices; this 
corresponds to the step in which the catalytic efficiency of the protein is markedly 
decreased (Figure 3.16(step 6 to 7)). Similar suppression of UVPD is observed as one 
ADP product molecule is released implying local unfolding of these regions has ceased 
(Figure 3.16(step 7 to 8)). Loss of the second product ADP molecule to yield apo AK 
returns the protein to an open, inactive conformation, suggested by the significant 
enhancement in UVPD cleavage efficiency throughout the three α-helices (Figure 
3.16(step 8 to 1)). In general, tracking the variations in UVPD fragmentation during the 
catalytic cycle specifically implicates the α-helices of the AMPbd and the adenosine binding 
regions of AMP and ATP as key features that undergo significant reorganization during 
the catalytic reaction trajectory of AK (Figure 3.17). 
Given that the catalytic efficiency is not being measured during ESI-UVPD-MS 
analysis, conclusions about whether the apparent conformational fluctuations play a role 
in the chemical step of enzyme catalysis or to what extent they assist in pre-organizing 
active site residues in the configuration needed to facilitate the phosphoryl transfer cannot 
be drawn. However, it has been previously demonstrated that addition of a small amount 
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of denaturant, specifically urea, to AK complexes redistributes preexisting structural 
microstates and stabilizes a substrate-bound open state at the expense of a substrate-bound 
closed state. This urea-dependent structural redistribution resulted in an increase in 
catalytic activity of AK and was attributed to an increased rate for the rate-limiting lid 
opening step.66 Additionally, previous in vacuum molecular dynamics simulations of AK 
conclude that although the absolute magnitude of the fluctuations is different in the gas 
phase (as would be expected without solvent present), the same regions of the protein 
(AMPbd and ATPLID) have the highest rms deviation values from the crystal structure 
during ligand binding and catalysis for both solution and the gas phase.67–69 In summary, 
UVPD-MS appears to be sensitive to the dynamic conformational equilibria that exist as 
AK samples various structural microstates in the presence of substrates to align reactive 
atoms during catalysis. 
3.4.4 Examining the Impact of the Mg2+ Cofactor 
Metal ion cofactors are often required for enzyme catalysis but controversies 
regarding the specific role of Mg cofactors in kinase catalysis remain. Specifically, some 
kinases are activated by a single Mg2+ ion while for others binding of additional Mg2+ might 
be necessary or may result in inhibition of the enzyme.22 A recent comprehensive study of 
the energy landscape of AK during its reaction cycle investigated the mechanism of 
transition state stabilization and demonstrated a single divalent Mg2+ ion as a key player in 
both orienting active site groups on the ligands for efficient phosphoryl transfer and 
facilitating opening of the AMPbd and ATPlid after reaction catalysis.
22 In addition to 
balancing the negative charge of the adenosine phosphate ligands in the active site, the 
positively charged Mg2+ maintains its position during the transition state and acts as an 
electrostatic pivot to anchor the donor phosphoryl group for a more favorable nucleophilic 
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attack by the oxygen of the acceptor ligand.22,70 Additionally the cation serves to weaken 
strong electrostatic interactions that coordinate the Arg side-chains and phosphates of the 
adenosine ligands to accelerate opening of the complex, the rate-limiting step of catalysis 
for this enzyme.22 UVPD-MS can provide complementary insight into changes of the 
protein conformation in response to the recruitment or release of the Mg2+ cofactor during 
the catalytic cycle.  
Specifically, examining the variations in AK fragmentation after binding and 
release of the metal ion reveals residues that may be engaging in new interactions 
(suppressed backbone cleavage) or are situated in regions that become flexible after 
weakening of previous interactions (enhanced backbone cleavage).39–41 Figure 3.18 gives 
an expanded view of steps 3-7 from Figure 3.16 demonstrating the enhancement (red) and 
suppression (blue) of UVPD upon addition of the Mg2+ cofactor (step 3 to 4), locking into 
the transition state (step 4 to 5), yielding two ADP molecules (step 5 to 6), and releasing 
the Mg2+ cofactor (step 6 to 7). 
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Figure 3.18: Expanded view of steps 3-7 from Figure 3.16 demonstrating the enhancement 
(red) and suppression (blue) of UVPD (step 3 to 4) upon addition of the Mg2+ 
cofactor, (step 4 to 5) locking into the transition state, (step 5 to 6) yielding 
two ADP molecules, and (step 6 to 7) releasing the cofactor. The green ovals 
highlight two regions that are engaged in stabilizing interactions with the 
phosphate groups of the adenosine substrates and where significant variations 
in UVPD backbone efficiency are observed as the Mg2+ cation is recruited 
and released. 
The green ovals in Figure 3.18 highlight two regions that are engaged in stabilizing 
interactions with the phosphate groups of the adenosine substrates and exhibit significant 
variation in UVPD backbone cleavage efficiency as the Mg2+ cation is recruited and 
released. In particular, enhancement in fragmentation of the loop binding the phosphates 
of ATP (G15-K21) is observed upon Mg2+ binding (Figure 3.18(step 3 to 4) and Figure 
3.16(step 3 to 4)). This result supports the role of Mg2+ in interrupting intramolecular 
interactions between the side-chains of the protein and the phosphates of the ligand to 
accelerate opening the AMPbd and ATPlid regions after catalysis of the phosphoryl transfer. 
Conversely locking the enzyme in a transition-like state with the AP4A inhibitor causes 
suppression of fragmentation in that same loop region (G15-K21) as well as a second loop 
region (K63-V67) engaged in interactions with the phosphate of AMP (Figure 3.18(step 
4 to 5) and Figure 3.16(step 4 to 5)), suggesting that for this complex these stabilizing 
interactions have been re-established. Returning the enzyme to its catalytically active state 
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with Mg2+ present once again yields enhanced backbone cleavage in these two loop regions 
(Figure 3.18(step 5 to 6) and Figure 3.16(step 5 to 6)). Removal of the Mg2+ cofactor 
results in suppression of fragmentation of the loop adjacent to the phosphate groups of ATP 
(G15-K21) as the cation is no longer present to disrupt these interactions (Figure 3.18(step 
6 to 7) and Figure 3.16(step 6 to 7)). The conformational impact of addition and removal 
of the Mg2+ cofactor on AK revealed by UVPD-MS correlates well with previous findings 
of the important role of the cation in stabilizing groups involved in the phosphoryl transfer 
and accelerating opening of the enzyme after catalysis.22 
3.4.5 Tracking Conserved Residue R138 during the Catalytic Cycle 
The active site residue R138, conserved across all species of AK, has previously 
been implicated as a significant factor for catalysis by this enzyme. Specifically, mutation 
of this residue, even to a similarly positively charged Lys, drastically inhibits the rate of 
enzyme turnover for AK.71 This finding implies that the specific guanidinium interaction 
with the β-phosphate of the donor substrate is necessary, an interaction not replicated by a 
surrogate positively charged group.22 Additionally, x-ray crystallographic analysis of 
transition-state AK structures reveals that R138 shifts in concert to mirror the position of 
the donor phosphoryl group.22 However previous quantification of phosphoryl transfer and 
lid opening rates for an R138K mutant revealed that the R to K mutation only influenced 
the rate of transfer of the phosphoryl group, but not the rate of opening of the ATPlid region 
after catalysis.22  
Tracking the variations in UVPD backbone cleavage efficiency specifically for 
R138 supports these findings. The position of R138 is indicated by a gray dotted line in 
Figure 3.15. The most notable variations in fragmentation at this amino acid backbone 
position occur during steps 4 to 5, 5 to 6, and 6 to 7. As the enzyme is locked into a 
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catalytically inactive state bound to AP4A (Figure 3.15(step 4 to 5)), the backbone 
cleavage efficiency is suppressed suggesting that the residue is strongly interacting with 
the phosphate of the donor substrate. Return of the enzyme to a catalytically active state 
(Figure 3.15(step 5 to 6)) results in significantly enhanced cleavage at R138 implying that 
the segment containing this residue regains flexibility, engaging in only transient 
interactions as it mirrors the movement of the donor phosphoryl group. Loss of the Mg2+ 
cofactor (Figure 3.15(step 6 to 7)) lowers the catalytic activity of the enzyme, and once 
again cleavage at R138 is suppressed suggesting a loss of dynamic flexibility and 
engagement in interactions with the donor phosphoryl group. Upon examination of the holo 
ions produced upon UVPD of the ternary AK•AMP•ATP complex, R138 was directly 
identified as interacting strongly with ATP. This result implies that the enhancement and 
suppression of the cleavage at this residue arises from its interaction with the phosphoryl 
group of the donor ligand and not some other stabilizing interaction (Figure 3.11B(3)). 
Additionally, if R138 was directly involved in lid opening, suppression of cleavage at this 
residue for the catalytically inactive complex (AK•AP4A) would be expected instead of 
the observed enhancement (Figure 3.16(step 4 to 5)). 
3.5 CONCLUSION 
UVPD-MS was successfully used to probe structural changes of the 
phosphotransferase AK during its reaction cycle. Mapping holo fragment ions for binary 
and ternary AK•ligand complexes allowed both AMP and ATP to be traced back to their 
putative binding sites and offered insight into the preference of each substrate for their 
respective binding pockets. Variations in UVPD backbone cleavage efficiencies were 
tracked to examine the dynamic plasticity of the enzyme throughout its catalytic cycle. The 
changes in fragmentation efficiencies are attributed to differences in the intra- and 
 89 
intermolecular interactions in which the residues of AK engage as the protein binds each 
of the substrates, recruits a divalent cofactor (Mg2+), carries out the phosphoryl-transfer 
reaction, and releases the product molecules. Specifically, three α-helices of the AMPbd 
and the adenosine binding regions of AMP and ATP were implicated as undergoing 
conformational fluctuations during a global open-to-closed transition as the protein 
samples various structural microstates to optimize the environment for phosphoryl transfer 
and suppress hydrolysis. Additionally, closer examination of the changes in UVPD 
fragmentation efficiency for amino acids in the active site of the enzyme upon recruitment 
and removal of a divalent Mg2+ cofactor by the ternary complex highlights two loop regions 
known to engage in interactions with the phosphate groups of the substrates. This finding 
supports the role of Mg2+ in accelerating opening of the AMPbd and ATPlid regions by 
disrupting electrostatic interactions between the side-chains and bound ligands. Lastly, 
UVPD-MS allowed the conformational variations of the conserved active site residue 
R138, known to aid in transfer of the phosphoryl group from the donor to the acceptor 
ligand, to be tracked. Suppression of cleavage efficiency when the enzyme is catalytically 
active and observation of ATP-bound holo ions at this residue echo the role of R138 in 
aiding the catalysis of the phosphoryl transfer. Pairing UVPD-MS with more extensive 
molecular dynamics simulations and integrating complementary data from other 
biophysical tools, such as vibrational Stark effect spectroscopy,72 will allow further 
validation of UVPD as a probe of protein conformation and help unravel the fundamental 
underpinnings of the UVPD mechanism with respect to the dominant structural or chemical 
factors that influence the variations in protein fragmentation caused by UVPD.UVPD-MS 
has shown to be a promising new tool that can provide multiple layers of information on 
the individual contributions of structural dynamics, metal cofactors, and side-chain 
chemistries during enzyme catalysis. 
 90 
3.6 REFERENCES 
(1)  Daniel, R. M.; Dunn, R. V.; Finney, J. L.; Smith, J. C. The Role of Dynamics in 
Enzyme Activity. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 69–92. 
(2)  Henzler-Wildman, K. A.; Thai, V.; Lei, M.; Ott, M.; Wolf-Watz, M.; Fenn, T.; 
Pozharski, E.; Wilson, M. A.; Petsko, G. A.; Karplus, M.; Hübner, C. G.; Kern, D. 
Intrinsic Motions along an Enzymatic Reaction Trajectory. Nature 2007, 450, 838–
844. 
(3)  Henzler-Wildman, K. A.; Lei, M.; Thai, V.; Kerns, S. J.; Karplus, M.; Kern, D. A 
Hierarchy of Timescales in Protein Dynamics Is Linked to Enzyme Catalysis. 
Nature 2007, 450, 913–916. 
(4)  Kamerlin, S. C. L.; Warshel, A. At the Dawn of the 21st Century: Is Dynamics the 
Missing Link for Understanding Enzyme Catalysis? Proteins Struct. Funct. 
Bioinforma. 2010, 78, 1339–1375. 
(5)  Vonrhein, C.; Schlauderer, G. J.; Schulz, G. E. Movie of the Structural Changes 
during a Catalytic Cycle of Nucleoside Monophosphate Kinases. Structure 1995, 3, 
483–490. 
(6)  Noda, L. Adenosine Triphosphate-Adenosine Monophosphate Transphosphorylase 
Iii. Kinetic Studies. J. Biol. Chem. 1958, 232, 237–250. 
(7)  Abele, U.; Schulz, G. E. High-Resolution Structures of Adenylate Kinase from 
Yeast Ligated with Inhibitor Ap5A, Showing the Pathway of Phosphoryl Transfer. 
Protein Sci. 1995, 4, 1262–1271. 
(8)  Sinev, M. A.; Sineva, E. V.; Ittah, V.; Haas, E. Domain Closure in Adenylate Kinase. 
Biochemistry 1996, 35, 6425–6437. 
(9)  Sheng, X. R.; Li, X.; Pan, X. M. An Iso-Random Bi Bi Mechanism for Adenylate 
Kinase. J. Biol. Chem. 1999, 274, 22238–22242. 
(10)  Miyashita, O.; Onuchic, J. N.; Wolynes, P. G. Nonlinear Elasticity, Proteinquakes, 
and the Energy Landscapes of Functional Transitions in Proteins. Proc. Natl. Acad. 
Sci. 2003, 100, 12570–12575. 
(11)  Krishnamurthy, H.; Lou, H.; Kimple, A.; Vieille, C.; Cukier, R. I. Associative 
Mechanism for Phosphoryl Transfer: A Molecular Dynamics Simulation of 
Escherichia Coli Adenylate Kinase Complexed with Its Substrates. Proteins Struct. 
Funct. Bioinforma. 2005, 58, 88–100. 
(12)  Bae, E.; Phillips, G. N. Roles of Static and Dynamic Domains in Stability and 
Catalysis of Adenylate Kinase. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2132–
2137. 
(13)  Ådén, J.; Wolf-Watz, M. NMR Identification of Transient Complexes Critical to 
Adenylate Kinase Catalysis. J. Am. Chem. Soc. 2007, 129, 14003–14012. 
(14)  Arora, K.; Brooks, C. L. Large-Scale Allosteric Conformational Transitions of 
Adenylate Kinase Appear to Involve a Population-Shift Mechanism. Proc. Natl. 
Acad. Sci. 2007, 104, 18496–18501. 
(15)  Hanson, J. A.; Duderstadt, K.; Watkins, L. P.; Bhattacharyya, S.; Brokaw, J.; Chu, 
J.-W.; Yang, H. Illuminating the Mechanistic Roles of Enzyme Conformational 
Dynamics. Proc. Natl. Acad. Sci. 2007, 104, 18055–18060. 
 91 
(16)  Whitford, P. C.; Miyashita, O.; Levy, Y.; Onuchic, J. N. Conformational Transitions 
of Adenylate Kinase: Switching by Cracking. J. Mol. Biol. 2007, 366, 1661–1671. 
(17)  Schrank, T. P.; Bolen, D. W.; Hilser, V. J. Rational Modulation of Conformational 
Fluctuations in Adenylate Kinase Reveals a Local Unfolding Mechanism for 
Allostery and Functional Adaptation in Proteins. Proc. Natl. Acad. Sci. 2009, 106, 
16984–16989. 
(18)  Daily, M. D.; Phillips Jr., G. N.; Cui, Q. Many Local Motions Cooperate to Produce 
the Adenylate Kinase Conformational Transition. J. Mol. Biol. 2010, 400, 618–631. 
(19)  Olsson, U.; Wolf-Watz, M. Overlap between Folding and Functional Energy 
Landscapes for Adenylate Kinase Conformational Change. Nat. Commun. 2010, 1, 
111. 
(20)  Ådén, J.; Verma, A.; Schug, A.; Wolf-Watz, M. Modulation of a Pre-Existing 
Conformational Equilibrium Tunes Adenylate Kinase Activity. J. Am. Chem. Soc. 
2012, 134, 16562–16570. 
(21)  Rao, V. V. H. G.; Gosavi, S. In the Multi-Domain Protein Adenylate Kinase, 
Domain Insertion Facilitates Cooperative Folding While Accommodating Function 
at Domain Interfaces. PLOS Comput. Biol. 2014, 10, e1003938. 
(22)  Kerns, S. J.; Agafonov, R. V.; Cho, Y.-J.; Pontiggia, F.; Otten, R.; Pachov, D. V.; 
Kutter, S.; Phung, L. A.; Murphy, P. N.; Thai, V.; Alber, T.; Hagan, M. F.; Kern, D. 
The Energy Landscape of Adenylate Kinase during Catalysis. Nat. Struct. Mol. Biol. 
2015, 22, 124–131. 
(23)  Ferreiro, D. U.; Hegler, J. A.; Komives, E. A.; Wolynes, P. G. On the Role of 
Frustration in the Energy Landscapes of Allosteric Proteins. Proc. Natl. Acad. Sci. 
2011, 108, 3499–3503. 
(24)  Warshel, A.; Bora, R. P. Perspective: Defining and Quantifying the Role of 
Dynamics in Enzyme Catalysis. J. Chem. Phys. 2016, 144, 180901. 
(25)  Konermann, L.; Vahidi, S.; Sowole, M. A. Mass Spectrometry Methods for Studying 
Structure and Dynamics of Biological Macromolecules. Anal. Chem. 2014, 86, 213–
232. 
(26)  Konermann, L.; Tong, X.; Pan, Y. Protein Structure and Dynamics Studied by Mass 
Spectrometry: H/D Exchange, Hydroxyl Radical Labeling, and Related Approaches. 
J. Mass Spectrom. 2008, 43, 1021–1036. 
(27)  Fitzgerald, M. C.; West, G. M. Painting Proteins with Covalent Labels: What’s In 
the Picture? J. Am. Soc. Mass Spectrom. 2009, 20, 1193–1206. 
(28)  Cammarata, M.; Lin, K.-Y.; Pruet, J.; Liu, H.; Brodbelt, J. Probing the Unfolding of 
Myoglobin and Domain C of PARP-1 with Covalent Labeling and Top-Down 
Ultraviolet Photodissociation Mass Spectrometry. Anal. Chem. 2014, 86, 2534–
2542. 
(29)  Pirrone, G. F.; Iacob, R. E.; Engen, J. R. Applications of Hydrogen/Deuterium 
Exchange MS from 2012 to 2014. Anal. Chem. 2014, 87, 99–118. 
(30)  Sharon, M.; Robinson, C. V. The Role of Mass Spectrometry in Structure 
Elucidation of Dynamic Protein Complexes. Annu. Rev. Biochem. 2007, 76, 167–
193. 
 92 
(31)  Heck, A. J. R. Native Mass Spectrometry: A Bridge between Interactomics and 
Structural Biology. Nat. Methods 2008, 5, 927–933. 
(32)  Hopper, J. T. S.; Oldham, N. J. Collision Induced Unfolding of Protein Ions in the 
Gas Phase Studied by Ion Mobility-Mass Spectrometry: The Effect of Ligand 
Binding on Conformational Stability. J. Am. Soc. Mass Spectrom. 2009, 20, 1851–
1858. 
(33)  Konermann, L.; Ahadi, E.; Rodriguez, A. D.; Vahidi, S. Unraveling the Mechanism 
of Electrospray Ionization. Anal. Chem. 2012, 85, 2–9. 
(34)  Schennach, M.; Breuker, K. Proteins with Highly Similar Native Folds Can Show 
Vastly Dissimilar Folding Behavior When Desolvated. Angew. Chem. Int. Ed. 2014, 
53, 164–168. 
(35)  Cubrilovic, D.; Haap, W.; Barylyuk, K.; Ruf, A.; Badertscher, M.; Gubler, M.; 
Tetaz, T.; Joseph, C.; Benz, J.; Zenobi, R. Determination of Protein–Ligand Binding 
Constants of a Cooperatively Regulated Tetrameric Enzyme Using Electrospray 
Mass Spectrometry. ACS Chem. Biol. 2014, 9, 218–226. 
(36)  Li, H.; Wongkongkathep, P.; Orden, S. L. V.; Loo, R. R. O.; Loo, J. A. Revealing 
Ligand Binding Sites and Quantifying Subunit Variants of Noncovalent Protein 
Complexes in a Single Native Top-Down FTICR MS Experiment. J. Am. Soc. Mass 
Spectrom. 2014, 25, 2060–2068. 
(37)  Li, H.; Wolff, J. J.; Van Orden, S. L.; Loo, J. A. Native Top-Down Electrospray 
Ionization-Mass Spectrometry of 158 KDa Protein Complex by High-Resolution 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. Anal. Chem. 2014, 
86, 317–320. 
(38)  O’Brien, J. P.; Li, W.; Zhang, Y.; Brodbelt, J. S. Characterization of Native Protein 
Complexes Using Ultraviolet Photodissociation Mass Spectrometry. J. Am. Chem. 
Soc. 2014, 136, 12920–12928. 
(39)  Cammarata, M. B.; Brodbelt, J. S. Structural Characterization of Holo- and Apo-
Myoglobin in the Gas Phase by Ultraviolet Photodissociation Mass Spectrometry. 
Chem. Sci. 2015, 6, 1324–1333. 
(40)  Cammarata, M. B.; Thyer, R.; Rosenberg, J.; Ellington, A.; Brodbelt, J. S. Structural 
Characterization of Dihydrofolate Reductase Complexes by Top-Down Ultraviolet 
Photodissociation Mass Spectrometry. J. Am. Chem. Soc. 2015, 137, 9128–9135. 
(41)  Cammarata, M. B.; Schardon, C. L.; Mehaffey, M. R.; Rosenberg, J.; Singleton, J.; 
Fast, W.; Brodbelt, J. S. Impact of G12 Mutations on the Structure of K-Ras Probed 
by Ultraviolet Photodissociation Mass Spectrometry. J. Am. Chem. Soc. 2016, 138, 
13187–13196. 
(42)  Zechel, D. L.; Konermann, L.; Withers, S. G.; Douglas, D. J. Pre-Steady State 
Kinetic Analysis of an Enzymatic Reaction Monitored by Time-Resolved 
Electrospray Ionization Mass Spectrometry. Biochemistry 1998, 37, 7664–7669. 
(43)  Li, Z.; Sau, A. K.; Shen, S.; Whitehouse, C.; Baasov, T.; Anderson, K. S. A Snapshot 
of Enzyme Catalysis Using Electrospray Ionization Mass Spectrometry. J. Am. 
Chem. Soc. 2003, 125, 9938–9939. 
 93 
(44)  Liuni, P.; Jeganathan, A.; Wilson, D. J. Conformer Selection and Intensified 
Dynamics During Catalytic Turnover in Chymotrypsin. Angew. Chem. Int. Ed. 2012, 
51, 9666–9669. 
(45)  Lermyte, F.; Sobott, F. Electron Transfer Dissociation Provides Higher-Order 
Structural Information of Native and Partially Unfolded Protein Complexes. 
PROTEOMICS 2015, 15, 2813–2822. 
(46)  Breuker, K.; Oh, H.; Horn, D. M.; Cerda, B. A.; McLafferty, F. W. Detailed 
Unfolding and Folding of Gaseous Ubiquitin Ions Characterized by Electron 
Capture Dissociation. J. Am. Chem. Soc. 2002, 124, 6407–6420. 
(47)  Breuker, K.; McLafferty, F. W. Stepwise Evolution of Protein Native Structure with 
Electrospray into the Gas Phase, 10−12 to 102 S. Proc. Natl. Acad. Sci. 2008, 105, 
18145–18152. 
(48)  Zhang, H.; Cui, W.; Wen, J.; Blankenship, R. E.; Gross, M. L. Native Electrospray 
and Electron-Capture Dissociation in FTICR Mass Spectrometry Provide Top-down 
Sequencing of a Protein Component in an Intact Protein Assembly. J. Am. Soc. Mass 
Spectrom. 2010, 21, 1966–1968. 
(49)  Zhang, H.; Cui, W.; Gross, M. L.; Blankenship, R. E. Native Mass Spectrometry of 
Photosynthetic Pigment–Protein Complexes. FEBS Lett. 2013, 587, 1012–1020. 
(50)  Zhang, H.; Cui, W.; Gross, M. L. Native Electrospray Ionization and Electron-
Capture Dissociation for Comparison of Protein Structure in Solution and the Gas 
Phase. Int. J. Mass Spectrom. 2013, 354–355, 288–291. 
(51)  Zhou, M.; Wysocki, V. H. Surface Induced Dissociation: Dissecting Noncovalent 
Protein Complexes in the Gas Phase. Acc. Chem. Res. 2014, 47, 1010–1018. 
(52)  Shaw, J. B.; Li, W.; Holden, D. D.; Zhang, Y.; Griep-Raming, J.; Fellers, R. T.; 
Early, B. P.; Thomas, P. M.; Kelleher, N. L.; Brodbelt, J. S. Complete Protein 
Characterization Using Top-Down Mass Spectrometry and Ultraviolet 
Photodissociation. J. Am. Chem. Soc. 2013, 135, 12646–12651. 
(53)  Cannon, J. R.; Cammarata, M. B.; Robotham, S. A.; Cotham, V. C.; Shaw, J. B.; 
Fellers, R. T.; Early, B. P.; Thomas, P. M.; Kelleher, N. L.; Brodbelt, J. S. Ultraviolet 
Photodissociation for Characterization of Whole Proteins on a Chromatographic 
Time Scale. Anal. Chem. 2014, 86, 2185–2192. 
(54)  Brodbelt, J. S. Ion Activation Methods for Peptides and Proteins. Anal. Chem. 2016, 
88, 30–51. 
(55)  Warnke, S.; Baldauf, C.; Bowers, M. T.; Pagel, K.; von Helden, G. Photodissociation 
of Conformer-Selected Ubiquitin Ions Reveals Site-Specific Cis/Trans 
Isomerization of Proline Peptide Bonds. J. Am. Chem. Soc. 2014, 136, 10308–10314. 
(56)  Warnke, S.; von Helden, G.; Pagel, K. Analyzing the Higher Order Structure of 
Proteins with Conformer-Selective Ultraviolet Photodissociation. PROTEOMICS 
2015, 15, 2804–2812. 
(57)  Briand, G.; Perrier, V.; Kouach, M.; Takahashi, M.; Gilles, A. M.; Bârzu, O. 
Characterization of Metal and Nucleotide Liganded Forms of Adenylate Kinase by 
Electrospray Ionization Mass Spectrometry. Arch. Biochem. Biophys. 1997, 339, 
291–297. 
 94 
(58)  Daniel, J. M.; McCombie, G.; Wendt, S.; Zenobi, R. Mass Spectrometric 
Determination of Association Constants of Adenylate Kinase with Two 
Noncovalent Inhibitors. J. Am. Soc. Mass Spectrom. 2003, 14, 442–448. 
(59)  Yin, S.; Loo, J. A. Elucidating the Site of Protein-ATP Binding by Top-Down Mass 
Spectrometry. J. Am. Soc. Mass Spectrom. 2010, 21, 899–907. 
(60)  Bunkoczi, G.; Filippakopoulos, P.; Jansson, A.; Longman, E.; Von Delft, F.; 
Edwards, A.; Arrowsmith, C.; Sundstrom, M.; Weigelt, J.; Knapp, S. Structure of 
Adenylate Kinase 1 in Complex with P1, P4-Di(Adenosine)Tetraphosphate, 2017, 
to be submitted for publication. 
(61)  Yin, S.; Loo, J. A. Top-Down Mass Spectrometry of Supercharged Native Protein-
Ligand Complexes. Int. J. Mass Spectrom. 2011, 300, 118–122. 
(62)  Pai, E. F.; Sachsenheimer, W.; Schirmer, R. H.; Schulz, G. E. Substrate Positions 
and Induced-Fit in Crystalline Adenylate Kinase. J. Mol. Biol. 1977, 114, 37–45. 
(63)  Schulz, G. E.; Müller, C. W.; Diederichs, K. Induced-Fit Movements in Adenylate 
Kinases. J. Mol. Biol. 1990, 213, 627–630. 
(64)  Tsai, M. D.; Yan, H. Mechanism of Adenylate Kinase: Site-Directed Mutagenesis 
versus x-Ray and NMR. Biochemistry 1991, 30, 6806–6818. 
(65)  Müller, C. W.; Schulz, G. E. Structure of the Complex between Adenylate Kinase 
from Escherichia Coli and the Inhibitor Ap5A Refined at 1.9 Å Resolution. J. Mol. 
Biol. 1992, 224, 159–177. 
(66)  Rogne, P.; Wolf-Watz, M. Urea-Dependent Adenylate Kinase Activation Following 
Redistribution of Structural States. Biophys. J. 2016, 111, 1385–1395. 
(67)  Kern, P.; Brunne, R. M.; Folkers, G. Nucleotide-Binding Properties of Adenylate 
Kinase from Escherichia Coli: A Molecular Dynamics Study in Aqueous and 
Vacuum Environments. J. Comput. Aided Mol. Des. 1994, 8, 367–388. 
(68)  Elamrani, S.; Berry, M. B.; Phillips, G. N.; McCammon, J. A. Study of Global 
Motions in Proteins by Weighted Masses Molecular Dynamics: Adenylate Kinase 
as a Test Case. Proteins Struct. Funct. Bioinforma. 1996, 25, 79–88. 
(69)  Orzechowski, M.; Tama, F. Flexible Fitting of High-Resolution X-Ray Structures 
into Cryoelectron Microscopy Maps Using Biased Molecular Dynamics 
Simulations. Biophys. J. 2008, 95, 5692–5705. 
(70)  Baxter, N. J.; Blackburn, G. M.; Marston, J. P.; Hounslow, A. M.; Cliff, M. J.; 
Bermel, W.; Williams, N. H.; Hollfelder, F.; Wemmer, D. E.; Waltho, J. P. Anionic 
Charge Is Prioritized over Geometry in Aluminum and Magnesium Fluoride 
Transition State Analogs of Phosphoryl Transfer Enzymes. J. Am. Chem. Soc. 2008, 
130, 3952–3958. 
(71)  Yan, H.; Tsai, M.-D. Nucleoside Monophosphate Kinases: Structure, Mechanism, 
and Substrate Specificity. In Advances in Enzymology and Related Areas of 
Molecular Biology; Purich, D. L., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 
1999; pp 103–134. 
(72)  Fried, S. D.; Boxer, S. G. Measuring Electric Fields and Noncovalent Interactions 
Using the Vibrational Stark Effect. Acc. Chem. Res. 2015, 48, 998–1006. 
 95 
Chapter 4: Elusive Structural Changes of New Delhi Metallo-β-
Lactamase Revealed by Ultraviolet Photodissociation Mass 
Spectrometry† 
4.1 OVERVIEW 
We use mass spectrometry (MS), under denaturing and non-denaturing solution 
conditions, along with ultraviolet photodissociation (UVPD) to characterize structural 
variations in New Delhi metallo-β-lactamase (NDM) upon perturbation by ligands or 
mutation. Mapping changes in the abundances and distributions of fragment ions enables 
sensitive detection of structural alterations throughout the protein. Binding of three 
covalent inhibitors were characterized: a pentafluorphenyl ester, an O-aryloxycarbonyl 
hydroxamate, and ebselen. The first two inhibitors modify Lys211 and maintain dizinc 
binding, although the pentafluorophenyl ester is not selective (Lys214 and Lys216 are also 
modified). Ebselen reacts with the sole Cys (Cys208) and ejects Zn2 from the active site. 
For each inhibitor, native UVPD-MS enabled simultaneous detection of the closing of a 
substrate-binding beta-hairpin loop, identification of covalently-modified residue(s), 
reporting of the metalation state of the enzyme, and in the case of ebselen, induced partial 
disorder in the C-terminus of the protein. Owing to the ability of native UVPD-MS to track 
structural changes and metalation state with high sensitivity, we further used this method 
to evaluate the impact of mutations found in NDM clinical variants. Changes introduced 
by NDM-4 (M154L) and NDM-6 (A233V) are revealed to propagate through separate 
networks of interactions to direct zinc ligands, and the combination of these two mutations 
                                                 
†Mehaffey, M. R.; Ahn, Y. C.; Rivera, D. D.; Thomas, P. W.; Cheng, Z.; Crowder, M. W.; Pratt, R. F.; Fast, 
W.; Brodbelt, J. S. Elusive structural changes of New Delhi metallo-β-lactamase revealed by ultraviolet 
photodissociation mass spectrometry. Chem. Sci. 2020, doi: 10.1039/d0sc02503h. 
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in NDM-15 (M154L, A233V) results in additive as well as additional structural changes. 
Insight from UVPD-MS helps to elucidate how distant mutations impact zinc affinity in 
the evolution of this antibiotic resistance determinant. UVPD-MS is a powerful tool 
capable of simultaneous reporting of ligand binding, conformational changes and 
metalation state of NDM, revealing structural aspects of ligand recognition and clinical 
variants that have proven difficult to probe. 
4.2 INTRODUCTION 
Infection by antibiotic resistant organisms remains a serious health threat. A 2019 
report from the Centers for Disease Control and Prevention (CDC) indicates that in the 
U.S., bacteria and fungi cause over 2.8 million antibiotic resistant infections each year and 
that 35,000 people die due to these infections.1 The CDC ranks carbapenem-resistant 
Enterobacteriaceae in the top tier of “Urgent Threats.” Resistance against carbapenems is 
particularly dangerous because these β-lactam drugs are often held in reserve as life-saving 
“drugs of last resort” for patients with complicated infections.2 Some carbapenems can 
serve two purposes: dual inhibition of peptidoglycan biosynthesis and activity of some 
serine-β-lactamases. However, these drugs do not inhibit metallo-β-lactamases (MBLs), 
which instead use active-site zinc ion(s) to catalyze efficient hydrolysis and inactivation of 
carbapenems. For example, New Delhi metallo-β-lactamase (NDM) readily catalyzes 
hydrolysis of meropenem and imipenem with specificity constants (kcat/KM) >10
6 M-1s-1.3 
Currently, there are no FDA approved drugs that counter the activity of NDM, or any other 
MBL, so NDM inhibitors are an unmet clinical need.4  
Despite more than 100 structural models of NDM deposited in the protein data 
bank, there are still significant gaps in our knowledge about NDM structure. NDM drug 
development efforts would greatly benefit from specific information detailing how ligands 
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bind to active site loops and how clinical variants of the enzyme impact structure, but 
aspects of these structural differences often remain elusive. For example, MBLs similar to 
NDM have a flexible beta-hairpin loop containing a hydrophobic amino acid at the apex 
that closes down over a ligand upon inhibitor binding or during catalysis, making important 
binding interactions with the ligand as revealed by mutagenesis, kinetic analysis, X-ray 
crystallography, and protein NMR studies.5–9 However, the conformation of the 
homologous beta-hairpin loop in NDM is often obscured or artifactually constrained in X-
ray studies owing to interactions with a neighboring NDM monomer during crystal 
formation.10 Mutagenesis and kinetic studies indicate an important role for this NDM loop 
in ligand binding and substrate turnover that may differ somewhat from its role in 
homologous MBLs, underscoring the need to better characterize structural changes upon 
ligand binding.11,12 Two spectroscopic methods (19F NMR and RFQ-DEER) have been 
used along with covalent incorporation of labels into the NDM loop to detect 
conformational changes upon ligand binding.13,14 The conformations that this loop adopts 
appear to be ligand dependent and ligand binding may even trigger loop opening, although 
the covalent incorporation of these labels may perturb the system and complicate 
interpretation.13,14 Alternative methods are needed to better understand the structural 
implications of ligand-binding, preferably using unlabeled proteins. 
A second example of inadequate structural information relates to clinical variants 
of NDM. Almost 30 different protein sequences have been reported for NDM clinical 
variants (NDM-1 through NDM-29). Many of these variants improve thermostability and 
the affinity of Zn2 (some variants have 10-fold lower Kd values) and appear to be emerging 
due to the combined selective pressures of antibiotic treatment and zinc scarcity at infection 
sites brought on by the host innate immune response.3,15–18 The structural models of seven 
different NDM variants (NDM-1, 3, 4, 5, 8, 9, 12) are deposited in the protein data bank, 
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but the structural differences observed among these variants by X-ray crystallography are 
small and the mechanisms whereby mutations lead to improvements in zinc affinity are 
difficult to discern.15 Alternative strategies that can better detect the impact of mutation on 
NDM structure would help elucidate how clinical variants achieve improved resistance and 
aid in predicting the impact of newly sequenced variants. 
The development of native mass spectrometry (MS) represents an alternative 
technique to probe protein structure by enabling the transfer of intact protein complexes 
with bound ligands into the gas phase using electrospray ionization (ESI) of high ionic 
strength solutions.19,20  While traditional collisional activation provides some sequence 
information on native protein complexes in the gas phase, typically this MS/MS approach 
disrupts non-covalent interactions and ejects ligands and individual protein constituents. 
As such, alternative MS/MS methods are necessary to probe the structure of intact protein 
complexes.21,22 The ability of electron-based activation methods, including electron 
transfer dissociation (ETD),23 electron capture dissociation (ECD),24–26 and electron 
ionization dissociation (EID),27 to allow retention of noncovalent ligands and metal 
cofactors on fragment ions, referred to as holo ions, has been used to identify structural 
differences between ligand-bound (holo) and ligand-free (apo) ions. The propensity of 
these electron-based strategies for fragmenting a given region correlates with protein 
flexibility (i.e. B-factors), enabling aspects of tertiary structure to be determined.23,28 In 
many ways mirroring the scope of electron-based activation methods, ultraviolet 
photodissociation (UVPD) at 193 nm has proven capable of providing sequence 
information, localizing ligand binding sites, and probing conformational changes of 
ligand:protein complexes.29–31 Retention of noncovalent ligands during photoactivation 
yields ligand-bound “holo” fragment ions that can be mapped along the sequence to 
elucidate binding sites.30 Tracking enhancement or suppression of backbone cleavages 
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upon UVPD highlights regions where there are changes in stabilizing noncovalent 
interactions and in protein flexibility (i.e. enhancement of backbone fragmentation 
indicates fewer interactions, more flexibility, and typically leads to greater production of 
sequence ions; whereas suppression signifies more extensive interactions that limit the 
separation and detection of fragment ions).31 Additionally, UVPD affords unsurpassed 
sequence coverage29,30 and retention of labile covalent moieties32 with little dependence on 
precursor charge state.33 This native UVPD-MS approach has previously been applied for 
detecting conformational changes induced by ligand binding to dihydrofolate reductase 
(DHFR),34 sequence variants of rat sarcoma GTPase K-Ras35,36 and DHFR,37 and structural 
re-organization of the phosphotransferase enzyme adenylate kinase during its catalytic 
cycle.38 
Here, we use native UVPD-MS to track changes in fragmentation patterns as a 
means to infer changes in the active site loop conformation, zinc binding, and 
conformations of surrounding residues in NDM-1 upon binding to three different small 
molecule inhibitors known to covalently modify the enzyme. Combining a native MS 
strategy with UVPD allows us to simultaneously define changes in protein conformation 
and zinc binding arising from interaction with inhibitors. We also compare four 
representative clinical NDM variants: NDM-1 (the reference sequence), NDM-4 (M154L), 
NDM-6 (A233V), and NDM-15 (M154L, A233V), specifically focusing on variations in 
backbone fragmentation adjacent to the six zinc-coordinating residues. Application of this 
method reveals structural differences not easily monitored by other approaches and 
provides information useful for NDM inhibitor development and better understanding how 
clinical variants lead to increased zinc affinity and enhanced drug resistance. 
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4.3 EXPERIMENTAL 
4.3.1 Sample Preparation 
The reference sequence (NDM-1) and three clinical variants (NDM-4, NDM-6, and 
NDM-15) of recombinant NDM were expressed and purified as previously described, all 
of which include an N-terminal truncation to remove a lipidation signal sequence to make 
soluble versions of each protein.3,17 The expressed protein sequence with mutated sites 
highlighted and structures of the small molecule inhibitors are shown in Figure 4.1. The 
numbering scheme includes the initial 35 residues although the coding region for this 
sequence is omitted in the expression constructs. The three covalent inhibitors (1-3) were 
synthesized or purchased. 
A covalent inhibitor of imipenemase-1 (IMP-1), the pentafluorophenyl ester of 3-
mercaptopropionic acid (1), was synthesized as described elsewhere39 and reconstituted in 
dimethyl sulfoxide stock solutions immediately prior to incubation with NDM-1 [1H NMR 
(400 MHz, CDCl3):  3.01 (2H, t), 2.91 (2H, dt), 1.75 (1H, t); ESI-MS (m/z): 273.0014 (M 
+H)+]. Inhibitor 1 and NDM-1 were combined at various stoichiometric ratios (1:1, 5:1, 
and 100:1 inhibitor:NDM-1) in 20 mM ammonium acetate (pH 6.8) and incubated at 25 
°C for 1 h. The synthesis of a covalent inhibitor of NDM-1, N-(benzyloxycarbonyl)-O-
[(phenyoxycarbonyl)]hydroxylamine, which is an O-aryloxycarbonyl hydroxamate (2), 
was previously described,40,41 and a 125:1 stoichiometric ratio (inhibitor:NDM-1) was  
incubated with NDM-1 at 2 °C for 18 h in 50 mM HEPES (pH 7.0). The covalent NDM-1 
inhibitor ebselen,42 a benzisoselenazol (3), was purchased from Sigma-Aldrich (St. Louis, 
MO) and incubated at a 1:1 stochiometric ratio (inhibitor:NDM-1) at 25 °C for 30 min in 
20 mM ammonium acetate (pH 6.8). Prior to use in MS experiments, these incubation 
solutions, as well as stock solutions of the variants NDM-1, -4, -6, and -15, were desalted 
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and exchanged into water or 20 mM ammonium acetate using 10 kDa molecular weight 
cutoff filter devices (MilliporeSigma, Burlington, MA). Samples were subsequently 
diluted for MS analysis to 10 μM protein concentration in 50/49.5/0.5 (v/v/v) 
acetonitrile/water/formic acid for denaturing experiments or 20 mM ammonium acetate 
(pH 6.8) for native conditions. 
 
 
Figure 4.1: Sequence of (A) New Delhi Metallo-β-Lactamase-1. In subsequent figures, 
residues are numbered accounting for a 29 (no FHM) or 32 (with FHM) 
residue N-terminal region that is absent in the expressed sequence. Some of 
the proteins used in this study contain the FHM residues shaded in yellow 
owing to differences in cleavage of the expression tag. Use of two different 
NDM expression and purification systems resulted in variation in the 4 and 5 
positions with X4X5 = GM or GQ. The two positions mutated resulting in 
clinical variants are shaded: M154L (red) and A233V (green). The two 
reaction sites for covalent inhibitors, C208 and K211, are shaded in pink or 
orange, respectively. (B) Structures of covalent inhibitors of NDM-1 (1) 
pentafluorophenyl 3-mercaptopropionate, (2) N-(benzyloxycarbonyl)-O-
[(phenoxycarbonyl)] hydroxylamine, and (3) ebselen. The chemical structure 
of the resulting modification of an amino acid side-chain is shown along with 
the expected mass shift. 
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4.3.2 Mass Spectrometry 
An offline nano-ESI source with borosilicate emitters fabricated in-house and 
coated in Au/Pd was used to ionize proteins and protein complexes. The source was 
operated at applied voltages of 1.0 – 1.1 kV and set at a temperature of 200 °C to transfer 
proteins into a Thermo Scientific Orbitrap Elite mass spectrometer (Bremen, Germany). 
This instrument was modified previously by aligning an Excistar 193 nm ArF excimer laser 
(Coherent, Santa Cruz, CA) with the HCD cell to perform UV photodissociation.29 MS/MS 
experiments involved ion trap isolation of a single charge state of the protein species of 
interest using isolation widths of 10-20 m/z and subsequent collisional activation using 15-
20% NCE or a single 3 mJ pulse for UVPD. MS1 spectra represent sixty scans, while 
MS/MS spectra contain 500 transients with a scan range of m/z 220-4000. Using a resolving 
power of 240K at 400 m/z and a maximum ion time of 2 s, the automatic gain control was 
set at 1 × 106 for MS1 and 5 × 105 for MS/MS spectra. All MS/MS spectra were collected 
in triplicate. 
4.3.3 Data Analysis 
The Thermo Xtract algorithm was used to de-charge and de-isotope all ESI mass 
spectra and HCD or UVPD mass spectra (S/N ratio of 3, fit factor of 44%, remainder of 
25%). ProSight Lite v1.4 assigned monoisotopic fragment ions from the MS/MS spectra 
as apo sequence ions by searching against the NDM sequence. For HCD mass spectra, only 
b- and y-type ions were considered, while for UVPD mass spectra all nine ion types were 
considered (a, a+1, b, c, x, x+1, y, y-1, z). Holo fragment ions bound to zinc(II) resulting 
from photodissociation were also identified for the clinical variants and protein-inhibitor 
complexes by including the corresponding mass shifts at the termini: 61.913 – 63.929 Da 
for one zinc(II) or 123.827 – 127.858 Da for two zinc(II) ions. Covalently attached 
 103 
inhibitors were considered static modifications and included in searches using the expected 
mass shifts listed in Figure 4.1.  
The relative efficiencies of backbone cleavages induced upon UVPD were 
calculated for clinical variants and protein-inhibitor complexes using the fragment 
abundance tab of the Web-based utility UV-POSIT.43 Briefly, in a protein with R residues 
(numbered 1 to R  from N-terminus to C-terminus), this program sums the abundances of 
all the fragment ions resulting from backbone cleavages adjacent to each individual amino 
acid and calculates a backbone cleavage yield for each amino acid position. In essence, the 
total backbone cleavage yield of amino acid n is the sum of all N-terminal sequence ions 
(an, bn, cn) resulting from cleavage C-terminal to the n
th residue and all C-terminal product 
ions (xR-n+1, yR-n+1, zR-n+1) produced by backbone cleavage N-terminal to the n
th residue. 
The summed values for each backbone position are then normalized to the total ion current 
of the spectrum and reported as the cleavage “efficiencies” (i.e. relative propensities) 
adjacent to each amino acid.43 This method provides a semi-quantitative way to evaluate 
variations in fragmentation throughout the protein sequence. Two protein states are 
compared (e.g. NDM-1 versus clinical variant, or unmodified versus inhibitor-bound) by 
subtraction of corresponding backbone cleavage efficiencies and represented as difference 
plots or heatmaps. Statistical significance of observed differences is established by pooling 
standard deviations and calculating p-values using a two-tailed Student’s t-test. The log of 
these values is plotted for each protein:inhibitor complex compared to the corresponding 
unmodified protein (Figure 4.2A,B) or for each clinical variant compared to the reference 
NDM-1 protein (Figure 4.2C(1,2,3)). A histogram of p-values for the entire clinical variant 
data set is included in Figure 4.2C(4). The ~25% of residues with p-values of 1.00 
correspond to those with no adjacent backbone cleavages (i.e. no sequence coverage). The 
p-values less than 1.00 (~75% of the values which also correlates to the observed 75% 
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sequence coverage) correspond to those residues for which bracketing backbone cleavages 
were observed for both NDM-1 and an NDM-1:inhibitor complex or for both NDM-1 and 
a variant, thus allowing comparison of the abundances and calculation of a statistical 
significance. All differences in backbone fragmentation efficiencies discussed below are 
significant at a confidence threshold of 99% (i.e. p-value < 0.01), with this cutoff 
represented as a black line for each of the five difference graphs in Figure 4.2 and 
collectively represented by the left-most blue bar in Figure 4.2C(4) (highest significance). 
A crystal structure of NDM-1 (PDB ID: 3SPU)44 with important regions labelled is 
included to aid in visualization and detail the residues involved in the defined active site 
loops (ASLs)  (Figure 4.3). 
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Figure 4.2: Log of p-values plotted per residue calculated from the differences for (A) 
NDM-1 bound to inhibitor (2) (Figure 4.13), (B) ebselen-bound NDM-1 
(Figure 4.20), and (C) clinical variants of NDM (Figure 4.25). Student’s t-test 
was used with pooled standard deviations to compare differences in UVPD 
backbone cleavage efficiencies of each inhibitor-bound protein (A, B) or 
clinical variant (1-3) to unreacted NDM or the reference NDM-1 sequence. 
Calculated t-values were converted to p-values assuming a two-tailed 
hypothesis. At a given residue for the inhibitor-bound or variant NDM, a p-
value smaller than 0.01 (assuming a 99% confidence threshold represented as 
a black solid line) designates that the average of the triplicate measurement 
of UVPD intensity is statistically different from the corresponding measured 
average of unreacted NDM or NDM-1. (C) A histogram of calculated p-
values in (1-3) is shown in (4) with the cumulative percentage plotted. 
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Figure 4.3: Crystal structure and 180° view of NDM-1 (PDB ID: 3SPU) with important 
loops and residues highlighted and labelled. The five active site loops (ASL) 
responsible for the broad substrate specificity of the protein are colored as 
follows: ASL1 (slate), ASL2 (turquoise), ASL3 (purple), ASL4 (olive), ASL5 
(lime green). The six residues along these loops known to anchor two Zn(II) 
ions (shown as gray spheres) in the active site are labelled and shown as sticks 
(H120, H122, D124, H189, C208, H250). Located on ASL1 and shown as 
sticks, F70 is important for substrate binding and recognition. An important 
target for covalent inhibitors, K211 is shown as sticks along ASL4. The two 
residues mutated in the clinical variants used for this study are shown as sticks 
as well: M154 (red) and A233 (green). 
4.4 RESULTS AND DISCUSSION 
4.4.1 Inhibitor Selection 
We applied a native UVPD-MS approach to simultaneously detect changes in 
protein structure and zinc content upon inhibitor binding to NDM-1, using two distinct 
types of MBL covalent inhibitors as examples: lysine 211-modifying inhibitors that retain 
binding of both zinc ions, and a cysteine 208-modifying inhibitor that ejects one zinc from 
the active-site. The first Lys-modifying inhibitor, 3-mercaptopropionic acid 
pentafluorophenylester (1), contains a zinc-binding thiol group tethered to a reactive ester 
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and was previously shown to serve as an affinity label that covalently modifies the Lys244 
in IMP-1 (KI= 3.45 M; kinact = 4.6 min
-1), and retains both zinc ions at the active site after 
inhibition.39 Because of the homology between IMP and NDM, we reasoned that 1 would 
also serve as an affinity label for Lys211 in NDM-1 (Figure 4.4). Due to an unexpected 
lack of selectivity for 1 (vide infra), we also investigated a second Lys-modifying affinity 
label, an O-aryloxycarbonyl hydroxamate (2), that we previously determined to modify 
Lys211 in NDM-1 (KI = 140 M; kinact =0.045 min
-1) and to leave the dizinc active site 
intact (Figure 4.4).41 For a Cys-modifying inhibitor, we chose a non-selective thiol-
modifying reagent ebselen (3) that has been previously shown to covalently modify the 
sole Cys in soluble NDM-1 constructs (Cys208) as an affinity label (KI = 0.38 M; kinact 
=0.034 min-1), and to eject one equivalent of zinc from the dinuclear zinc cluster (Figure 
4.4).42 
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Figure 4.4: Proposed covalent NDM-1 inactivation mechanisms: (A) A reactive 
pentafluorophenol (PFP) ester (1) is bound in proximity to active-site K211 
to facilitate reaction and loss of pentafluorophenol (PFP). (B) A reactive O-
aryloxycarbonyl hydroxamate (2) is bound in proximity to active-site K211 
to facilitate reaction. (C) Because the C208 thiol is not solvent accessible in 
the dinuclear zinc form of NDM-1, and Zn2 is bound relatively weakly,3 a 
dynamic equilibrium is depicted between dizinc and monozinc metalloforms, 
enabling binding of the thiol-reactive ebselen (3) in proximity to Cys208 to 
facilitate reaction and loss of Zn2 affinity. 
4.4.2 UVPD-MS to Localize a Lysine-Selective Covalent Inhibitor of NDM-1 
We found that a Lys-targeted pentafluorophenyl ester affinity label reported for 
IMP-1 (1) can also readily inactivate the homologous NDM-1 enzyme in a manner that is 
irreversible to dilution into excess substrate (Figure 4.5). A full kinetic characterization 
was not completed owing to unexpected lack of selectivity noted below. ESI-MS data were 
collected for denaturing and non-denaturing (high ionic strength) solutions containing 
NDM-1 without or with inhibitor 1 (Figure 4.6, inhibitor:protein ratios 1:1, 5:1, 100:1). 
Even at a 1:1 inhibitor:protein ratio, up to two inhibitors were observed to bind covalently 
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to NDM-1 with up to three inhibitors per protein for solutions containing higher 
inhibitor:protein ratios. This outcome indicates that inhibitor 1 is less specific for one 
particular Lys in NDM-1 as compared to IMP-1.39 Similar results were observed for spectra 
collected after various incubation time-points. Using non-denaturing ESI conditions yields 
similar results with addition of up to three inhibitor molecules to NDM-1 and also confirms 
that neither of the active site Zn(II) ions are displaced due to the reaction (Figure 4.6B). 
 
 
Figure 4.5: Time-dependent Inactivation of NDM-1 by 1. Purified NDM-1 (0.5 μM) was 
incubated with inhibitor (1) (10 μM) in the presence of ZnSO4 (10 μM), 
HEPES (50 mM), DMSO (1% v/v) at pH 7.0, 25 °C. At various timepoints, 
aliquots were diluted 25-fold into a reaction mixture containing chromacef 
(20 μM), ZnSO4 (10 μM), and HEPES (50 mM) at pH 7.0, 25 °C, and the 
activity monitored by UV-vis as described previously.1 Values for activity 
remaining were calculated as a percent of the uninhibited activity at each 
timepoint determined using a parallel incubation in which inhibitor was 
omitted (but 1% DMSO cosolvent included for consistency). The fit shown is 
to a single exponential decay to yield kobs 0.035 ± 0.003 min
-1 for this 
concentration of (1). 
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Figure 4.6: ESI mass spectra of (-) NDM-1 and (+) NDM-1 reacted with inhibitor (1) at 
various inhibitor:protein ratios (1:1, 5:1, 100:1) sprayed under (A) denaturing 
or (B) native conditions. Deconvolution reveals that up to three inhibitors can 
bind to NDM-1 and, under native conditions, attachment of the inhibitor does 
not displace the Zn(II) ions. Open circles in (B) denote uninhibited NDM-1 
in the reacted sample. Reported mass accuracies (ppm) account for mass shifts 
due to the covalent inhibitor or Zn(II) cofactors. 
To localize the reaction sites of inhibitor 1, the 25+ charge states of the singly, 
doubly, and triply modified NDM-1 were individually isolated and characterized using 
HCD and UVPD (Figure 4.7). As opposed to the diverse array of sequence ions produced 
by UVPD, HCD results in a relatively small number of b/y ions dominated by preferential 
Pro cleavages (e.g., y100 and b114). Maps of the backbone cleavage sites corresponding to 
the observed fragment ions shown in Figure 4.8 highlight the higher sequence coverage 
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afforded by UVPD (74-84%) compared to HCD (16-26%). The mass shifts of the y100
11+ 
ions observed for both HCD and UVPD in Figure 4.7 corresponds to addition of one, two, 
or three equivalents of 1. In this context, the specific positions of the each adduct can be 
determined by accounting for the mass shift(s) at each of the eight possible Lys residues of 
NDM-1. Covalent attachment of inhibitor 1 through disulfide bridging of the thiol end 
(opposite the expected reactive moiety) to C208 was considered but the retention of both 
Zn(II) ions (Figure 4.6B) after modification as well as the similar HCD and UVPD 
fragmentation patterns observed even after addition of a reducing agent provide strong 
evidence against this possibility. Both HCD and UVPD methods indicate that the 
modification sites are all located along the same loop that borders the active-site (ASL4: 
G207-H228). Localization of binding sites is summarized in Figure 4.9 for NDM-1 
containing one, two, or three equivalents of inhibitor 1. Briefly, for the singly-bound 
species, the UVPD data indicates that reaction occurs at either K211 (expected site) or 
K214. When two equivalents of 1 are bound, UVPD confidently localizes them to K211 
and K214. The UVPD results indicate that the third equivalent is added at K216. There is 
no evidence for covalent modification by 1 at K125 (buried), or at other solvent accessible 
Lys residues (K106, K181, K242, K268). The only Lys residues that are modified are 
contained within a single loop consisting of residues 209-224 that neighbor the active site 
(ASL4), and none of the other Lys residues are targeted. In comparison, the homologous 
loop in IMP-1 is considerably shorter and lacks the two Lys residues in NDM-1 that 
account for additional modifications. Therefore, sequence differences likely underlie the 
apparent difference in Lys modification selectivity between IMP-1 and NDM-1. 
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Figure 4.7: (A) HCD and (B) UVPD MS/MS spectra resulting from activation of the 25+ 
charge state of (-) NDM-1 or (+) NDM-1 covalently bound to one, two, or 
three of inhibitor (1). Abundant fragment ions are labelled for the uninhibited 
sample. Mass shifts of +88 Da in one of the most abundant fragment ions 
(y100
11+) in both the HCD and UVPD spectra due to sequential addition of 
inhibitor (1) can be observed and is denoted by ♦. 
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Figure 4.8: Deconvoluted (A) HCD and (B) UVPD spectra produced by activation of (-) 
NDM-1 or (+) NDM-1 covalently bound to one, two, or three of inhibitor (1). 
The corresponding MS/MS spectra are shown in Figure 4.7. Surviving 
precursor is labelled with a filled circle. Sequence coverage maps of identified 
fragment ions are shown with corresponding sequence coverage values. Static 
modifications of +88 Da were added to highlighted Lys residues. UVPD 
allowed complete localization of up to three inhibitor (1). 
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Figure 4.9: Summary of the localization of (A) one, (B) two, or (C) three inhibitor (1) 
moieties (with loss of pentafluorophenol) covalently attached to Lys residues 
of NDM-1 by using (1) HCD and (2) UVPD. Green shaded regions indicate 
localization according to the MS/MS spectra in Figure 4.7 and corresponding 
sequence coverage maps of identified fragment ions in Figure 4.8. The eight 
possible Lys sites are labelled above the gray residue bar in (A). (D) Sites at 
which the inhibitor was localized (K211, K214, K216) are labelled and shown 
as green sticks on the crystal structure of NDM-1 (PDB ID: 3SPU). The six 
Zn(II) binding residues are also labelled and shown as black sticks. 
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4.4.3 Tracking Closure of an Active Site Loop over a Lysine-Modifying Covalent 
NDM-1 Inhibitor 
To characterize conformational changes resulting from a more well-defined 
binding event, we substituted a different affinity label, an O-aryloxycarbonyl hydroxamate 
(2), that selectively modifies Lys211 in NDM-1 (although minor amounts of an undefined 
secondary modification site were reported when excess 2 was used for labeling).41 In a 
previous study both X-ray crystallography and MS  were used to confirm covalent 
modification of K211, but the positioning of the substrate-binding beta-hairpin loop was 
perturbed artifactually by interaction with a second monomer found in the crystal lattice, 
and by non-enzymatic degradation of the adduct during crystallization.41 Here, we used 
native ESI-MS to better characterize structural changes that occur upon incubation of 2 
with NDM-1. Even with treatment of excess 2, only one equivalent of expected adduct was 
detected on NDM-1 (Figure 4.10), with retention of both zinc ions after modification. The 
degraded adduct (a carbamoylated K211) observed earlier by X-ray crystallography was 
not observed under these conditions. 
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Figure 4.10: Native ESI mass spectra of (-) NDM-1 and (+) NDM-1 reacted with inhibitor 
(2) with observed charge states labelled (8+, 9+). Unreacted NDM was 
observed in the reacted sample (open circles). The right panel shows the 
corresponding deconvoluted spectra. Both Zn(II) cofactors were retained after 
covalent attachment of inhibitor (2). Mass shifts for the inhibitor and Zn(II) 
cofactors are accounted for when calculating accuracies (ppm). 
We then used UVPD-MS to characterize the structural impact on NDM-1 caused 
by inhibition with 2 via changes in observed fragmentation. Specifically, we have 
consistently found that regions of a protein that exhibit increased flexibility and/or fewer 
stabilizing interactions frequently result in enhanced fragmentation and thus yield more 
abundant sequence ions. In contrast, engagement of a region in stabilizing noncovalent 
interactions may prevent separation of fragment ions, thus hindering their detection and 
leading to an apparent suppression in the backbone cleavages.31 UVPD of the 9+ charge 
state yielded a wide array of sequence ions, including those retaining both the covalently-
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bound inhibitor and one or two non-covalently bound Zn(II) ions (Figure 4.11). The 
binding site of the inhibitor was localized to the expected residue, K211 (Figure 4.11B, 
4.11C), based on backbone cleavages that confidently bracketed the mass shift of the 
inhibitor. Summation of all the fragment ions arising from backbone cleavages as described 
in the Experimental section yielded the graphical displays shown in Figure 4.12 for 
unmodified NDM-1 and the inhibitor 2:NDM-1 complex. A plot of calculated p-values per 
residue in Figure 4.2A assigns statistical significance to observed differences from t-test 
calculations. Conversion of the two displays to a difference plot in Figure 4.13A or as a 
heatmap in Figure 4.13B facilitates visualization of the variations in fragmentation of 
NDM-1 after reaction with this affinity label. 
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Figure 4.11: (A) UVPD MS/MS spectra of the 9+ charge state of (-) NDM-1 and (+) NDM-
1 bound covalently to inhibitor (2). Corresponding deconvoluted UVPD 
spectra are shown in (B) with the precursor identified by a filled circle. 
Several abundant fragment ions are labelled in which the ♦ denotes a mass 
shift corresponding to inhibitor (2). (C) Apo and holo (Zn-bound) fragment 
ions produced by UVPD are mapped along the protein sequence. A +193 Da 
static modification at K211 (highlighted yellow) was considered to localize 
covalent attachment of the inhibitor. 
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Figure 4.12: (A) Intensities (summed and normalized to the TIC) of identified UVPD 
fragment ions plotted per residue for uninhibited NDM-1 (blue) and NDM-1 
bound to inhibitor (2) (orange). Subtracting the values for uninhibited NDM-
1 from the corresponding values for inhibitor-bound NDM-1 yields the 
difference plot in Figure 4.13. (B) Heatmap representing the log of the values 
in (A) shown along the linear protein sequence. 
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Figure 4.13: (A) Difference plot showing the change in summed abundances of Zn(II) 
bound holo and apo fragment ions produced upon UVPD of NDM-1 
covalently bound to inhibitor (2) (with loss of phenol) compared to 
uninhibited NDM-1. The UVPD fragmentation plots for both samples are 
shown in Figure 4.12. The five active site loops are outlined with dotted lines 
while the residue at which the inhibitor attaches (Lys211) is denoted with a 
dashed line. Heatmaps of these differences are represented (B) linearly along 
the protein sequence or (C) mapped on the crystal structure of NDM-1 bound 
to inhibitor (2) (PDB ID: 6OVZ). Red regions correspond to enhancement of 
backbone cleavage efficiency for the inhibitor bound sample compared to the 
uninhibited while blue regions indicate suppression. Active site loop 1 
(including F70), Lys211, and inhibitor (2) are displayed as sticks, while the 
Zn(II) ions are shown as spheres in (C). 
Suppression of backbone fragmentation (colored blue in the heatmap) is observed 
throughout large stretches of the protein for inhibitor-bound NDM-1, particularly 
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encompassing the N-terminal half of the protein that includes two of the active site loops 
(ASL1: M67-G71 and ASL2: V117-D124) as well as the three other active site loops in 
the C-terminal region (Figure 4.13). ASL3 (F183-T195) and ASL5 (M248-S251) are short 
loops that form a deep cavity in which the two Zn(II) ions reside. ASL4 (G207-H228) is 
significantly longer and creates the floor, while ASL2 acts as the ceiling. Notably, ASL1 
is the beta-hairpin loop proposed to play an important role in substrate binding (Figure 
4.3). The suppression of fragmentation indicates a general loss of flexibility in all five 
active site loops that frame the active site. This observation is consistent with other studies 
that show a general increase in overall thermostability of NDM-1 upon binding inhibitors.45 
More specifically, our use of native UVPD-MS reveals that fragmentation of the backbone 
spanning the ASL1 region shows the greatest suppression, specifically bracketing the 
residue F70, which is positioned at the apex of this substrate-binding beta-hairpin loop 
(Figure 4.13). This observation is a clear indication that the beta-hairpin loop neighboring 
the active site NDM-1 closes and rigidifies over the bound ligand. The use of UVPD-MS 
avoids several artifacts in the crystallography of ligand:NDM-1 complexes: commonly 
observed ASL1 intertwining between neighboring monomers in the crystal lattice and 
degradation of the covalent adduct made by 2. Additionally, this MS approach avoids the 
requirement to covalently install reporter labels in the beta-hairpin loop that could perturb 
function, and clearly favors a loop closing event upon inhibitor binding. Our result is more 
consistent with prior 19F NMR results indicating loop closure upon ligand binding and 
implies that the loop opening previously suggested by RFQ-DEER studies may instead be 
due to perturbation by the spin label or loop twisting resulting in an apparent distance 
increase.13,14 
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4.4.4 Detecting Displacement of Zn2 by a Cysteine-Modifying Covalent NDM-1 
Inhibitor 
Determining the impact of inhibitors on the metalation state of NDM-1 is an 
important yet often overlooked aspect of developing inhibitors suitable for therapeutic use.4 
Compounds that inhibit by stripping both metal ions from the dinuclear zinc NDM-1 and 
sequestering them as small molecule complexes are likely to have significant off-target 
effects making them less suitable as potential therapeutics. Native MS has previously been 
used to detect changes in the metalation state of NDM-1 upon inhibitor binding.42,45 Here 
we apply UVPD-MS and an established Zn2 ejector to more extensively elucidate 
structural changes that occur throughout the NDM-1 protein upon inhibitor binding. 
The non-selective thiol reagent ebselen (3) has been examined as a ligand for a wide 
variety of cysteine-containing proteins by using mass spectrometry.46 In particular, ebselen 
is a potent inhibitor of NDM-1 that functions by covalently modifying the sole Cys residue 
found in soluble NDM-1 constructs (Cys208).42 Cys208 is a direct ligand to Zn2 
(coordinated by D124, C208, H250) and treatment with ebselen (3) induces the loss of one 
zinc ion, previously presumed to be Zn2, from NDM-1 as detected by native MS. Based 
on using denaturing conditions for initial collection of ESI mass spectra in the present 
study, we confirmed addition of one ebselen equivalent to NDM-1 (Figure 4.14A). Using 
non-denaturing conditions, a narrow envelope of low charge states (8+ – 11+) is observed 
for uninhibited NDM-1 with the retention of two Zn(II) ions (Figure 4.14B). After reaction 
with ebselen, NDM-1 yields a much wider distribution of charge states (8+ – 18+) and the 
net mass shift corresponds to the attachment of a single ebselen along with the loss of one 
Zn(II) ion (Figure 4.14B). These results confirm removal of a metal cofactor after 
modification by ebselen, and also indicate unfolding of a portion of the NDM-1 protein as 
evidenced by the extended tail of the charge state distribution. 
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Figure 4.14: ESI mass spectra sprayed under (A) denaturing and (B) native conditions of 
(-) NDM-1 and (+) NDM-1 reacted with ebselen. The charge states observed 
in (B) are labelled (uninhibited: 8+ – 11+; reacted: 8+ – 18+). Corresponding 
deconvoluted spectra are shown to the right. Addition of ebselen causes loss 
of one of the Zn(II) ions as evidenced in (B). Accuracies (ppm) are calculated 
accounting for mass shifts due to covalent attachment of the inhibitor or non-
covalent retention of metal cofactors. 
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UVPD of the most abundant charge state (24+ for denaturing conditions; 9+ for 
non-denaturing conditions) allows the structure of the modified protein to be characterized 
in more detail. High sequence coverages were obtained for the protein in both the high 
(denatured) and low (non-denaturing) charge states (78% and 79%, respectively) and 
allowed confident localization of the inhibitor adduct to Cys208 based on bracketing the 
mass shift via backbone cleavages (Figure 4.15 and Figure 4.16). Under non-denaturing 
conditions, zinc-bound holo fragment ions are observed in addition to apo (zinc-free) 
fragment ions (Figure 4.16B). Owing to the high energy deposited during UV 
photoactivation, backbone bonds are cleaved preferentially over the disruption of non-
covalent interactions, resulting in production of holo (containing Zn) fragment ions as well 
as apo (without Zn) fragment ions that elucidate binding sites.30,34–36,38 For uninhibited 
NDM-1, holo fragment ions can contain up to two zinc(II) ions, whereas the ebselen-
modified protein only has one remaining Zn(II) that can be retained in fragment ions (in 
addition to the covalently-bound ebselen moiety). Zn-bound holo ions resulting from 
UVPD were mapped along the protein sequence and upon the crystal structure for 
uninhibited NDM-1 (Figure 4.17). Corresponding structures for inhibited NDM-1 in 
which holo ions containing one or two Zn(II) were considered separately are shown in 
Figure 4.18. Based on this analysis, it is evident that it is exclusively Zn2, and not Zn1, 
that is lost upon binding of ebselen to NDM-1. Specifically, Zn-bound holo fragment ions 
are no longer observed from backbone cleavages adjacent to the three residues responsible 
for coordinating Zn2 (D124, C208, H250). Also, N-terminal holo ions are only produced 
C-terminal to the first Zn1 binding residue (H120) and C-terminal holo ions N-terminal to 
H189 (Figure 4.17). This assessment of the appearance and disappearance of key Zn-
containing fragment ions allows the identity of the lost Zn ion to be directly observed as 
Zn2.  
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Figure 4.15: (A) UVPD MS/MS spectra collected while spraying under denaturing 
conditions of the 24+ charge state of (-) NDM-1 and (+) NDM-1 bound 
covalently to ebselen. The corresponding deconvoluted spectra are shown in 
(B) with the precursor identified with a filled circle and several abundant 
fragment ions labelled. Fragment ions labelled with a ♦ are mass shifted +273 
Da and contain the inhibitor. (C) Sequence coverage maps of identified 
fragment ions resulting from UVPD. For the reacted sample, a static 
modification was added at the highlighted Cys (C208) allowing localization 
of the inhibitor to that residue. 
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Figure 4.16: (A) MS/MS spectra produced by UV photoactivation of the 9+ charge state 
of (-) NDM-1 and (+) NDM-1 bound covalently to ebselen sprayed under 
native conditions. (B) Deconvoluted UVPD spectra corresponding to the 
MS/MS spectra in (A). The precursor is denoted by a filled circle. The inset 
(m/z 9300-9500) highlights a fragment ion observed in both the apo and holo 
(Zn-bound; indicated by an *) forms for the uninhibited sample but only in 
the apo form for the inhibitor bound species. (C) Sequence coverage maps 
accounting for identified apo and holo (Zn-bound) fragment ions resulting 
from UVPD. Searching with a +273 Da static modification at C208 
(highlighted yellow) allows localization of the inhibitor to that residue. 
 127 
 
Figure 4.17: (A) Sequence of NDM-1 with Zn(II)-containing holo ions observed during 
UVPD of the uninhibited (solid line) and ebselen (3) reacted (dotted line) 
samples mapped above as linear segments. Coloring of the lines corresponds 
to N-terminal (blue), C-terminal (red), or bi-directional (green) Zn(II)-
containing holo fragment ions identified from the UVPD spectra of the 
corresponding 9+ species shown in Figure 4.16. Complementary N- and C-
terminal holo ions arising from the same backbone position indicate bi-
directional fragmentation. For the uninhibited protein, one or two bound 
Zn(II) ions were considered while for the reacted protein, only holo ions 
containing a single Zn(II) were identified. The residue at which ebselen 
covalently attaches (Cys208) is highlighted in yellow. This information is 
mapped along the crystal structure of NDM-1 (PDB ID: 3SPU) for the 
uninhibited (B) and (+) ebselen (C) proteins. Corresponding crystal structure 
maps for the uninhibited protein separately identifying singly and doubly 
Zn(II) bound holo ions are given in Figure 4.18. Zn(II) binding residues are 
shown as sticks and the two Zn(II) ions are represented as yellow spheres. 
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Figure 4.18: Crystal structure map (PDB ID: 3SPU) of (A) singly and (B) doubly Zn(II) 
bound holo ions for an unreacted NDM-1 sample. A corresponding combined 
map is shown in Figure 4.17. Residue color indicates whether the holo 
fragment ion is N-terminal (blue), C-terminal (red), or bi-directional (green). 
Ions were identified from the UVPD spectra shown in Figure 4.16. Bi-
directional fragmentation is defined as complementary N- and C-terminal 
holo ions resulting from cleavage at the same backbone position. The six 
residues known to bind the cofactors are represented as sticks. 
Lastly, considering both apo and holo fragment ions, variations in the backbone 
fragmentation efficiencies for ebselen-modified NDM-1 versus uninhibited NDM-1 were 
charted (Figure 4.19) and shown as a difference plot in Figure 4.20. Suppression of 
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backbone cleavages is observed for the ASL1 region (the substrate-binding beta-hairpin 
loop) as well as for the three residues coordinating Zn1 (H120, H122, H189), suggesting a 
reorganization that curbs fragmentation throughout the N-terminal region of the protein 
after modification by ebselen. Interestingly, there is slight suppression of UVPD at D124 
suggesting that this residue, no longer coordinated to Zn2, may engage in new interactions 
with the bound inhibitor, which is expected to be located nearby due to the proximity of 
Cys208. 
 
 
Figure 4.19: (A) Plot per residue of the abundances of identified fragment ions summed 
and normalized to the TIC for uninhibited NDM-1 (blue) and ebselen-bound 
NDM-1 (pink). The difference plot in Figure 4.20 was created by subtraction 
of the values for uninhibited NDM-1 from the corresponding values for 
ebselen-bound NDM-1. (B) Log of the values in (A) shown as a linear 
heatmap along the sequence. 
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Figure 4.20: (A) Changes in abundances represented as a difference plot of apo and holo 
UVPD fragment ions between NDM-1 bound covalently to ebselen and an 
uninhibited sample resulting from subtraction of the UVPD fragmentation 
plots shown in Figure 4.19. ASL1 is outlined with a dashed slate line while 
the six residues known to bind the Zn(II) cofactors are highlighted with 
dashed black lines. (B) Linear and (C) crystal structure (PDB ID: 3SPU) 
heatmap representations are shown. Suppression in backbone cleavage 
efficiency of the inhibitor-bound species compared to the uninhibited is 
indicated by blue regions while enhancement is represented by red regions. 
In (C), ASL1  is displayed as spheres and the Zn(II)-binding residues are 
shown as sticks. The inhibitor attaches covalently at C208. 
Here we demonstrate the application of UVPD-MS to characterize inhibitor 
binding, and to simultaneously report on the site of covalent reaction (Cys208), the 
metalation state of NDM-1 (specifically the loss of Zn2), the closure of the substrate-
binding beta-hairpin loop (ASL1), and the partial denaturation of C-terminal domain of the 
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protein. These results are consistent with prior work that shows loss of one zinc equivalent 
upon addition of one equivalent of ebselen, and additionally provide direct evidence that 
Cys208 is adducted and that Zn2 is ejected.42 Our results are also consistent with prior 
studies that show an overall decrease in thermostability upon loss of Zn2 and the formation 
of putative inclusion bodies upon ebselen treatment, but provide more specific structural 
details about how the structure of Zn2 ligands, surrounding residues, and the C-terminal 
domain of the protein are impacted by Zn2 ejection.15,47 
4.4.5 Examining Structural Changes in NDM Clinical Variants Associated with 
Zn(II) Binding Residues 
Given the capability of UVPD-MS to detect structural changes in NDM-1 upon 
Zn2 ejection by ebselen (3), we reasoned that this MS technique may also be useful to 
detect and better understand the structural implications of sequence differences introduced 
by clinical variants of NDM. Many of the NDM variants (currently NDM-1 through NDM-
29) have increased thermostability and increased affinity for Zn2, presumably indicating 
that the blaNDM gene is evolving in response to the dual selective pressures of antibiotic 
treatment and zinc depravation by host innate immune responses.3,15–18 Here, we compare 
NDM-1 (the reference sequence) and the double mutant NDM-15 (M154L, A233V), which 
has a ~10-fold increase in Zn2 Kd value and ~7 C increase in thermostability, as well as 
the individual single mutants NDM-4 (M154L) and NDM-6 (A233V) (Figure 4.3).17 X-
ray crystallography has revealed only minor structural differences between NDM-1 and 
NDM-4 (or other variants), and the mechanism whereby these mutations communicate to 
the Zn2 site to impact affinity is not obvious. Here, we apply UVPD-MS to interrogate 
structural differences among representative clinical NDM variants. 
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Upon electrospray ionization, each of the variants was observed to produce intact 
protein ions in low charge states (9+, 10+, 11+) bound to two Zn(II) (Figure 4.21). 
Isolation and UV photoactivation of the 9+ charge state yielded the fragmentation patterns 
in Figure 4.22. Deconvolution allows the isotopically-resolved fragments to be readily 
assigned as sequence ions (Figure 4.23). In addition to apo (Zn-free) fragment ions, holo 
(Zn-bound) fragment ions were identified, the latter readily assigned based on inclusion of 
a mass shift of one or two Zn(II) ions relative to the metal-free fragment ions. Combining 
the observed metal-free and holo fragment ions accounts for coverage of 69-78% of the 
protein sequence as shown in the maps in Figure 4.23. 
 
 
Figure 4.21: (1) Native ESI mass spectra of (A) NDM-1, (B) NDM-4, (C) NDM-6, and 
(D) NDM-15 with observed charge states labelled (9+, 10+, 11+). 
Corresponding deconvoluted spectra are shown in (2). Observed masses were 
+126 Da from theoretical masses based on protein sequence indicating that 
two Zn(II) ions are retained. Accuracies (ppm) are calculated accounting for 
the mass shift of the metal cofactors. 
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Figure 4.22: UVPD MS/MS spectra (one pulse at 3 mJ) of the 9+ charge state of NDM 
clinical variants: (A) NDM-1, (B) NDM-4, (C) NDM-6, and (D) NDM-15. In 
panel (A) several of the most abundant fragment ions are labelled. Surviving 
precursor is identified with a filled circle. 
 134 
 
Figure 4.23: (A-D) Deconvoluted UVPD mass spectra of the corresponding spectra shown 
in Figure 4.22 for activation of the 9+ charge state of four clinical variants of 
NDM. The precursor is labelled with a filled circle. Sequence coverage maps 
and values of identified fragment ions are shown for each spectrum. These 
account for apo (Zn-free) and holo (Zn-bound) fragment ions. For the 
variants, the mutated residue(s) is highlighted in yellow. 
Differences in relative abundances of some of the fragment ions between variants 
are apparent upon visual inspection of the UVPD mass spectra in Figure 4.22. Regions of 
the protein in which noncovalent interactions or flexibility are impacted by single point 
mutations can be elucidated by examining the enhancement or suppression of UVPD 
backbone clevages.35–37 For each NDM variant, the backbone cleavage efficiency upon 
UVPD was determined and is represented graphically in Figure 4.24 as a function of each 
residue of the protein. The fragmentation behavior of three clinical variants (NDM-4, 
NDM-6, NDM-15) is compared to that of the reference sequence of NDM-1 by subtraction 
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of the backbone cleavage values at each residue and visualized as difference plots (Figure 
4.25). Negative values are indicative of suppression in UVPD backbone cleavages for each 
clinical variant compared to NDM-1, whereas positive values designate enhancement in 
backbone cleavages for the clinical variant compared to NDM-1. Statistical significance of 
the observed differences is determined from t-test calculations and represented as p-values 
plotted per residue in Figure 4.2C. To aid in visualization, the changes are represented as 
a heatmap spanning blue (suppression of fragmentation of the clinical variant) to red 
(enhancement of fragmentation of the clinical variant) along the protein sequence from N-
terminus to C-terminus (Figure 4.26A). Imprinting the heatmap on the crystal structure 
allows differences in fragmentation to be related to structural features and specific regions 
of the protein, as illustrated Figure 4.26B-D. 
Overall, the variations in backbone fragmentation (enhancement of some regions 
and suppression of others) observed for NDM-15 (Figure 4.26D) generally mirror the 
collective differences for NDM-4 and NDM-6 (Figures 4.26B-C). Specifically, for NDM-
15 suppression in UVPD fragmentation is observed along the loop containing H120-D124 
(ASL2) and the loop containing C208 (ASL4), with the same modest degree of suppression 
occurring for both NDM-4 and NDM-6. These two loop regions are shaded in blue on the 
crystal structure in Figure 4.26D to highlight the suppression of backbone fragmentation 
of NDM-15. The suppression in fragmentation likely represents a rigidification of these 
domains that is qualitatively consistent with the observed changes in thermostability. 
Reported melting temperatures (Tm) for NDM-1, -4, -6, and -15 (54.5, 58.4, 56.3, and 61.5 
C, respectively) show increases in stability and the gain for NDM-15 (~7 C) is only 
slightly more than the sum of the two individual mutants, which is also consistent with the 
mostly additive nature of the observed structural changes.17 
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Figure 4.24: (A) Abundance of apo and holo fragment ions (summed and normalized to 
TIC) plotted per residue for NDM-1 (blue), NDM-4 (red), NDM-6 (green), 
and NDM-15 (yellow). Larger values indicate greater extents of backbone 
cleavages adjacent to the amino acid. Subtraction of the values for NDM-1 
from the corresponding values for each of the variants was used to create the 
difference plots in Figure 4.25. (B) Linear heatmap of the log of the values in 
(A) shown along the sequence. 
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Figure 4.25: (A-C) Changes in the summed abundances of apo and Zn-bound holo 
fragment ions resulting from UVPD of three clinical variants of NDM 
compared to the reference NDM-1 sequence represented as difference plots. 
Values greater than zero indicate that the backbone cleavages are enhanced 
for the variant relative to NDM-1; values less than zero indicate that the 
backbone cleavages are suppressed for the variant. A plot of the summed 
backbone cleavage values used to create these graphs is shown in Figure 4.24. 
The six Zn-binding residues and two mutated residues (M154, A233) are 
indicated with dashed lines. 
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Figure 4.26: Changes in backbone cleavage efficiency during UVPD for three clinical 
variants of NDM (NDM-4, NDM-6, NDM-15) compared to the reference 
sequence (NDM-1) represented as heatmaps along the (A) linear sequence or 
(B-D) crystal structure (PDB ID: 3SPU) of NDM-1. Regions colored red 
indicate enhancement while blue regions denote suppression in UVPD 
cleavage efficiency of the variant compared to NDM-1, based on the 
difference plots shown in Figure 4.25. The mutated sites are shown as sticks 
(M154L, A233V). The six residues involved in binding the two Zn(II) ions 
represented as gray spheres are shown as sticks and labelled in (B). 
We then focused particularly on the six residues that anchor the dinuclear zinc ion 
cluster at the active site. The higher affinity Zn1 site consists of H120, H122, and H189 
ligands, and the lower-affinity Zn2 site consists of D124, C208, and H250 (Figure 4.3).48 
The relative degrees of backbone fragmentation bracketing these six key residues of NDM-
1 and each of the other variants are highlighted in Figure 4.27. For NDM-4 (M154L) 
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compared to NDM-1, the only significant differences in fragmentation related to the six 
targeted Zn-binding residues are suppression of backbone cleavages at H120 and H122. 
This observation aligns well with the location of M154 near the α-carbon of H122, and 
with a prior proposal that substitution of Met to Leu shifts the position of H122 to enable 
more stabilizing interactions with Zn1.15 Here, we clearly observe the stronger H122:Zn1 
interactions experimentally as a suppression in the efficiency of backbone cleavages at 
H122. This same type of suppression of fragmentation at H122 is not noted for NDM-6 
(A233V), indicating a different stabilization mechanism is used for these two variants.  
  For NDM-6 (A233V), the backbone cleavage efficiency is substantially 
suppressed at a different Zn1-ligand, H120, as well as at two Zn2-ligands, C208 and H250. 
The shift of the flexible loop containing C208 owing to the introduction of a bulkier Val 
for Ala would place C208, H120 and H250 (on neighboring loops) in more ideal positions 
for stabilizing Zn2. Lastly, for NDM-15 (M154L, A233V), suppression of backbone 
fragmentation was observed at four of the six zinc-binding residues, representing mostly a 
sum of the changes observed in individual single mutations. However, backbone 
fragmentation at C208 was not suppressed for NDM-15, suggesting that the M154L 
substitution has a greater impact on enhancing Zn(II) affinity compared to A233V when 
both mutations are present. The use of native UVPD-MS reveals in increased detail how 
distant structural changes located on each side of the dizinc site are propagated and 
combine to increase metal ion affinity, helping to elucidate the mechanisms used by clinical 
variants to overcome zinc scarcity at infection sites. 
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Figure 4.27: Graph displaying summed UVPD fragment ion abundances normalized to the 
total ion current (TIC) corresponding to fragment ions originating from 
cleavages occurring proximal to each of the six Zn(II) binding residues for 
NDM-1 (blue), NDM-4 (red), NDM-6 (green), and NDM-15 (yellow). 
Corresponding values for the entire protein sequence are given in the UVPD 
abundance plots in Figure 4.24. Asterisks indicate residues at which the 
difference in backbone cleavages for the clinical variant compared to the 
reference NDM-1 protein is statistically significant (99% confidence 
threshold). 
4.5 CONCLUSION 
Structural information detailing ligand:NDM interactions is important for design 
and optimization of selective and potent inhibitors to serve as probes for chemical biology 
experiments and as lead compounds for therapeutic development. However, interactions 
between ligand and the essential substrate-binding beta-hairpin loop are obscured due to 
method-dependent artifacts. Additionally, structure activity relationships are often difficult 
to extract from libraries if the mechanisms of inhibition are not determined. Attributes that 
lead to more effective metal stripping and attributes that lead to more effective ternary 
complex formation (inhibitor:dizinc cluster:NDM) can both show increased inhibition, but 
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only the latter category is suitable for developing NDM-selective probes and therapeutic 
leads. Here, we demonstrate a powerful strategy utilizing native MS along with UVPD 
relying on observed changes in fragmentation to interrogate structural differences between 
uninhibited and inhibited NDM-1, simultaneously revealing conformational changes in the 
substrate-binding beta-hairpin loop, reporting on the metalation state of the enzyme, 
identifying modified residues (if any), and tracking other changes throughout the protein 
structure. We characterized two structurally divergent inhibitors, a K211-selective covalent 
inhibitor and a C208 covalent modifier and found that each induced a similar structural 
change - closure of the beta-hairpin loop.  These cases were characterized using covalent 
inhibitors, but native UVPD-MS can also be applied to the similar characterization of non-
covalent ligands.31,34–36,38 Previous solution phase studies of NDM led to conflicting 
conclusions, that ligand binding either induces loop closure or opens the cavity even 
wider.13,14 However, the prior studies required mutation and chemical modification of the 
loop which likely impact both structure and dynamics, and one approach used a non-native 
metalloform. Here, native UVPD-MS was completed using wild type dizinc NDM to 
conclusively show loop closing upon ligand binding. This result is particularly significant 
because optimization of loop:inhibitor interactions is required for NDM drug design, and 
native UVPD-MS now provides a novel strategy to probe this interaction with minimal 
perturbation that was not possible with previous methods.  
Another advantage of native UVPD-MS as showcased here for NDM is the ability 
to simultaneously report on modification sites (for covalent inhibitors), metalation state, 
and structural perturbations in addition to loop closure. Several notable conclusions can be 
drawn from the study of inactivators 1-3. The pentafluorophenyl ester (1) was previously 
shown to be specific for one Lys residue in IMP-1, but we find it readily modifies three 
Lys residues neighboring the active site (although no other surface Lys residues). This 
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finding reveals two additional Lys residues as alternative available targets for design of 
more effective covalent NDM inhibitors. Simultaneous targeting of multiple Lys residues 
could be useful in overcoming resistance-causing mutations. Previous characterization of 
the O-aryloxycarbonyl hydroxyamate inactivator (2) by X-ray crystallography revealed 
two covalent adducts, and one was proposed to be a degradation product of the other.41 
Here, native UVPD-MS revealed only the parent modification and not the degradation 
product, supporting the proposed inactivation mechanism and suggesting that the MS 
method may give less ambiguous results. Finally, native UVPD-MS of ebselen (3)-treated 
NDM-1 confirms a prior report that one zinc ion is ejected,15,47 and now reveals the identity 
of the ejected zinc as Zn2 and provides direct evidence that Cys208 is the modified residue. 
Unexpectedly, we also detected partial denaturation of the C-terminus of the protein, which 
provides structural information that helps explain decreased thermostability and inclusion 
body formation upon Zn2 loss and ebselen treatment. We note that ebselen is a useful probe 
to show the structural and mechanistic implications of Cys modification and Zn2 loss in 
NDM-1 that may be more broadly applicable. NDM-1 appears to be less effective than 
other carbapenemases in some infection models and patients.49 One possibility is that the 
weak affinity for Zn2 allows NDM-1 to be more easily inhibited by host zinc sequestering 
proteins such as calprotectin or Cys oxidation by ROS during inflammation, which would 
be expected to result in deleterious structural changes similar to those we observed with 
ebselen using native UVPD-MS.  
The ability of native UVPD-MS to report on structural changes related to 
metalation state prompted us to use this method to characterize select NDM clinical 
variants. Notably, we were able to track the structural impact of distant mutations to direct 
zinc ligands. Specifically, the increased Zn2 affinity (with respect to NDM-1) previously 
measured for NDM-4 (M154L) and NDM-6 (A233V) appear to be due to structural 
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changes largely propagated through different networks of residues emanating from the 
distant mutated sites toward the dizinc cluster. Many of the structural changes induced by 
the individual mutations are conserved when combined in the NDM-15 variant (M154L, 
A233V), but additional structural changes are also observed, highlighting the structural 
basis of the small synergism observed in this double mutant. Identification of these 
networks of residues may enable prediction of how newly emerging clinical variants 
perturb structure, function and zinc affinity. These structural changes were not easily 
observed using X-ray crystallography, but native UVPD-MS provides an innovative 
approach to determine the impact of NDM clinical variants on structure and dynamics and 
elucidates in greater mechanistic detail how structural changes at distant mutation sites are 
propagated to the zinc binding site. 
In summary, native UVPD-MS is a powerful analytical tool that enables 
simultaneous detection of inhibitor binding, covalent modification sites, metalation state, 
and structural changes to NDM, including closing of the active-site beta-hairpin loop and 
other perturbations owing to ligand binding or mutation, all using unlabeled wild-type 
dizinc protein. This tool should help to easily distinguish metal stripping agents from 
ternary complex forming inhibitors, which are preferred for drug design,4 while providing 
additional information about inhibitor interactions with the substrate-binding beta-hairpin 
loop that were not easily obtained previously. Moreover, new insight into the structure and 
dynamics of emerging NDM clinical variants has been uncovered. 
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Chapter 5: Investigation of GTP-Dependent Dimerization of G12X K-
Ras Variants Using Ultraviolet Photodissociation Mass Spectrometry‡ 
5.1 OVERVIEW 
Mutations in the GTPase enzyme K-Ras, specifically at codon G12, remain the 
most common genetic alterations in human cancers. The mechanisms governing activation 
of downstream signaling pathways and how they relate back to the identity of the mutation 
have yet to be completely defined. Here we use native mass spectrometry (MS) combined 
with ultraviolet photodissociation (UVPD) to investigate the impact of three G12X 
mutations (G12C, G12V, G12S) on the homodimerization of K-Ras as well as 
heterodimerization with a downstream effector protein, Raf. Electrospray ionization (ESI) 
was used to transfer complexes of WT or G12X K-Ras bound to guanosine 5’-diphosphate 
(GDP) or GppNHp (non-hydrolyzable analogue of GTP) into the gas phase. Relative 
abundances of homo- or hetero-dimer complexes were estimated from ESI-MS spectra. K-
Ras + Raf heterocomplexes were activated with UVPD to probe structural changes 
responsible for observed differences in the amount of heterocomplex formed for each 
variant. Holo (ligand-bound) fragment ions resulting from photodissociation suggest the 
G12X mutants bind Raf along the expected effector binding region (β-interface) but may 
interact with Raf via an alternative α-interface as well. Variations in backbone cleavage 
efficiencies during UV photoactivation of each variant were used to relate mutation identity 
to structural changes that might impact downstream signaling. Specifically, oncogenic 
upregulation for hydrogen-bonding amino acid substitutions (G12C, G12S) is achieved by 
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stabilizing β-interface interactions with Raf, while a bulkier, hydrophobic G12V 
substitution leads to destabilization of this interface and instead increases the proximity of 
residues along the α-helical bundles. This study deciphers new pieces of the complex 
puzzle of how different K-Ras mutations exert influence in downstream signaling.  
5.2 INTRODUCTION 
The canonical rat sarcoma (Ras) family of GTPases H-, N-, and K-Ras function as 
molecular switches and key regulators of cell proliferation and survival through effector 
pathways, including Raf-MAPK, which communicates signals from surface receptors to 
the cell nucleus.1,2 The G-domain (GTPase and effector binding regions) of these proteins 
are highly conserved while their C-terminal hypervariable regions are post-translationally 
modified in an isoform specific manner.1,3–5 Ras remains inactive in a GDP-bound state 
until upstream stimuli cause a switch to the GTP-bound active state, catalyzed by 
interaction with a guanine-nucleotide exchange factor (GEF). Once activated, Ras binds 
effector proteins to transmit receptor-initiated signals until it is returned to the inactive state 
by interaction with a GTPase activating protein (GAP).1 Single point mutations most 
commonly in the Gly12 (G12X) position (or less frequently at the residues specified by 
codons 13 or 61) prevent GTP hydrolysis, causing the protein to stall in the active state and 
resulting in activation of cell cycle progression and proliferation.6 Consequently, Ras is the 
most frequently mutated gene in human cancer and an important oncogene for targeting in 
cancer therapy.7,8 Based on the knowledge that Ras requires membrane localization and 
GTP-loading to be active, previous therapeutic strategies involved prevention of membrane 
localization by inhibiting isoprenylation9, targeting the GTP-binding pocket10–17, or 
interfering with interaction of upstream and downstream effectors.18–21 However, these 
efforts to pharmacologically inhibit mutant Ras have met limited success.22 Recent 
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evidence from immuno-EM23, spectroscopy24,25, dynamic light scattering26, and 
microscopy27–29 experiments suggest that Ras functions as a dimer (or less likely as a 
nanocluster30,31), not as a monomer. Accordingly, therapeutic efforts have expanded to 
disruption of the mechanisms modulating Ras oligomerization instead of solely the 
enzymatic ones.32–36 The regulation of Ras dimer formation and signaling is still poorly 
understood, although based on modeling there are two known dimer interfaces along the 
protein: (1) β-sheet interface at the Switch I/effector binding region and (2) α-helix 
interface at the C-terminal allosteric lobe of the G domain.26,36 Studies that reveal integral 
components of Ras dimers, decipher mechanisms regulating formation of these complexes, 
and define how oncogenic mutations impact these processes are needed to guide the 
development of more effective therapeutic strategies. 
In recent years, mass spectrometry (MS) has proven to be a useful experimental 
technique to probe theoretical models and address structural biology questions in a 
sensitive, rapid manner.37,38 The use of covalent chemical probes, such as 
hydrogen/deuterium exchange (HDX) or cross-linking reagents, in conjunction with 
bottom-up tandem mass spectrometry (MS/MS) is now a standard approach for evaluating 
solvent accessibilities and mapping protein interfaces.39–41 Top-down techniques have 
more recently gained traction for characterization of protein structure with the advent of 
native MS and advances in MS/MS methods.37,38 The framework for native MS entails the 
transfer of intact protein complexes to the gas phase by electrospray ionization of solutions 
of high ionic strength which largely preserves tertiary and quaternary structures of 
macromolecules.42 Consequently, native MS is now routinely used for identification of 
oligomeric states of proteins and elucidation of binding stoichiometry with other proteins 
or ligands.38 To further discern three-dimensional shapes of protein complexes in the gas 
phase, ion mobility (IM) mass spectrometry has proved to be an indispensable technique 
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for providing information complementary to static high resolution structures resulting from 
X-ray crystallography, NMR spectroscopy, or cryo-EM.43  
MS/MS methods sensitive to protein structure have been developed to study the 
architecture of protein-protein and protein-ligand complexes. Traditional collisional 
activation of native-like complexes mainly yields ejection of ligands or subunits,44,45 which 
is often uninformative and has spurred the application of alternative activation methods. 
Electron-based methods, including electron transfer dissociation (ETD) and electron 
capture dissociation (ECD), and surface induced dissociation (SID) represent the most 
widely used alternative methods to characterize protein structure.46–52 ETD and ECD yield 
mostly diagnostic sequence ions with abundances that can be correlated with 
crystallographic B-factors and used to probe the topology of protein assemblies for flexible 
regions, thus revealing insight into the higher order structure of the complexes.46–51 
Conversely, SID causes disassembly of protein-protein complexes into intact subunits in a 
way that conserves the symmetry of charge distribution among the separating proteins or 
subunits.52 Coupled with IM, this MS/MS technique allows for the rapid determination of 
stoichiometry and topology for computationally designed protein complexes.53 Ultraviolet 
photodissociation (UVPD) represents a third alternative MS/MS method that utilizes fast, 
high-energy excitation via 193 nm photons and yields the widest array of diagnostic 
sequence ions for protein complexes.54–58 The abundances of holo (ligand-bound) and apo 
(ligand-free) product ions resulting from activation of protein-ligand complexes by 193 nm 
UVPD have been demonstrated to reflect secondary and tertiary structural features.59–62 
The suppression or enhancement of UVPD at each position along the backbone is thought 
to be modulated by non-covalent interactions that stabilize structural features and prevent 
separation of fragments after bond cleavage. Recent studies have demonstrated this 
approach is sensitive to loop movements upon ligand binding in dihydrofolate reductase 
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(DHFR)60, dynamic plasticity throughout a catalytic cycle of the active enzyme adenylate 
kinase61, and even long-range conformational changes resulting from single residue 
mutations in K-Ras.62 
Previously variations in UVPD backbone cleavage efficiencies were monitored for 
monomeric protein-ligand complexes of K-Ras (wild-type (WT) and three G12X mutants: 
G12C, G12V, G12S) upon exchange of GDP for a non-hydrolyzable GTP analogue, 
guanosine 5’-[β,γ-imido]triphosphate (GppNHp).62 Switching from the inactive 
diphosphate bound state to the active triphosphate bound protein yielded unique structural 
changes for each mutant. Based on the examination of monomeric K-Ras and a series of 
G12X variants, the way each mutation modulated homo- or hetero-dimer formation with 
downstream effectors was inferred. Given that the G12 position lies on the surface of the 
protein, longer-range conformational changes in areas of the protein related to dimer 
formation are likely involved. Specifically, observations included stabilization of the α-
helical bundle for G12C K-Ras, stabilization of the β-sheet region for G12V K-Ras, and 
increased flexibility of the β-sheet region for G12S K-Ras.62 Although the mechanism is 
not yet well defined, this supports that the identity of the G12 substitution impacts 
downstream signaling and patient survival differently.63–69  
Here we report the use of native MS and UVPD to directly interrogate homo- and 
hetero-dimers of WT and three clinically relevant G12X mutants of K-Ras (G12C, G12S, 
G12V). We use native MS to define the relative abundance of homodimer formation for 
each K-Ras G12X mutant bound to either GDP or GppNHp (the non-hydrolyzable 
analogue of GTP), and compare the amount of heterodimer formed between each of the K-
Ras mutants and the Ras binding domain (RBD) of a downstream effector kinase, rapidly 
accelerated fibrosarcoma (Raf). Comparing UVPD cleavage efficiencies of K-
Ras•GppNHp + RafRBD heterodimers for each of the mutants to the WT suggests hydrogen-
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bonding amino acid substitutions (G12C, G12S) rely on directly stabilizing the β-interface 
interactions with Raf for oncogenic upregulation, whereas a bulkier, hydrophobic G12V 
substitution causes destabilization of this interface and instead results in tightened α-helical 
bundles. Direct structural interrogation of intact dimers by UVPD-MS represents an 
advance in unraveling the mutation-dependent interplay of structure and binding 
interactions for K-Ras signaling phenotypes. 
5.3 EXPERIMENTAL 
5.3.1 Sample Preparation 
Four variants of recombinant human K-Ras (WT, G12C, G12V, G12S) were 
expressed and purified as previously described.62 The RBD of c-Raf-1 was expressed using 
a purchased plasmid and purified as follows. A pET 15-b vector containing the gene for 
the Ras Binding Domain (RBD) of c-Raf-1 with an N-terminal 6X-Histidine tag separated 
by a thrombin cleavage site was purchased from Genscript. The vector was transformed 
into BL21(DE3) competent E. coli cells (New England Biolabs) for expression. Single 
colonies of E. coli containing the desired plasmid were inoculated in 5 mL of Luria-Bertani 
(LB) Broth and grown at 37 °C for 14-16 hours. The 5 mL cultures were used to seed 2 L 
flasks containing Terrific Broth (TB, Millipore) which were incubated with shaking at 37 
°C for 4-6 hours until an OD600 ~0.6 was obtained. Isopropyl β-D-1-thiogalactopyranoside 
(IPTG, GoldBio) was added to a final concentration of 1 mM, and protein expression was 
carried out at 30 °C while shaking for 6 hours. 
Cells were collected via centrifugation at 6000 RPM for 15 minutes, and re-
suspended in lysis buffer containing 50 mM phosphate, 500 mM NaCl, 40 mM imidazole, 
and 10% glycerol at pH = 8.0. Re-suspended cells were lysed by sonication with a probe 
sonicator for 3 rounds consisting of 1 minute of pulsed sonication followed by 5 minutes 
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of resting on ice, for a total sonication time of 3 minutes. The cell debris was separated via 
centrifugation at 19000 RPM for 30 minutes, and the supernatant was passed through a 10 
μM filter then added to an Ni-nitrilotriacetic acid (Ni-NTA) column pre-equilibrated with 
lysis buffer for affinity chromatography. The flow through was reapplied to the column 
and then the column was washed with lysis buffer prior to elution with a buffer containing 
50 mM phosphate, 500 mM NaCl, 500 mM imidazole, and 10% glycerol at pH = 8.0. The 
eluent containing the target protein was exchanged into a cleavage buffer containing 20 
mM tris, 150 mM NaCl, 2.5 mM CaCl2, and 10% glycerol at pH = 8.0. Protein 
concentration was estimated via absorbance at 280 nm and thrombin (Millipore) was added 
to a concentration of 2 U thrombin per mg Raf and incubated overnight at 4 °C. The cleaved 
Raf was separated from thrombin by applying the protein solution to a benzamidine column 
equilibrated in cleavage buffer, and the flow through containing Raf was collected. The 
protein was then exchanged into a final buffer of 50 mM ammonium acetate (pH 7.8).  
Typical yield was 20-30 mg per liter of growth. Expressed sequences of K-Ras and Raf, 
and structures of the guanosine phosphate ligands GDP and GppNHp (the stable GTP 
analogue) are shown in Figure 5.1.  
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Figure 5.1: Sequence of (A) WT K-Ras4b (1-169) and (B) the Ras binding domain (RBD) 
of Raf. Residues are numbered from the first glycine (G) of K-Ras4b in 
subsequent figures. The G12X position mutated to Cys, Val, or Ser is shaded 
in a gold box. (C) Structures of the guanosine phosphate ligands (1) guanosine 
5’-diphosphate (GDP) and (2) guanosine 5’-[β,γ-imido]triphosphate 
(GppNHp). 
Given that purified K-Ras was already bound to GDP, the procedure for nucleotide 
exchange to GppNHp is described here. To remove GDP and load K-Ras with the non-
hydrolyzable GTP mimic GppNHP, variants were diluted to 30 μM in an exchange buffer 
(pH 8.0) consisting of 25 mM Tris, 10 mM EDTA, 1 mM dithiothreitol (DTT), and 1.5 
mM guanosine 5’-[β,γ-imido]triphosphate (GppNHp, Sigma Aldrich, St. Louis, MO). This 
solution was incubated on ice for 1 hour. Subsequently magnesium acetate was added at a 
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final concentration of 25 mM and the mixture was incubated on ice for an additional 30 
min. These steps were repeated once after using a 10 kDa molecular weight cutoff filter 
device (EMD Millipore, Billerica, MA) to put the protein back into exchange buffer. 
Afterwards, a final buffer exchange was performed to put the GppNHp-loaded protein into 
MS spray buffer (50 mM ammonium acetate with 5 μM magnesium acetate, pH 7.8). 
Protein samples were diluted to 20 µM or 80 µM dimer concentration in 50 mM ammonium 
acetate containing 5 μM magnesium acetate (pH 7.8) and desalted for MS analysis using 3 
kDa molecular weight cutoff filter devices (EMD Millipore, Billerica, MA). For 
heterodimer experiments, K-Ras (~19.3 kDa) and Raf (~9.4 kDa) were combined at a 1:1 
ratio before desalting.  
5.3.2 Mass Spectrometry 
Experiments were performed on a Thermo Scientific Orbitrap Elite mass 
spectrometer (Bremen, Germany) modified with a 193 nm Coherent Excistar excimer laser 
(Santa Cruz, CA) to allow photodissociation in the HCD cell.54 An offline nano-ESI source 
with Au-coated borosilicate emitters ionized the native complexes using source voltages 
of 1.0-1.1 kV and a source temperature of 200 °C. A resolving power of 240K at m/z 400 
was used to collect all MS spectra. MS1 spectra represent sixty scans with an automated 
gain control (AGC) setting of 1E6. On-line size-exclusion chromatography experiments of 
K-Ras•GppNHp + RafRBD complexes were performed by interfacing a Dionex LC system 
to the modified Thermo Scientific Orbitrap Elite instrument. For each run, 5 µg of a 1:1 K-
Ras•GppNHp:RafRBD solution (5 µL injection volume) in 50 mM ammonium acetate 
containing 5 μM magnesium acetate (pH 7.8) was injected onto a 2.1 mm × 150 mm 
ACQUITY UPLC Protein BEH SEC column with a 200 Å pore size and 1.7 µm particle 
size (Waters, Milford, MA). An isocratic mobile phase of 50 mM ammonium acetate at pH 
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6.8 was flowed at a rate of 100 µL min-1. The LC effluent was introduced into the MS using 
a HESI source with an applied voltage of 4 kV. ESI-MS spectra were collected with a 
resolving power of 240 K at m/z 400. Normalized relative abundances of K-Ras•GppNHp 
+ RafRBD complexes were calculated from peak areas of EIC traces of m/z values 
corresponding to each species. MS/MS analysis of K-Ras•GppNHp + RafRBD heterodimers 
involved selection of the 12+ charge state of the complex using an isolation width of 20 
m/z and activation with a single 3 mJ pulse. Each UVPD mass spectrum represents 500 
transients with a scan range m/z 220-4000 using an AGC value of 5E5 and maximum ion 
time of 2 sec. For each K-Ras•GppNHp + RafRBD heterocomplex triplicate UVPD data was 
collected. 
5.3.3 Data Analysis 
For MS1 spectra, the amount of K-Ras homodimer formation was assessed by 
normalizing the summed abundances of all charge states corresponding to the observed 
dimer to the total ion current of the spectrum. UVPD MS/MS spectra were de-charged and 
de-isotoped using the Thermo Xtract algorithm (S/N ratio of 3, fit factor of 44%, remainder 
of 25%). Monoisotopic apo fragment ions were identified using ProSight Lite v1.4 which 
accounts for the nine ion types typically observed during UVPD (a, a + 1, b, c, x, x + 1, y, 
y – 1, z). Holo fragment ions were also identified by including mass shifts in the search 
corresponding to the GppNHp ligand, coordinating Mg2+ ion, and intact RafRBD subunit. 
Although RafRBD itself likely underwent fragmentation during UV activation, to streamline 
data interpretation this subunit was treated as a ligand bound to K-Ras and only the intact 
mass shift of RafRBD was searched. Confident identification of holo fragment ions 
containing a cleaved portion of K-Ras bound to a cleaved portion of RafRBD is impeded 
given the nearly unlimited array of possible fragment ion assignments that can arise from 
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combinations of partial protein sequence segments. Thus, assignment of these types of holo 
ions was not considered owing to low statistical confidence. Given that RafRBD is much 
smaller than K-Ras and has a different sequence, the unidentified fragments of RafRBD 
should not overlap significantly with the K-Ras fragments of interest. Specific mass 
additions included in the searches for holo ions are: 9952.879 – 9954.894 Da for RafRBD + 
GppNHp•Mg2+, and 542.969 – 544.984 Da for GppNHp•Mg2+ alone. The divalent Mg2+ 
cofactor necessary to coordinate the GppNHp ligand contributed a +21.969 Da shift. The 
fragment abundance utility of UV-POSIT70 was used to sum cleavage yields at each 
backbone position upon UVPD if the amino acids of a protein are numbered from 1 (N-
terminus) to R (C-terminus) for a protein containing R amino acids. This Web-based 
program normalizes the abundances of identified holo and corresponding apo ions to the 
total ion current of the spectrum by collectively summing N-terminal product ions (an, bn, 
cn) arising from backbone cleavage C-terminal to a given amino acid, n, with C-terminal 
fragment ions (xR-n+1, yR-n+1, zR-n+1) resulting from cleavage N-terminal to residue n.
70 This 
calculated value is used to convey the UVPD backbone cleavage efficiency adjacent to 
each amino acid throughout the protein. Student’s t-test with pooled standard deviations 
was used to determine the statistical significance of differences in backbone cleavage 
efficiency upon UVPD for WT and G12X K-Ras•GppNHp + RafRBD heterocomplexes. A 
two-tailed test was assumed to determine p-values from calculated t-values. Figure 5.2 
gives graphs of the log of calculated p-values per residue for backbone cleavage efficiency 
of heterodimers of each G12X K-Ras variant compared to WT. The black dotted line 
represents a confidence threshold at 99%. A histogram of calculated p-values for the entire 
data set is shown in Figure 5.2 demonstrating over 55% of measured UVPD backbone 
cleavage efficiencies within a triplicate measurement are statistically different for G12X 
variants from the measured average of the corresponding WT backbone position at the 99% 
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confidence level. For reference, Figure 5.3 is the crystal structure of WT K-Ras bound to 
GppNHp and complexed with RafRBD (PDB ID: 4G0N)
71 with important helical and loop 
regions labelled and the two dimer interfaces highlighted. 
 
 
Figure 5.2: (A) Log of calculated p-values per residue for the differences plotted in Figure 
5.19. The black dotted line represents a confidence threshold at 99%. (B) 
Histogram of all calculated p-values in (A-C) with the cumulative percentage 
shown in blue. Pooled standard deviations were used to perform Student’s t-
test for comparison of UVPD of each K-Ras variant to the WT. Assuming a 
two-tailed hypothesis, p-values were determined from calculated t-values. In 
summary, a p-value smaller than 0.01 at a given residue for a variant of K-
Ras indicates that the average measured UVPD intensity within a triplicate 
measurement is statistically different from the measured average of the WT 
at the 99% confidence level. 
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Figure 5.3: (A) Crystal structure of WT K-Ras bound to GppNHp and complexed with 
RafRBD (PDB ID: 4G0N) highlighting important loop and α-helical regions. 
The two possible dimer interfaces include the α-interface at α-C and α-D 
helices (shaded yellow) and β-interface at Switch I (shaded purple). Binding 
with most upstream or downstream effector proteins occurs at the stronger β-
interface, but the α-interface might be used for homodimerization. (B) 
Secondary structure map of the catalytic domain of the Ras family of proteins. 
Isoforms are almost identical in these regions but differ significantly in the C-
terminal hypervariable region (HVR). For this study, only residues 1-169 
were examined. 
Owing to the fact that UVPD-MS is a new approach for characterization of 
structural variations in protein complexes and providing insight into potential changes in 
conformation and binding motifs, there is need for critical evaluation of the method via 
appropriate controls and statistical tests. Some of the statistical tests and controls are 
described above and shown in Figures 5.2, 5.12 and 5.21. Moreover, the K-Ras protein 
used in the present study was also the subject of a prior study (ref. 62). Additional controls 
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and statistical tests were performed previously, as provided in Figures S2–S4 in ref. 62, 
including the assessment of the statistical significance of backbone cleavage efficiency for 
K-Ras and the G12C, G12V, and G12S mutants, both as native-like and denatured forms. 
One relevant control entailed the examination of UVPD of the denatured proteins, 
confirming that the relative fragment ion abundances were identical for 166 out of 169 
comparisons of specific backbone positions. In contrast, the UVPD fragment ion 
abundances of the native-like proteins showed numerous statistically significant 
differences in fragment ion abundances. These types of control experiments support the 
premise that UVPD is sensitive to protein structure. 
5.4 RESULTS AND DISCUSSION 
5.4.1 Native MS to Detect GTP-Dependent Formation of K-Ras Homodimers 
In addition to membrane localization and GTP-loading, recent studies posit the 
formation of homodimers as a significant factor in signaling output related to K-Ras.23–29 
Specifically, dimerization of K-Ras might promote self-association of downstream 
effectors necessary for their activation.23,28 Consequently, defining the extent to which 
specific G12X mutations impact the formation of K-Ras homodimers when bound to either 
GDP or GTP is essential. ESI-mass spectra were collected under native conditions for WT, 
G12C, G12V, and G12S K-Ras sprayed with a 1:1 ratio of either GDP or GppNHp (the 
non-hydrolyzable analogue of the GTP ligand) at both a relatively standard (20 μM) and 
high (80 μM) protein concentration (Figure 5.4). In addition to the ligand-bound 
monomers (9+, 10+, 11+), homodimers (12+, 13+, 14+) were observed for all K-Ras 
protein except G12V at 20 μM. Table 5.1 summarizes the measured intact masses for 
observed dimers containing two protein molecules and two ligands. Native MS represents 
a unique strategy to determine both stoichiometries and compositions of complexes.  The 
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experimentally measured masses confirm that each subunit of the dimer is bound to the 
same ligand (GDP or GppNHp) as the other subunit (since the nucleotide exchange is 90-
95% efficient, there is always a portion of GDP-bound K-Ras in solution). Other 
biochemical techniques have been used to demonstrate the existence of K-Ras dimers but 
lacked sufficient mass resolution to confirm their specific compositions.23–29  
 
 
Figure 5.4: Native ESI mass spectra of (A) WT, (B) G12C, (C) G12V, and (D) G12S K-
Ras bound to GDP (top) or GppNHp (bottom) (1:1 protein:ligand ratio) at a 
protein concentration of 20 µM or 80 µM. Observed species are labelled in 
panel (D, right-side) (9+, 10+, 11+ monomers and 12+, 13+, 14+ 
homodimers). A bar graph displaying the abundance of each observed 
homodimer normalized to the TIC is given in Figure 5.5. The theoretical and 
measured monoisotopic masses for each observed homodimer are reported in 
Table 5.1. 
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Table 5.1: Table of theoretical and measured monoisotopic masses for each observed 
dimer in Figure 5.4. All expected masses account for one divalent Mg2+ ion 
bound per monomer subunit. The reported standard deviations represent 
triplicate data. 
 
 
The distribution of homodimers versus monomers for each variant are estimated by 
comparing normalized abundances of the ions in the native ESI mass spectra shown in 
Figure 5.4. Figure 5.5 illustrates the relative abundances of each observed K-Ras 
homodimer normalized to the total ion current for WT, G12C, G12V, and G12S K-Ras 
bound to GDP or GppNHp for protein concentrations of 20 or 80 µM. A larger bar indicates 
a greater portion of the dimeric form of the protein relative to the monomeric protein. 
GppNHp-bound WT K-Ras was observed to form significantly more abundant 
homodimers compared to its GDP-bound counterpart. This result is in line with the 
significant role of dimerization in the activation of K-Ras. The same general trend 
indicating enhanced formation of dimers containing GppNHp over GDP was observed for 
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both G12C and G12S K-Ras, and for each of these two variants the overall abundances of 
homodimers containing GDP or GppNHp were substantially higher than the abundances 
of WT homodimers. Since the G12C and G12S mutations result in constitutively active 
variants of K-Ras, higher abundances of the homodimers support the idea that 
oligomerization is important for activation of the enzyme. Interestingly, the abundances of 
G12V K-Ras homodimers were low in general and were only observed at the higher (80 
µM) protein concentration, suggesting dimerization is not a significant factor in 
maintaining an active state when the bulky Val is substituted for Gly. 
 
 
Figure 5.5: Graph displaying the abundance of each K-Ras homodimer normalized to the 
total ion current (TIC) for the native ESI mass spectra (Figure 5.4) for WT 
(blue), G12C (red), G12V (green), and G12S (yellow) bound to two GDP or 
two GppNHp (1:1 ratio) at a protein concentration of 20 µM (solid bars) or 
80 µM (hashed bars). GppNHp is a non-hydrolyzable analogue of GTP and 
represents the active state ligand of K-Ras. The theoretical and measured 
monoisotopic masses for each observed homodimer are reported in Table 5.1. 
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In general, the relatively low percentage of dimers (<1% to 11% in Figure 5.5) 
compared to the corresponding monomers is not surprising given that the protein is in 
solution with no membrane localization to aid in self-assembly.23,28 Previous dynamic light 
scattering experiments observed higher order oligomers only for K-Ras bound to another 
GTP-analogue, guanosine 5'-O-[γ-thio]triphosphate (GTP-γ-S), not GDP nor GppNHP.26 
Although GTP-γ-S is expected to be a better mimic of GTP, for the experimental conditions 
tested herein this compound hydrolyzed too quickly to allow confident measurements of 
protein complexation (Figure 5.6). 
 
 
Figure 5.6: ESI mass spectra of the non-hydrolyzable mimics of GTP: (A) GppNHp and 
(B) GTP-γ-S sprayed in 50 mM ammonium acetate (pH 7.8). The spectrum 
for GTP-γ-S suggests the ligand is mostly hydrolyzed to GDP. 
There is accumulating evidence that WT K-Ras can act as a tumor suppressor and 
counteract the activating effects of G12X mutations.72 To mimic cells heterozygous for 
G12X mutations, each of the three mutants bound to GDP or GppNHp was mixed in a 1:1 
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ratio with WT K-Ras at 20 or 80 µM total protein concentration prior to ESI. No dimers 
were observed in the ESI-MS spectra, thus suggesting that homodimers composed of two 
protein variants (WT and G12X K-Ras) are less stable or membrane localization is required 
for formation (Figure 5.7). 
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Figure 5.7: Native ESI mass spectra of (A) G12C, (B) G12V, and (C) G12S K-Ras bound 
to GDP (top) or GppNHp (bottom) (1:1 ratio) with an equimolar amount of 
WT K-Ras present in solution (total protein concentration of 20 µM or 80 
µM). Observed species are labelled in panel (A, top right) (9+, 10+, 11+ 
monomers of each variant). No dimers were observed under these conditions. 
Insets show zoomed-in views of 10+ charge states of each variant of GDP-
bound K-Ras (m/z 1970–2000). 
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5.4.2 Impact of G12X Mutations on K-Ras:Raf Heterodimer Formation 
Understanding how specific G12X mutations in K-Ras affect interactions with 
downstream effectors is another piece of the puzzle encompassing the mechanism by which 
individual substitutions impact signaling.65  Each of the four K-Ras variants bound to either 
GDP or GppNHp (the non-hydrolyzable analogue of GTP) was combined in a 1:1 ratio 
with the Ras binding domain of Raf (RafRBD) to determine the extent to which 
heterocomplexes are formed in solution. ESI-MS spectra are shown for WT K-Ras in 
Figure 5.8 and for the three G12X variants in Figure 5.9. K-Ras:RafRBD heterodimers were 
observed only for GppNHp-bound K-Ras but not for GDP-bound K-Ras (Figure 5.8), a 
result consistent with the fact that only activated K-Ras (GTP-bound form) should bind 
RafRBD. The same outcome is true for the formation of heterodimers of the G12X variants 
in Figure 5.9: G12X:RafRBD heterodimers were only observed for solutions containing 
GppNHp, not GDP.  
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Figure 5.8: Native ESI mass spectra of 1:1 K-Ras:RafRBD solution of WT K-Ras bound 
to (A) GDP or (B) GppNHp (1:1 ratio). Observed species are labelled as 
colored circles (6+, 7+, 8+, 9+ RafRBD monomers, 9+, 10+, 11+ K-Ras 
monomers, and 10+, 11+, 12+, 13+, 14+ heterodimers). Corresponding 
spectra for G12C, G12V, and G12S K-Ras are shown in Figure 5.9. K-
Ras:RafRBD heterodimers were only observed for solutions containing 
GppNHp (non-hydrolyzable analogue of GTP), not GDP. The relative 
abundances of each species are estimated from SEC-MS and reported in 
Figure 5.11 The 12+ heterodimer was selectively isolated and activated to 
yield the UVPD spectra shown in Figure 5.13. 
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Figure 5.9: Native ESI mass spectra of 1:1 K-Ras:RafRBD solution of (A) G12C, (B) 
G12V, and (C) G12S K-Ras bound to GDP (top) or GppNHp (bottom) (1:1 
ratio). Observed species are labelled as colored spheres (6+, 7+, 8+, 9+ 
RafRBD monomers, 9+, 10+, 11+ K-Ras monomers, and 10+, 11+, 12+, 13+, 
14+ heterodimers). Corresponding spectra for WT K-Ras are given in Figure 
5.8. K-Ras + RafRBD heterodimers were only observed for solutions 
containing GppNHp, not GDP. Very low abundances of G12C and G12S 
homodimers are also observed. The relative abundances of each species are 
estimated from SEC-MS and reported in Figure 5.11. The 12+ heterodimer 
was selectively isolated and activated to yield the UVPD spectra shown in 
Figure 5.13. 
Given that the observed monomeric and dimeric protein complexes span a broad 
m/z range, on-line size-exclusion chromatography was used to separate the various 
complexes in order to allow optimization of MS tuning parameters and improve the 
accurate measurement of abundances. Figure 5.10 illustrates extracted ion chromatograms 
(EICs) derived for the m/z values corresponding to each key species (K-Ras•GppNHp, 
RafRBD, and K-Ras•GppNHp + RafRBD). Peak areas from the EICs were used to estimate 
the distributions of the monomeric proteins (K-Ras•GppNHp and RafRBD) and 
heterodimers (K-Ras•GppNHp + RafRBD) for WT K-Ras and each of the three variants 
(Figure 5.11). The portions of K-Ras•GppNHp + RafRBD heterodimers (green segments) 
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are the focal point of Figure 5.11. G12V yields a significantly lower percentage of 
heterodimers than WT K-Ras, and conversely G12C and G12S display a larger percentage 
of heterodimers than WT K-Ras. This general trend in the formation of K-Ras•GppNHp + 
RafRBD heterodimers mirrors the results reported above for K-Ras homodimer formation. 
These results suggest that amino acid substitutions (G12C, G12S) that have enhanced 
hydrogen-bonding capabilities contribute to stabilizing the β-interface interactions with 
Raf.  In contrast, the bulkier, hydrophobic G12V substitution causes destabilization of this 
interface.  
 
 
Figure 5.10: EIC traces (2.0–6.0 min) of the m/z values corresponding to K-Ras•GppNHp 
(red), RafRBD (blue), and K-Ras•GppNHp + RafRBD heterodimer (green) from 
on-line SEC of solutions containing WT, G12C, G12V, or G12S K-
Ras•GppNHp with an equimolar amount of RafRBD. Peak areas were used to 
calculate the percent normalized relative abundance of each species reported 
in the bar graph in Figure 5.11. 
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Figure 5.11: Distribution of the normalized relative abundances of K-Ras•GppNHp (red), 
RafRBD (blue), and K-Ras•GppNHp + RafRBD heterodimer (green) from on-
line SEC of solutions containing WT, G12C, G12V, or G12S K-Ras•GppNHp 
with an equimolar amount of RafRBD. Peak areas of the EIC traces of m/z 
values corresponding to each species were used to calculate the reported 
percentages (Figure 5.10). 
5.4.3 Analysis of UVPD Holo Fragment Ions to Examine K-Ras:Raf Heterodimer 
Interface 
To further probe the differences in protein-protein interactions governing the 
binding of WT and G12X K-Ras to RafRBD, the most abundant charge state (12+) of each 
observed heterocomplex (K-Ras•GppNHp + RafRBD) was subjected to 193 nm UV 
photoactivation. Deconvoluted mass spectra of the isolated species are shown in Figure 
5.12 confirming that the isolated population is similar for WT and all three variants. Figure 
5.13 displays the UVPD MS/MS spectra for all four K-Ras•GppNHp + RafRBD complexes. 
In addition to disassembly of the complexes into their constituent subunits (K-
Ras•GppNHp (9+) and RafRBD (3+)), UVPD also yields diagnostic sequence ions.
56 
Deconvolution of the UVPD spectra allows identification of these fragment ions (Figure 
5.14). Based on the fragmentation patterns from UVPD, sequence coverage maps for each 
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K-Ras variant are given in Figure 5.15. UVPD afforded 85-89% coverage of WT K-Ras 
or G12X for each of the four complexes. 
 
 
Figure 5.12: (A-D) Deconvoluted mass spectra of the K-Ras•GppNHp + RafRBD 
complexes (12+ charge state) selectively isolated for activation by UVPD. 
The isolated species activated are fairly homogenous with up to two Na 
adducts present for each variant. 
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Figure 5.13: (A-D) UVPD mass spectra of the 12+ charge state of K-Ras•GppNHp + 
RafRBD heterodimers activated using a single 3 mJ pulse. Selected fragment 
ions are labelled in the expanded inset (m/z 1300-1350) in panel (A). Intact 
subunits are labelled for K-Ras•GppNHp in the 9+ charge state or RafRBD in 
the 3+ charge state. 
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Figure 5.14: (A-D) Deconvoluted UVPD mass spectra (corresponding to the spectra in 
Figure 5.13) of all K-Ras•GppNHp + RafRBD complexes (12+ charge state) 
using one 193 nm pulse at 3 mJ. Several abundant fragment ions are labelled 
in (A). Holo fragment ions (K-Ras•GppNHp bound to intact RafRBD) are 
denoted with ♦. The asterisks represent surviving precursor ions (non-
deconvoluted) as an artifact during deconvolution. 
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Figure 5.15: Sequence coverage maps of K-Ras based on identification of apo (ligand-
free) fragment ions identified in the deconvoluted UVPD spectra shown in 
Figure 5.14 (12+ charge state of the K-Ras•GppNHp + RafRBD heterodimer). 
The β-interface is shaded in purple. The apo ion sequence coverage was 85–
89% for K-Ras in all complexes. 
The fragment ions generated upon UVPD can be further categorized as apo 
(RafRBD-free) or holo (containing RafRBD) product ions. While traditional HCD typically 
causes ejection of the intact ligand prior to backbone fragmentation owing to the 
preferential cleavage of non-covalent interactions during collisional activation, UV 
photoactivation of protein-ligand complexes yields diagnostic sequence ions that retain 
non-covalent interactions with the bound ligands, termed holo fragment ions.55,60–62,73 HCD 
has been reported to yield holo ions consisting of a portion of a non-covalently bound 
nucleotide74 but UVPD consistently allows retention of intact nucleotides like GTP or 
GppNHp.62 The high energy imparted to a protein via absorption of 193 nm photons results 
in activation to excited electronic states and affords preferential cleavage of backbone 
bonds rather than disruption of electrostatic interactions with bound ligands. Consequently, 
mapping the location of observed holo ions along the protein backbone affords insight into 
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ligand-binding interfaces. Figure 5.16A displays the sequence of K-Ras with indicators 
above specific residues to show the sites of backbone cleavages that lead to production of 
holo ions. The indicators are color-coded to reflect whether the backbone cleavage sites 
correspond to formation of N-terminal ions (a,b,c), C-terminal ions (x,y,z), or bi-directional 
ions (i.e. backbone cleavages resulting in complementary N- and C-terminal holo ions). 
Although UVPD of the K-Ras•RafRBD complexes caused backbone fragmentation of both 
the K-Ras and RafRBD subunits, for streamlined data interpretation RafRBD was treated as 
one large ligand and only holo ions containing the intact RafRBD protein were considered. 
The crystal structure of K-Ras bound to RafRBD is shown in Figure 5.16B with residues 
corresponding to the observed sites of backbone cleavages color coded to aid in 
visualization for WT K-Ras (and corresponding structures for the three G12X mutants 
given in Figure 5.17). 
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Figure 5.16: (A) The backbone cleavage sites upon UVPD of the K-Ras•GppNHp + 
RafRBD heterodimer (12+) are mapped above the sequence of K-Ras (X13 = 
G, C, V, or S) as lines or symbols for WT (solid), G12C (dashes), G12V 
(dots), and G12S (pattern). The backbone cleavages that result in N-terminal 
ions (a,b,c) are colored blue; those that result in C-terminal ions (x,y,z) are 
colored red; and those that yield complementary N-terminal and C-terminal 
ions are categorized as bi-directional and are colored green.  The β-interface 
region is shaded in purple. (B) Crystal structure of K-Ras bound to GppNHp 
and complexed with RafRBD (PDB ID: 4G0N) with residues colored 
corresponding to N-terminal (a, b, c-type ions; blue), C-terminal (x, y, z-type 
ions; red), and bi-directional (green) holo fragment ions observed during 
UVPD of the 12+ WT heterodimer. Corresponding structures for the G12X 
mutants are given in Figure 5.17. The original UVPD spectra are shown in 
Figure 5.13. The GppNHp ligand (a non-hydrolyzable analogue of GTP) is 
shown as pink sticks and labelled in (B). 
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Figure 5.17: Crystal structures of K-Ras bound to GppNHp and complexed with RafRBD 
(PDB ID: 4G0N) with residues colored corresponding to backbone cleavages 
that produce N-terminal (a, b, c-type ions; blue), C-terminal (x, y, z-type ions; 
red), and bi-directional (green) holo fragment ions observed during UVPD of 
the 12+ heterodimer formed between (A) WT, (B) G12C, (C) G12V, and (D) 
G12S K-Ras and RafRBD. These structures correspond with the sequence 
shown in Figure 5.16A. The original UVPD spectra are shown in Figure 5.13. 
The GppNHp ligand (a non-hydrolyzable analogue of GTP) is shown as pink 
sticks and is labelled in (A). 
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Of the two known interfaces along K-Ras (α- and β-interfaces), effector binding is 
expected to occur at the stronger β-interface containing Switch-I (residues 27-36, 41-45, 
shaded in Figure 5.16A).26 The observed backbone cleavage sites that lead to RafRBD-
bound holo ions upon UVPD of the K-Ras•RafRBD complexes support the β-interface as 
the primary binding region for WT K-Ras as well as for the three G12X mutants. In 
particular, backbone cleavages that result in C-terminal (x,y,z) holo ions only occur in the 
region of K-Ras that is N-terminal to the β-interface, and backbone cleavages that lead to 
N-terminal (a,b,c) ions occur exclusively in the region C-terminal to the β-interface 
(Figure 5.16A). Moreover, the bi-directional holo ions that result in complementary C-
terminal and N-terminal product ions originate from backbone cleavages along or near this 
expected interface. Further evidence is provided by the apo sequence coverage maps 
(Figure 5.15) in which coverage of the β-interfacial region (shaded in purple) is relatively 
sparse, suggesting two possibilities. One possibility is that backbone cleavages in the β-
interfacial region might instead preferentially produce the mass-shifted holo fragment ions 
showcased in Figure 5.16A (thus depleting the abundances of apo sequence ions). 
Alternatively, fragmentation along the β-interfacial region might be suppressed owing to 
its engagement in interactions with RafRBD (thus stabilizing the β-interfacial region and 
preventing separation of fragment ions).  
Interestingly, there are several C-terminal and bi-directional holo fragment ions 
originating from backbone cleavages adjacent to residues N86-E92 (C-terminal to the β-
interface) which are observed for all three G12X mutants but not WT K-Ras (Figure 
5.16A). This region is part of the weaker α-interface (residues 86-105, 126-138) where K-
Ras homodimerization is thought to occur.16,26 Perhaps G12X mutants also use the α-
interface to bind effector proteins and maintain an active state. However, the fact that fewer 
holo ions originate from this region suggests either it is a lower population effector binding 
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region compared to the β-interface or the non-covalent interactions stabilizing this 
alternative binding mode are too weak to survive photodissociation (thus preventing 
survival of holo ions). The observations about the involvement of the α-interface merit 
future investigation using other traditional biophysical methods. 
5.4.4 Variations in UVPD Cleavage Efficiency for G12X K-Ras:Raf Heterodimers 
Since the mutated G12 position is located along the outer surface of K-Ras, it is 
expected that the conformational changes induced by the substitution result in longer-range 
changes in regions of the protein involved in dimer formation.62 UVPD has previously been 
demonstrated to be sensitive to these types of structural changes for other protein 
complexes.59–62 Specifically, variations in the efficiency of backbone cleavage induced by 
UVPD relative to the same protein in a different state are determined for each residue. The 
extent to which a given region engages in stabilizing intramolecular interactions (i.e. 
protein organization and rigidity) can be inferred from enhancement or suppression in 
UVPD backbone cleavage efficiency.59–62 Details are provided in the Experimental section 
on how backbone fragment ion abundances are summed and how cleavage efficiency is 
determined to generate the UVPD backbone cleavage efficiency plots shown in Figure 
5.18. Comparisons of the backbone cleavage efficiencies of G12X mutants to WT K-Ras 
are best visualized as plots of the differences in UVPD backbone cleavage efficiency for 
each residue (i.e. backbone cleavage efficiency of WT subtracted from the backbone 
cleavage efficiency of each mutant at each position) (Figure 5.19). These differences are 
represented as a heat map in which suppression of UVPD (values that fall below the zero 
axis) or enhancement of UVPD (values that lie above the zero axis) compared to UVPD of 
WT K-Ras are highlighted in blue and red, respectively (Figure 5.20A). The heat map 
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values are imprinted on the crystal structure of K-Ras•GppNHp + RafRBD to aid in relating 
conformational changes to structural features of the protein (Figure 5.20B-D). 
 
 
Figure 5.18: (A) Normalized TIC abundance of summed holo and apo product ions plotted 
per residue for each K-Ras•GppNHp + RafRBD heterodimer examined. These 
plots were used to create the difference plots shown in Figure 5.19 by 
subtraction of the values for each K-Ras variant from the corresponding 
values for WT K-Ras. (B) Heat map of the log of the values shown in (A). 
Relevant loops, α-helices, and interfaces are labelled underneath the x-axis. 
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Figure 5.19: Difference plots showing the change in summed abundances of holo and apo 
fragment ions produced upon UVPD for RafRBD-bound heterodimers of (A) 
G12C, (B) G12V, and (C) G12S K-Ras variants compared to WT. The UVPD 
fragmentation plot for each of the complexes is shown in Figure 5.18. 
Relevant loops, α-helices, and interfaces are labelled underneath the x-axis, 
and the regions of particular interest (alpha interface, beta interface, and 
switch II) are bracketed for emphasis. 
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Figure 5.20: Heat maps of the enhancement (red) and suppression (blue) of UVPD for 
RafRBD-bound heterodimers shown as a linear map across the sequence (A) or 
displayed along the crystal structure of K-Ras bound to GppNHp (non-
hydrolyzable analogue of GTP) and complexed with RafRBD for (B) G12C, 
(C) G12V, and (D) G12S K-Ras variants relative to WT K-Ras. These heat 
maps are difference plots: (i.e. G12X – WT). The colored regions represent 
statistically significant changes in cleavage efficiency of the protein backbone 
during UVPD based on the difference plots in Figure 5.19. The GppNHp 
ligand (pink) is shown as sticks and labelled in (B). The β-interface region is 
highlighted in purple in (B). Relevant loops, α-helices, and interfaces are 
labelled underneath the x-axis of (A). 
To gain insight into how the identity of the G12X mutations impacts the effects on 
signaling, we focus on conformational differences observed in three key regions: β-
interface (switch I: residues 27-36, 41-45), switch II (residues 58-64), and α-interface (α-
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C and α-D helices: residues 86-105 and 126-138). Zoomed-in views for these three regions 
of the difference plots shown in Figure 5.19 help to clarify the trends in UVPD backbone 
cleavage efficiency for each of the three variants compared to WT (Figure 5.21). Figure 
5.22 summarizes the observed enhancement or suppression in UVPD backbone cleavage 
efficiency of those three regions for RafRBD-bound heterodimers of G12C, G12V, and 
G12S compared to WT K-Ras. G12C and G12S result in similar changes in these regions, 
mainly stabilization of the β-interface (e.g., suppression of UVPD). Conversely the G12V 
substitution favors increased proximity of the helices in the α-interfacial region (observed 
as suppression of UVPD) and destabilization of the β-interface (resulting in enhancement 
of UVPD). 
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Figure 5.21: Difference plots shown in Figure 5.19 for RafRBD-bound heterodimers of 
G12C, G12V, and G12S K-Ras variants compared to WT zoomed-in on three 
key regions: β-interface (switch I), switch II, and α-interface (α-C and α-D 
helices). Asterisks indicate residues at which the summed intensity for the 
given variant is significantly different than WT at the 99% confidence level 
(p ≤ 0.01). Figure 5.2 gives plots of calculated p-values for all residues. For 
the G12V variant, the difference plot is also shown considering only a/x-type 
fragment ions to demonstrate the same trends are observed when summing all 
ion types. 
 
 
 
 
 187 
 
Figure 5.22: Summary of the observed enhancement (red) or suppression (blue) in UVPD 
backbone cleavage efficiency compared to the WT K-Ras for RafRBD-bound 
heterodimers of G12C, G12V, and G12S K-Ras in three key regions: β-
interface (switch I), switch II, and α-interface (α-C and α-D helices). The 
difference plots from which these trends were determined are given in Figure 
5.19. 
These observations bring new light to a previous study that used UVPD-MS to 
evaluate conformational changes that occurred for K-Ras and its three G12X mutants 
during the GTP loading step of K-Ras activation.62 In the previous study, a more stable α-
helical region was inferred for G12C K-Ras in comparison to WT K-Ras based on 
suppression of UVPD in that region, whereas G12S K-Ras exhibited more flexibility in the 
β-interface region based on enhancement of UVPD.62 Both of these findings are consistent 
with the adoption of a more stable β-interface upon RafRBD binding in the present study 
(i.e. given the β-interface was found to be more flexible, more intramolecular contacts 
could be formed upon Raf binding). For G12V K-Ras compared to WT K-Ras, the 
converse was observed previously: the β-interface appeared to be more rigid (stabilized by 
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more interactions; lower UVPD fragmentation efficiency) after substitution of GppNHp 
for GDP.62 Again this finding correlates with the more stabilized α-interface of G12V after 
RafRBD binding as evidenced by the decreased UVPD fragmentation efficiency in the 
present study. This outcome implies engagement of fewer interactions between RafRBD and 
the β-interface, since G12V K-Ras was more rigidly pre-organized prior to effector 
binding. Collectively these results suggest that mutations of K-Ras which introduce 
hydrogen-bonding groups (G12C, G12S) result in a stabilized β-interface, although it is 
also acknowledged that thiols form weaker hydrogen bonds than alcohols.75 In contrast, a 
bulkier, more hydrophobic substitution (G12V) relies preferentially on contacts along the 
α-interface for oncogenic activation of K-Ras. 
5.5 CONCLUSION 
Native MS and UVPD-MS were used to probe homo- and hetero-dimers of WT and 
G12X mutants of K-Ras, along with its effector protein Raf. K-Ras formed more 
homodimers when bound to a GTP-analogue compared to GDP for the WT, G12C, and 
G12S variants. G12V K-Ras only formed homodimers at a relatively high protein 
concentration. Similar results were observed for heterodimer formation between K-Ras and 
the Ras binding domain of effector protein Raf: compared to WT K-Ras, G12V K-Ras 
yielded less abundant heterodimers in contrast to G12C and G12S K-Ras. Characterization 
of the K-Ras•GppNHp + RafRBD heterocomplexes by UVPD revealed that all three G12X 
mutants prefer binding along the β-interface, which is the expected effector binding region 
for WT K-Ras. However, there is also evidence that the three mutants, but not WT K-Ras, 
can bind Raf along the weaker α-interface as well. Moreover, comparison of UVPD 
backbone cleavage efficiencies for the G12X mutants relative to WT K-Ras afforded 
insight into longer-range conformational changes responsible for observed differences in 
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downstream signaling. Specifically, the G12C and G12S substitutions (ones that introduce 
hydrogen-bonding groups) resulted in a stabilized β-interface, whereas the G12V mutation 
(a bulky, hydrophobic substitution) yielded tighter helical bundles along the α-interface. 
G-domain non-covalent interactions (α- and β-interfaces) are only one of the factors 
governing homo- and hetero-dimerization, along with membrane localization by post-
translational modifications along the hypervariable region of K-Ras or other scaffold 
proteins. This work offers new insight into the seemingly complex mechanism relating the 
identity of G12X mutations to different downstream effects. 
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Chapter 6: Mapping a Conformational Epitope of Hemagglutinin A 
Using Native MS and Ultraviolet Photodissociation§ 
6.1 OVERVIEW 
As the importance of effective vaccines and the role of protein therapeutics in the 
drug industry continue to expand, alternative strategies to characterize protein complexes 
are needed. Mass spectrometry (MS) in conjunction with enzymatic digestion or chemical 
probes has been widely used for mapping binding epitopes at the molecular level. However, 
advances in instrumentation and application of activation methods capable of accessing 
higher energy dissociation pathways have recently allowed direct analysis of protein 
complexes. Here we demonstrate a workflow utilizing native MS and ultraviolet 
photodissociation (UVPD) to map the antigenic determinants of a model antibody-antigen 
complex involving hemagglutinin (HA), the primary immunogenic antigen of the influenza 
virus, and the D1 H1-17/H3-14 antibody which has shown to confer potent protection to 
lethal infection in mice despite lacking neutralization activity. Comparison of sequence 
coverages upon UV photoactivation of HA and of the HA•antibody complex indicates the 
elimination of some sequence ions that originate from backbone cleavages exclusively 
along the putative epitope regions of HA in the presence of the antibody. Mapping the 
number of sequence ions covering the HA antigen versus the HA•antibody complex 
highlights regions with suppressed backbone cleavage and allows elucidation of unknown 
epitopes. Moreover, examining the observed fragment ion types generated by UVPD 
demonstrates a loss in diversity exclusively along the antigenic determinants upon MS/MS 
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of the antibody-antigen complex. UVPD-MS shows promise as a method to rapidly map 
epitope regions along antibody-antigen complexes as novel antibodies are discovered or 
developed. 
6.2 INTRODUCTION 
The design of immunotherapeutic drugs and vaccines relies on identification of the 
epitopes to which antibodies bind. The location within the intact antibody of corresponding 
paratopes comprising predominantly but not exclusively loops within the variable domain, 
i.e. the complementarity determining regions (CDRs), is very important for understanding 
antibody function and also for generating improved variants having higher antigen affinity 
or specificity.1,2 Although structural biology approaches, namely X-ray crystallography, 
NMR spectroscopy, and cryo-electron microscopy, provide high resolution information on 
the residues at the antibody:antigen interface, alternative epitope/paratope mapping 
pipelines offer certain advantages including requiring lower quantities of proteins and 
allowing more rapid analysis.3 Over the past three decades, mass spectrometry (MS) has 
emerged as a rapid and sensitive technique for determining the higher order structure of 
antibodies and identifying residues comprising the binding epitope and paratope.4 
Traditionally MS-based approaches to map antigenic epitopes involve formation of the 
complexes in solution followed by enzymatic digestion to preserve structural information 
prior to mass spectrometric read-out.4 Proteolytic digestion of the antigen can occur before 
or after formation of the complex with the antibody, termed respectively epitope extraction 
and epitope excision, followed by washing of unbound peptides and MS analysis of epitope 
peptides.4,5 More modern MS-based epitope and paratope mapping methods rely on 
hydrogen/deuterium exchange (HDX),6–9 carboxyl footprinting,10,11 or fast photochemical 
oxidation of proteins (FPOP)12,13 to compare the uptake of unbound and bound antigens 
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and detect regions protected upon antibody binding. Chemical cross-linking of immune 
complexes has also been demonstrated for identifying antigenic determinants.14  
With the advent of native MS, intact antibody-antigen complexes that have not been 
subjected to proteolytic digestion can now be interrogated directly.15,16 The native MS 
approach utilizes electrospray ionization of analytes in solutions of high ionic strength to 
maintain non-covalent interactions and transfer intact proteins into the gas phase with 
architectures reminiscent of their solution structures.17–19 While the absence of solvent 
certainly impacts structure to some extent, there is growing evidence that charged protein 
complexes maintain a large portion of the folded tertiary and quaternary structures adopted 
in solution.20–22 An early experiment to address this issue involved electrospray ionization 
of the tobacco mosaic virus and subsequent capture of the sprayed protein by soft landing.20 
Visualization by transmission electron microscopy suggested the virus was still structurally 
viable, further demonstrated by its ability to infect tobacco plants after transition through 
the gas phase. More recently, ion mobility spectrometry (IMS) experiments have provided 
convincing evidence protein structures are partially retained based on gas-phase 
measurements of collision cross sections (CCS) that can be directly compared to solution-
phase values. 21,22 Such analysis has demonstrated similarity between solution-phase CCS 
values for the trp RNA-binding protein, TRAP, as well as GroEL-GroES complexes with 
those measured in the absence of bulk water.21,22 As such, the stoichiometry and higher 
order structures of antibodies and antibody-antigen complexes are now routinely detected 
with MS.23–26 Notable improvements in instrumentation have focused on extending the 
observable mass range to allow detection of high MW complexes such as those involved 
in complement initiation by the classical pathway, specifically the interaction of hexameric 
immunoglobulin G (IgG) with C1q.27,28 Most recently charge detection MS was utilized to 
probe virus-like particles conjugated to antibodies.29 Additionally, utilizing native MS 
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streamlines sample handling for epitope extraction workflows by allowing analysis of 
antigen digest and antibody mixtures.30,31 In this latter method, collisionally-activated 
separation of epitope peptides from the antibody-peptide complexes and subsequent 
sequencing of the peptides is carried out within the mass spectrometer.31 Ion mobility mass 
spectrometry (IM-MS) has also demonstrated utility in defining antibody heterogeneity and 
detecting immune complexes.26,32–34 Specifically, collision-induced unfolding (CIU) 
footprints can be used to distinguish antibodies with divergent higher order structures34 or 
those bound to the same antigen along different epitopes.33 
While collisional activation, including collision-induced dissociation (CID) and 
higher-energy collisional dissociation (HCD), is most commonly used to sequence 
resulting epitope or paratope peptides, studies aimed at detection of protected regions 
following antibody binding in the gas phase have opted for alternative MS/MS 
approaches.35 In particular, electron-based activation methods, including electron transfer 
dissociation (ETD) and electron capture dissociation (ECD), afford higher sequence 
coverage of epitope/paratope regions, allowing utilization of middle-down or even top-
down analysis to determine sites of chemical modification after HDX of antibody-antigen 
complexes or to characterize the amino acids along CDRs.36,37 Moreover, native MS and 
ECD of an antigen bound to the Fab region of an antibody yielded sequence ions 
exclusively from flexible regions of the complexes,38 a trend also commonly observed for 
ETD or ECD of protein complexes.39,40 Similarly, UVPD41 has afforded unsurpassed 
sequence coverage of CDRs for monoclonal antibody mixtures, but the feasibility of using 
UVPD for epitope mapping has not been reported.  
Previous UVPD-MS workflows include modification of the CDR of a monoclonal 
antibody with a chromogenic, cysteine-selective tag and subsequent liquid chromatography 
(LC) MS/MS analysis with 351 nm UVPD,42 and middle-down digestion of monoclonal 
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antibody mixtures followed by identification using 193 nm photoactivation.43 A recent 
study demonstrated the utility of both ECD and 157 nm UVPD for determining heavy and 
light chain antibody pairing and successful sequencing of the CDR-H3.44 Native 
MS/UVPD studies of other types of proteins and protein complexes have tracked 
suppression or enhancement of backbone cleavages as a means to characterize changes in 
non-covalent interactions and conformation, including loop movements and structural 
variations stemming from single point mutations.41 Owing to the production of a wide array 
of fragment ions which afford high sequence coverages for increasingly large proteins45–47 
in combination with the apparent sensitivity of UVPD for profiling secondary and tertiary 
structures,41,48 application of this frontier strategy for characterization of antibody-antigen 
complexes was warranted. 
Here we explore the epitope mapping capabilities of 193 nm UVPD-MS for a 
recently identified antibody that recognizes influenza A hemagglutinin (HA). Despite 
widespread vaccination efforts, seasonal outbreaks of influenza A virus remain a major 
threat to public health and affect millions of people worldwide every year.49 Along with 
the glycoside hydrolase neuraminidase (NA), HA resides on the surface of virus particles. 
It recognizes sialic acid moieties presented along the surfaces of target cells and facilitates 
fusion of the viral envelope with the host endosomal membrane.50 Functioning as a homo-
trimer, each HA protomer consists of two domains: HA1 and HA2.51 Apart from residues 
along the receptor binding site, HA1 is subject to intense evolutionary pressure causing 
antigenic drift, while HA2 remains relatively conserved.52–54 Vaccines must be updated 
continually to match predicted seasonal strains of influenza but are still ineffective against 
pandemic outbreaks resulting from more significant antigenic shift. Efforts to develop a 
prophylactic offering universal protection across influenza strains and subtypes rely on 
elucidation of the HA epitopes recognized by broadly protective antibodies.55–57 As 
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illustrated in the present study, comparison of sequence coverages of the HA1 antigen upon 
UVPD of unbound HA1 and antibody-bound HA1 suggests the presence of the antibody 
curbs fragmentation specifically along the putative epitope regions of the antigen, resulting 
in an observed suppression in sequence coverage. Moreover, charting the sequence 
coverage per residue based on UVPD reveals attenuation of sequence ions specifically 
along the two epitope regions and provides a more general approach for elucidation of an 
unknown epitope. 
6.3 EXPERIMENTAL 
6.3.1 Sample Preparation 
The D1 H1-17/H3-14 IgG monoclonal antibody and the monomeric HA1 domain 
(residues 57-267) of the corresponding HA protomer from H1N1 A/California/04/2009 
were expressed and purified as described as follows (expressed protein sequences of the 
antibody and antigen are shown in Figure 6.1). Genes for the antibody and antigen 
involved in the study were purchased as gBlocks (Integrated DNA Technologies) and 
cloned into the pcDNA3.4 vector (Invitrogen). For monoclonal antibody expression, heavy 
and light chain plasmids for D1 H1-17/H3-14 IgG were transfected into Expi293 cells 
(Invitrogen) at a 1:3 ratio. After incubating for 5 days at 37 °C with 8% CO2, the 
supernatant containing secreted antibodies was collected by centrifugation at 500×g for 15 
min at room temperature. Supernatant was passed over a column with 1 mL Protein A 
agarose resin (Thermo Scientific) three times to ensure efficient capture. After washing the 
column with 20 cv of PBS, antibodies were eluted with 3 mL of 100 mM glycine-HCl, pH 
2.7 and immediately neutralized with 1 mL of 1 M Tris-HCl, pH 8.0. Antibodies were 
buffer-exchanged into PBS utilizing Amicon Ultra-30 centrifugal spin columns 
(Millipore). Similarly, for the HA1 antigen expression, after incubating for 5 days at 37 °C 
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with 8% CO2, the supernatant containing secreted protein was collected by centrifugation 
at 500×g for 15 min at room temperature. Supernatant was passed over 2 mL Ni-NTA 
agarose (QIAGEN) affinity column in gravity mode. Flow-through sample was collected 
and passed through the column three times. The column was washed with 15 cv of 10 mM 
imidazole, 150 nM NaCl, 100 mM Tris-HCl, pH 7.5 prior to eluting with 5 cv of 250 mM 
imidazole, 150 nM NaCl, 100 mM Tris-HCl, pH 7.5. Eluates were then buffer-exchanged 
into PBS using Amicon Ultra-30 centrifugal spin columns (Millipore). 
 
 
Figure 6.1: Expressed sequences of the (A) D1 H1-17/H3-14 IgG monoclonal antibody 
and (B) HA1 domain (residues 57-267) of the corresponding HA protomer 
from H1N1 A/California/04/2009 used for all experiments. Cysteine residues 
are shown in yellow font, and expected disulfide linkages are represented as 
dotted lines. Calculated average masses for each sequence account for 
disulfide bonds. A G0F glycan is expected to exist at N306 on the heavy chain 
of the antibody (highlighted in blue). 
 202 
For glycan removal, 20 μg of the antigen was diluted in 50 mM sodium phosphate 
(pH 7.5) and incubated for 48 hours at room temperature with 1000 units of PNGase F 
(New England BioLabs Inc., Ipswich, MA). The antibody was then added to the antigen 
solution at a 1:2 or 1:20 antibody:antigen ratio, and the resulting solution was flash frozen 
in an effort to minimize deglycosylation of the antibody by PNGase F. Samples were 
desalted and exchanged into 20 mM ammonium acetate (pH 6.8) at 5-10 μM using 50 kDa 
molecular weight cut-off filters (MilliporeSigma, Burlington, MA) for MS analysis. 
6.3.2 Mass Spectrometry & Data Analysis 
MS experiments were performed on a Thermo Scientific Q Exactive UHMR 
(Bremen, Germany) modified as previously described58 to allow photodissociation in the 
HCD cell through incorporation of a 193 nm ArF Coherent Excistar excimer laser (Santa 
Cruz, CA). Protein solutions were subjected to electrospray ionization using source 
voltages of 1.0-1.2 kV and a source temperature of 200 °C. Solutions were introduced via 
an offline nano-ESI source using borosilicate emitters fabricated in-house and coated with 
Au/Pd. The on-line size-exclusion chromatography experiments were performed using a 
Dionex LC system (Thermo Scientific) interfaced to the modified Q Exactive UHMR mass 
spectrometer. Separation was carried out on a 2.1 mm × 150 mm Waters ACQUITY UPLC 
Protein BEH SEC column with a 200 Å pore size and 1.7 µm particle size (Milford, MA). 
An isocratic mobile phase comprised of 20 mM ammonium acetate (pH 6.8) and flowing 
at 100 μL min-1 was used to elute a 5 μL injection of the 1:2 antibody:antigen sample (1 
μg/μL) after deglycosylation. An applied voltage of 4 kV on the HESI source interfacing 
the LC to the MS was used to ionize the effluent. An in-source trapping value of -150 V 
allowed efficient desolvation of the antibody-antigen complex. ESI-MS were collected at 
a resolving power of 12500 at m/z 200.  
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In-source trapping (IST) provided low energy collisional activation to promote 
desolvation of the antibody or antibody-antigen complex with an optimal value of -100 V. 
All other ion optics were tuned to optimize transmission of the species of interest: the 
antigen (lower m/z region) or the antibody-antigen complex (higher m/z region). ESI mass 
spectra represent 60 transients collected at a resolving power of 12500 at m/z 200. For 
MS/MS spectra, a single charge state was isolated using a width of 10-15 m/z and activated 
in the HCD cell. A resolving power of 140K at m/z 200 was used while collecting 500 
transients for each MS/MS spectrum. Collision energies of 200-300 eV/q were used for 
HCD spectra while UVPD spectra represent a single laser pulse at 3 mJ. Automated gain 
control (AGC) was turned off during collection of all MS and MS/MS data and instead the 
ion population was controlled by adjusting the ion time (IT). Specifically, IT values were 
set at 20 ms and 350 ms for MS and MS/MS spectra, respectively. Lowering the nitrogen 
bath gas pressure of the HCD cell from a corresponding pressure in the ultra-high vacuum 
(UHV) region of 1E-9 mbar to 1E-10 mbar aided in detection of fragments after 
photoactivation. However, for collisional activation a minimum UHV pressure of 4E-10 
mbar was necessary for effective HCD to occur. 
Lower resolution ESI-MS was used to assign average masses of the antigen, 
antibody, and antibody-antigen complex species using UniDec.59 High resolution MS/MS 
spectra were de-charged and de-isotoped using the Xtract algorithm from Thermo 
Scientific (S/N ratio of 3, fit factor 44%, remainder 25%) to create lists of monoisotopic 
fragment ion masses that could be assigned as sequence ions using ProSight Lite v1.4. 
Identifications of HCD (b, y) and UVPD (a, a+1, b, c, x, x+1, y, y-1, z) sequence ions were 
made within ±10 ppm. All MS/MS spectra were collected in triplicate and only sequence 
ions identified in all three spectra are considered. For HCD or UVPD of the antibody-
antigen complex in which sequence ions could arise from the antibody or antigen, there 
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were no overlapping masses in the assigned fragment ions. Sequence coverage maps were 
made using ProSight Lite in which sequence ion types are color coded as a/x-type green, 
b/y-type blue, c/z-type red. All cysteine residues in the antigen and antibody sequences 
were assumed to be disulfide bound and identifications accounted for the loss of a hydrogen 
at each cysteine (-1.0078 Da).  
A custom script in R was used to calculate the number of sequence ions observed 
per residue for HCD or UVPD of the antigen and antibody-antigen complex. Briefly, for 
each amino acid the number of N-terminal product ions (a, b, c) resulting from cleavage of 
the backbone C-terminal to a given residue and C-terminal product ions (x, y, z) arising 
from backbone fragmentation N-terminal to that position were summed. Values are 
reported as a percentage of the total possible number of cleavages adjacent to a given 
residue (i.e. two for HCD and nine for UVPD, except residues at the N- and C-terminus). 
A crystal structure of the HA1 domain of an HA protomer bound to the antigen binding 
fragment (Fab) region of an IgG antibody (PDB ID: 6E4X)60 is shown in Figure 6.2. 
Although not the same sequence as the D1 H1-17/H3-14 antibody, both IgGs are known to 
bind along the HA1 domain near the trimeric interface.60,61 The two expected epitope 
regions are highlighted and, based on the HA protomer sequence, include: residues 90-109 
and 213-233, herein referred to respectively as epitope regions 1 and 2. This corresponds 
to amino acids T35-R55 and F163-Y183 in the HA1 sequence expressed for this study. 
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Figure 6.2: Crystal structure with a 180° view of the HA1 domain of an HA protomer 
(H3N2 A/Texas/50/2012) bound to the antigen binding fragment (Fab) region 
of the S5V2-29 IgG monoclonal antibody (PDB ID: 6E4X) with subunits 
labelled. The two epitope regions are highlighted (red, green) along the HA1 
subunit (gray) with the corresponding epitope sequences from the HA strain 
expressed for this study shown (numbering is based on the HA protomer 
sequence; these residues correspond to T35-R55 and F163-Y193 in the 
expressed HA1 sequence shown in Figure 6.1B). The heavy chain (HC) and 
light chain (LC) of the antibody are colored separately (turquoise and orange, 
respectively). 
6.4 RESULTS AND DISCUSSION 
6.4.1 Deglycosylation of HA1 Antigen for Improved MS Analysis 
Previous analysis of the repertoire of monoclonal antibodies that comprise the 
serological response to influenza vaccination led to the identification of a set of antibodies 
showing broad binding to HA from divergent influenza virus strains.61 In the present study, 
one such antibody (termed D1 H1-17/H3-14), which was shown to bind to the interface 
region of HA trimer via negative-stain EM, was expressed recombinantly to target the HA1 
domain of HA from an H1N1 strain of influenza A virus responsible for a pandemic in 
2009.62 Without the HA2 domain to stabilize trimer formation, HA1 exists in solution as a 
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25.4 kDa monomer. ESI-MS of HA1 under native conditions yields low charge states (9+ 
– 11+) of eight proteoforms corresponding to the attachment of up to seven variations of 
sugars at an asparagine residue along the sequence (Figures 6.3A, 6.3B). The locations of 
glycan modifications along the HA1 domain are known to vary by HA strain with the 
glycosylation sites likely evolving under selective pressure to provide steric blocking to 
antigenic sites and impede interaction with neutralizing antibodies.63  
 
 
Figure 6.3: (A) ESI mass spectrum of HA1 sprayed in 20 mM ammonium acetate. (B) 
An expanded view of the region of the spectrum spanning m/z 2520-2820 
reveals several proteoforms of the 10+ charge state resulting from 
glycosylation. Based on a mass shift of +1219 Da, one possible glycan 
structure is shown, with up to six additional sugars accounting for all observed 
glycoforms. (C) ESI mass spectrum of HA1 after glycan removal with 
PNGase F. Observed as a monomer, the experimental mass of deglycosylated 
HA1 matches the calculated mass accounting for two disulfide bonds. The 
m/z region in which antibody•HA1 complexes would be expected is 
highlighted in turquoise. 
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Although understanding HA glycosylation patterns can offer insight into viral 
mechanisms, the various glycoforms result in charge states overlapping with the 
unmodified protein of interest and hinder MS/MS analysis.64,65 The amidase PNGase F was 
used to cleave N-linked glycosylations from HA1.15 After the deglycosylation reaction, a 
substoichiometric amount of antibody was used to bind and isolate the antigen. The result 
is a simplified mass spectrum of the unmodified antigen with an intact mass matching the 
expected sequence, accounting for two disulfide bonds (Figure 6.3C). Owing to the lower 
concentration at which the antibody was present in solution compared to the antigen, the 
antibody-antigen complex is not observed under these conditions (m/z region of expected 
antibody-antigen complexes highlighted in turquoise in Figure 6.3C). The 10+ charge state 
of unmodified HA1 was selectively isolated and activated with HCD or UVPD (Figure 
6.4A). Deconvolution of the MS/MS spectra allowed fragment ions to be assigned as 
backbone cleavage sites along the sequence of HA1 (Figure 6.4B). Sequence coverage 
maps shown in Figure 6.4C demonstrate that UVPD affords coverage of over twice as 
much of the protein sequence compared to HCD (60% and 27%, respectively). As 
expected, the presence of two disulfide bonds along the N-terminal region hampers 
production of informative fragments between those cysteine residues using HCD and to a 
lesser extent UVPD.66,67 
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Figure 6.4: (A) MS/MS spectra resulting from activation of the 10+ charge state of HA1 
with HCD (left) and UVPD (right). Several abundant fragment ions are 
identified and labelled. (B) Corresponding deconvoluted MS/MS spectra in 
which the precursor is denoted with a filled circle. Monoisotopic masses 
identified as assignable fragment ions originating from backbone cleavages 
of HA1 are used to create the sequence coverage maps in (C). Searches 
accounted for disulfide bonds at all four cysteine residues (highlighted in 
gray). 
Given our workflow requires exposing the antibody to PNGase F as it is added to 
the deglycosylation reaction mixture to form the antibody-antigen complex and recover 
HA1, it is likely the amidase will also competitively cleave the G0F glycans present along 
the constant region (Fc) of the antibody. Glycosylation of the heavy chains alters the 
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affinity of Fc receptors but has little impact on antigen binding.68 As such, the antibody 
was reacted with PNGase F separately, mirroring the conditions used when the antigen was 
present, to determine the extent of deglycosylation. The most abundant species in Figure 
6.5A corresponds to removal of the glycan from each of the heavy chains. Nevertheless, 
the presence of the singly and doubly glycosylated antibody forms in the spectrum suggests 
the short reaction time in the presence of PNGase F prevented complete glycan removal. 
The 25+ charge state of the antibody with no glycans was subsequently isolated and 
activated using HCD or UVPD (Figures 6.5B, 6.5C). Owing to the presence of one 
intermolecular and seven intramolecular disulfide bonds that preserve the overall structure 
of the antibody, the majority of fragment ions identified as portions of the sequences of the 
light or heavy chain are observed in the region encompassing m/z 500-4000. By matching 
fragment ions from the deconvoluted MS/MS spectra, the resulting sequence coverages 
were 6% each for the light and heavy chains using HCD, and 45% and 37% respectively 
for the light and heavy chains using UVPD (Figure 6.6). While the cysteine bridges 
significantly hinder analysis with HCD as evidenced by the low sequence coverages, the 
majority of observed light and heavy chain sequence ions upon UVPD occur along regions 
not restricted by disulfide bonds. Overall, UVPD affords moderate to high sequence 
coverage of the each of the separate components that form the antibody-antigen complex. 
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Figure 6.5: (A) ESI-MS of the D1 H1-17/H3-14 antibody in 20 mM ammonium acetate 
after reaction with PNGase F. Observed charge states are labelled and 
glycoforms are denoted with turquoise colored circles. Even with the short 
reaction time, the most abundant species corresponds to removal of the G0F 
glycan from both heavy chains. The 25+ charge state of the antibody without 
glycans was selectively isolated and activated with (B) HCD and (C) UVPD. 
Several abundant fragment ions resulting from HCD (tan) and UVPD (purple) 
are labelled corresponding to the sequences of the light chain (light color) or 
heavy chain (dark color). 
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Figure 6.6: (A) Spectra resulting from deconvolution of the HCD and UVPD MS/MS 
spectra of the D1 H1-17/H3-14 antibody shown in Figure 6.5. Monoisotopic 
masses identified as assignable fragment ions originating from backbone 
cleavages of the (B) light chain and (C) heavy chain of the antibody are used 
to create the sequence coverage maps. The eight disulfide bonds that stabilize 
the antibody structure (highlighted in gray) were assumed to be intact for 
fragment ion identification. 
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6.4.2 Formation and MS Characterization of the Antibody-Antigen Complex 
Size-exclusion chromatography (SEC) MS was used to confirm the expected 1:2 
antibody:antigen stoichiometry after incubation of HA1 and the D1 H1-17/H3-14 antibody 
(Figure 6.7). The SEC trace shown in Figure 6.7A demonstrates one major species present 
in solution (RT 2.58 min) with a small amount of a second species (RT 3.56 min). 
Corresponding mass spectra confirm these species respectively as the antibody-antigen 
complex (Figure 6.7B) and unbound HA1 (Figure 6.7C). An inset of Figure 6.7B for the 
region encompassing m/z 6500 – 10000 shows the antibody-antigen complex was formed 
between the antibody retaining either 0, 1, or 2 G0F glycans (due to exposure of the 
antibody to PNGase F) and two HA1 subunits. In the mass spectrum of the complex, a 1:1 
antibody:antigen species is also observed as well as unbound HA1 (Figure 6.7B). 
Extracted ion chromatograms of the m/z values corresponding to these three species 
highlight that unbound HA1 (m/z 3175 (7+ charge state)) elutes in two separate peaks while 
the antibody-antigen complexes (1:1 and 1:2, m/z 8185 (24+ charge state) and 13157 (13+ 
charge state)) elute simultaneously (Figure 6.7A). As such, the unbound HA1 and 1:1 
antibody:antigen species co-eluting with the antibody-antigen complex (Figure 6.7A, RT 
2.58 min) are likely due to disassembly of the 1:2 Ab:HA1 complexes as a result of in-
source trapping (IST, a type of non-selective front-end collisional activation), a method 
typically used to desolvate large biomolecules in mass spectrometry workflows.69 The use 
of higher IST parameters can cause disassembly of desired protein complexes. To 
demonstrate this outcome, mass spectra of the complex were collected using various IST 
values (-10 V to -250V) for comparison of the relative abundances of the three major 
species: unbound HA1, the Ab•2HA1 complex, and the Ab•HA1 complex (Figure 6.8). 
Specifically, at low IST values (i.e. -10 V) the complex is poorly desolvated and the quality 
of the MS1 spectrum is sub-par. As the applied voltage is increased, the adducts are 
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collisionally removed resulting in a cleaner spectrum of the antibody-antigen complex. 
However, at the same time the abundances of ejected unbound HA1 and the corresponding 
1:1 antibody:antigen complex increase. While an IST value of -150 V was used during 
SEC-MS, an optimized value of -100 V was selected based on the trend in Figure 6.8, 
representing a justifiable compromise between removal of adducts and decomposition of 
intact Ab•2HA1 complexes. For the later eluting peak in the SEC trace (Figure 6.7A, RT 
3.56 min, corresponding to free HA1), its narrower charge state distribution (7+ to 9+) 
compared to the HA1 ejected from the complex in Figure 6.7B (6+ to 11+) suggests the 
former HA1 species was unbound in solution and ionized separately from the complex. 
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Figure 6.7: (A) SEC LC trace for HA1 with the antibody at a 1:2 antibody:antigen ratio. 
Extracted ion chromatograms of the m/z values corresponding to HA1 
(orange), Ab•HA1 (green), and Ab•2HA1 (turquoise) are shown. (B) ESI 
mass spectrum collected at retention time 2.58 min along with an expanded 
view of the range spanning m/z 6500-10000. Observed species include HA1, 
Ab•HA1, and Ab•2HA1 with 0-2 glycans (gly) attached to the antibody 
(glycoforms are denoted with colored circles for the complex). In-source 
trapping (-150 V) necessary to desolvate the Ab•2HA1 complex causes 
ejection of one HA1, resulting in the observed Ab•HA1 species and unbound 
HA1. Mass spectra of the complexes obtained using various in-source 
trapping energies are shown in Figure 6.8. (C) ESI mass spectrum collected 
at retention time 3.56 min suggests a low abundance of unbound HA1 is in 
solution. 
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Figure 6.8: ESI-MS of the antibody-antigen complex collected using various in-source 
trapping energies (-10 V to -250 V) to determine the ideal value for analysis. 
Up to three species are observed including HA1 monomer (orange), 1:2 
antibody:antigen complex (turquoise), and 1:1 antibody:antigen complex 
(green). At low IST values (top), the complex is poorly desolvated resulting 
in many adducts, while at high IST values (bottom) significant disruption of 
the complex and ejection of one HA monomer occurs. 
Using these optimized conditions, the 1:2 antibody:antigen mixture was infused by 
nano-ESI and the 29+ charge state of the antibody-antigen complex (with no G0F glycans 
bound to antibody) was activated with HCD or UVPD (Figure 6.9). Ejection of one HA1 
monomer to yield the 1:1 antibody:antigen complex was a dominant pathway following 
activation with HCD and to a lesser extent for UVPD (Figures 6.9B, 6.9C). In addition to 
 216 
production of intact protein subunits (unbound HA1 and Ab•HA1), both activation 
methods yielded a vast array of fragment ions that were deconvoluted and assigned as 
portions of the sequences of HA1 or the light and heavy chains of the antibody (Figure 
6.10). Briefly, sequence coverages were 20% (HCD) and 49% (UVPD) for HA1, 9% 
(HCD) and 46% (UVPD) for the antibody light chain, and 6% (HCD) and 37% (UVPD) 
for the antibody heavy chain. Activation of the Ab•2HA1 complex compared to activation 
of unbound HA1 resulted in lower sequence coverage of HA1 using either HCD or UVPD 
(Figure 6.11) whereas the observed coverage of either chain of the antibody was not 
significantly impeded by the presence of the antigen (Figures 6.6, 6.10). 
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Figure 6.9: (A) ESI mass spectrum of a solution containing 1:2 antibody:antigen using an 
in-source trapping energy of -100 V. Charge states of the two observed 
species are labelled: Ab•2HA1 (turquoise) and Ab•HA1 (green). The 29+ 
charge state of the antibody-antigen complex was selectively isolated and 
activated with (B) HCD or (C) UVPD to yield the MS/MS spectra. Observed 
charge states of intact subunits of HA1 (orange) or Ab•HA1 (green) are 
identified, suggesting antigen ejection was a more favored fragmentation 
pathway for HCD compared to UVPD. 
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Figure 6.10: (A) Deconvoluted HCD (left) and UVPD (right) mass spectra corresponding 
to the MS/MS spectra of the antibody-antigen complex in Figure 6.9. 
Fragment ions originating from backbone cleavages were searched against 
the sequences of (B) HA1, (C) antibody light chain, and (D) antibody heavy 
chain to create the sequence coverage maps. All cysteine residues 
(highlighted in gray) were assumed to be disulfide bound. None of the 
observed fragment ions matched expected backbone cleavages for more than 
one of the three sequences. Sequence coverages are reported for each protein 
in the complex. 
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Figure 6.11: Comparison of the sequence coverage of HA1 afforded by HCD (left) and 
UVPD (right) for activation of (A) unbound HA1 and the (B) 1:2 
antibody:antigen complex. Corresponding MS/MS spectra are shown in 
Figure 6.4 for unbound HA1 (10+) and Figure 6.9 for the complex (29+). 
Sequence coverages are reported below each map with the complex yielding 
lower sequence coverage than the unbound hemagglutinin A for both HCD 
and UVPD. The two epitope regions are highlighted: epitope region 1 (green) 
and epitope region 2 (red). 
6.4.3 UVPD-MS for Epitope Mapping 
Past studies leveraging UVPD-MS to probe protein-ligand and protein-protein 
complexes have relied on comparison of backbone cleavage propensities upon 
photoactivation of protein states of interest.41 In essence, observed enhancement of 
backbone cleavages for a specific protein region upon UVPD correlates with an increase 
in flexibility or reduction in noncovalent interactions, while suppression of backbone 
cleavages suggests the formation of new or strengthened stabilizing interactions that 
hamper the separation/release of fragment ions and inhibits their detection.41,70 As such, 
during UVPD experiments a decrease in the overall sequence coverage of HA1 upon 
complexation with the antibody is expected. Nevertheless, to be useful in mapping 
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antibody-antigen complex interactions, the reduction in backbone cleavages must occur 
specifically along the epitope regions of the antigen. The D1 H1-17/H3-14 antibody is 
known to bind a conformational epitope spanning two regions near the trimeric interface 
along the HA1 domain of H1 strains.61 Although existence of epitopes at the contact surface 
between HA subunits is not intuitive, this interface is exposed post-fusion as well as by 
molecular breathing of the HA trimer.60,71,72 A published crystal structure of the Fab 
fragment of the S5V2-29 antibody that binds similarly near the HA trimer interface (PDB 
ID: 6E4X) visualizes these two putative epitope regions for the HA1 domain of H3N2 
A/Texas/50/2014 corresponding to residues 90-109 and 213-233 in the H1 strain used in 
this study (or residues 35-55 and 163-183 in the expressed HA1 sequence) (Figure 6.2).60 
These two regions are highlighted in green and red along the HCD and UVPD sequence 
coverage maps of unbound HA1 and the antibody-antigen complex in Figure 6.11. 
Although coverage is visibly curbed along these regions upon HCD and UVPD of the 
complex compared to the monomeric antigen, sequence coverage was plotted by protein 
region to better assess the corresponding changes in identified sequence ions for the rest of 
the protein.  
Bar graphs of sequence coverages (i.e. the number of backbone cleavages as a 
percent of the total number of protein residues) are shown for HCD and UVPD of unbound 
HA1 versus the Ab•2HA1 complex for four different regions: entire protein, epitope region 
1, epitope region 2, and the rest of the protein excluding the epitope regions (Figure 6.12). 
Both HCD and UVPD resulted in statistically significant lower sequence coverages along 
the entire protein for activation of the Ab•2HA1 complex. Along the two epitope regions, 
HCD resulted in a significant suppression in sequence coverage for only one of the regions 
while UVPD did for both. Comparison of coverage for the rest of the protein sequence 
excluding the two epitope regions for HCD showed significant suppression but for UVPD 
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remained the same for activation of unbound HA1 or the Ab•2HA1 complex. These results 
suggest the presence of the antibody prevents production/detection of fragments 
originating from backbone cleavages of the epitope regions of the antigen during UVPD, 
resulting in the observed suppression in sequence coverage. An analogous change in 
sequence coverage of the antibody was not observed upon HCD nor UVPD likely owing 
to the overall lower sequence coverage, extensive disulfide bonding, and size difference 
between the antibody and antigen (e.g. the antibody accounts for 75% of the mass of the 
Ab•2HA1complex). 
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Figure 6.12: Graphs displaying sequence coverage of various regions of HA1 afforded by 
activation of HA1 (10+) (orange) or the Ab•2HA1 (29+) complex (turquoise) 
using (A) HCD and (B) UVPD. In the expressed HA1 sequence, epitope 
region 1 encompasses residues T35-R55, while epitope region 2 includes 
amino acids F163-Y183 (corresponding to residues 90-109 and 213-233 in 
the HA protomer). The rest of the protein is defined as the entire expressed 
HA1 protein sequence excluding the two epitope regions. Asterisks indicate 
statically significant differences in sequence coverage for the two precursors 
at a 95% or 99% confidence level (* p-value < 0.05, ** p-value < 0.01, n.s. 
not significant). 
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The distributions of fragment ion types for each of these four regions of HA1 were 
also plotted as a percentage of the total number of sequence ions identified upon HCD or 
UVPD of unbound HA1 or the Ab•2HA1 complex (Figure 6.13). While HCD typically 
yields only two ion types (b- and y-type from cleavage of the labile C-N amide backbone 
bond), UVPD produces up to nine different ion types from cleavage of different backbone 
bonds between pairs of amino acids (a, a+1, x, x+1 from cleavage of Cα – C bonds, b, y, 
and y-1 from C-N amide bonds, and c, z from N - Cα bonds).
41 For HCD generally more b-
type ions (containing the N-terminus) were observed for activation of the Ab•2HA1 
complex compared to the antigen alone, except along epitope region 1 spanning residues 
35-55 (Figure 6.13A). For UVPD only b- and y-type fragment ions were observed in the 
epitope regions upon activation of the Ab•2HA1 complex, while the entire array of 
expected ion types (a/x, b/y, c/z) were produced for the free antigen (Figure 6.13B). 
Moreover, the diversity in the ion type distributions upon UVPD was maintained for the 
rest of the protein excluding the two epitope regions.  
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Figure 6.13: Bar graphs of the distribution of fragment ion types across several different 
regions of HA1 for (A) HCD and (B) UVPD showing pairs of stacked bars 
representing unbound HA1 (left bar) and the Ab•2HA1 complex (right bar), 
corresponding to the sequence coverages shown in Figure 6.12 for the entire 
protein, epitope region 1, epitope region 2 and the rest of the protein. Residues 
35-55 and 163-183 of the expressed HA1 sequence encompass the two 
expected epitope regions (or residues 90-109 and 213-233 in the HA protomer 
sequence). The rest of the protein represents the entire sequence excluding 
those two regions. 
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While the complex mechanisms underlying UVPD of intact proteins have yet to be 
fully unraveled, the hypothesis that both direct fragmentation from excited states and 
dissociation from vibrationally excited ground states after internal conversion are at play 
is generally accepted.73 The latter leads to fragmentation pathways similar to those that 
occur during collisional activation and produces b- and y-type ions.74 The former describes 
direct cleavage of the backbone by excitation of an electron into an excited state orbital, 
typically yielding the other ion types observed upon UV photoactivation: a/x and c/z.73 
These considerations align with observation of exclusively b- and y-type ions upon UVPD 
of the Ab•2HA1 complex along epitope regions that produced the entire array of possible 
sequence ions in the absence of the antibody. In particular, upon formation of the Ab•2HA1 
complex, it seems that the network of non-covalent interactions between the antibody and 
antigen suppresses direct dissociation pathways (e.g. formation and release of a/x or c/z-
type ions) especially at residues involved in the protein-protein interface. However, the 
fragmentation pathways that proceed via redistribution of vibrational energy and disruption 
of weak non-covalent bonds result in cleavage of backbone bonds in the epitope region and 
concomitant release of b/y ions. 
6.4.4 Approach for Elucidation of an Unknown Epitope using UVPD-MS 
While the epitope regions for the model antibody-antigen system in the present 
study are reputed,61 a similar UVPD-MS approach could be used to resolve disputed sites 
or even elucidate unknown antigenic determinants. Examining the number of observed 
sequence ions bracketing each individual residue of the antigen after UVPD of the 
Ab•2HA1 complex compared to the unbound antigen highlights possible epitope regions. 
Stretches of amino acids exhibiting suppressed or completely curbed backbone cleavage 
for the complexes relative to the free Ab or HA1 subunits suggest involvement in the 
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interface. Such analysis is demonstrated in Figure 6.14 for the Ab•2HA1 complex. The 
number of observed HA1 sequence ions upon activation of the antibody-antigen complex 
or unbound antigen are graphed as a percentage of the total possible number of fragment 
ions per residue (e.g. two for HCD (b/y) and nine for UVPD (a, a+1, b, c, x, x+1, y, y-1, 
z)). Subtraction of the corresponding values for the Ab•2HA1 complex and monomeric 
antigen yields a difference plot and aids in visualization of changes (Figure 6.15). In short, 
for residues with values that lie below the x-axis, fewer sequence ions originated from 
backbone cleavage adjacent to that amino acid upon activation of the antibody-antigen 
complex compared to the unbound antigen. Conversely the production of more sequence 
ions arising from backbone cleavage adjacent to a given residue when comparing the 
Ab•2HA1 complex compared to HA1 is indicated by a value above the x-axis. For HCD 
there is no distinct pattern or specific region in which fewer sequence ions were observed 
(Figure 6.15A). On the contrary, for UVPD there are two main stretches of amino acids 
resulting in fewer sequence ions upon formation of the Ab•2HA1 complex: residues 35-59 
and residues 163-188 of the expressed HA1 sequence (Figure 6.15B). These regions 
largely align with the presumed antigenic determinants for the specific antibody-antigen 
complex used in this study (T35-R55 and F163-Y183 or residues 90-109 and 213-233 of 
the HA protomer).61 
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Figure 6.14: Plots of the number of HA1 sequence ions (originating from backbone 
cleavages along the protein sequence) as a percentage of the total number 
possible per residue resulting from activation of (1) unbound HA1 (10+) 
(orange) or (2) antibody-antigen Ab•2HA1 complex (29+) (turquoise) using 
(A) HCD and (B) UVPD. The two epitope regions (residues 90-109 and 213-
233 in the HA protomer sequence, or 35-55 and 163-183 in the expressed 
sequence) are outlined with dashed lines. Subtraction of the corresponding 
values yielded the difference plots in Figure 6.15. 
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Figure 6.15: Difference plots representing the changes in the number of observed sequence 
ions produced by backbone cleavages that bracket each residue upon 
activation of the Ab•2HA1 antibody-antigen complex (29+) compared to 
unbound HA1 (10+) using (A) HCD and (B) UVPD. Values greater than zero 
mean more sequence ions were observed from cleavages adjacent to a given 
residue when activating the complex compared to the unbound antigen, while 
values less than zero mean fewer sequence ions were observed. The two 
known epitope regions of HA1 (residues 90-109 and 213-233 in the HA 
protomer sequence or 35-55 and 163-183 in the expressed HA1 sequence) are 
outlined with dashed lines. Plots of the number of sequence ions per residue 
as a percentage of the possible number of backbone cleavages are shown in 
Figure 6.14. 
Moreover difference plot values can be represented as heatmaps by residue number 
or visualized along a crystal structure of HA1 bound to the Fab region of an antibody 
known to interact similarly with HA as D1 H1-17/H3-14 (PDB ID: 6E4X)60 (Figure 6.16). 
Suppression (blue) or enhancement (red) in the number of observed sequence ions 
generated upon backbone cleavages bracketing each residue is shown for activation of the 
antibody-antigen complex compared to the antigen alone using HCD and UVPD. Residues 
demarcated in blue (Figure 6.16A) or shaded in blue (Figure 6.16B) signal likely 
involvement in the antibody-antigen complex interface. Conversely an increase in the 
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number of sequence ions produced adjacent to a given residue after formation of the 
antibody-antigen complex (colored red) can result from increased flexibility/fewer 
stabilizing interactions in that region or simply the redistribution of energy to dissociation 
pathways that were inaccessible in the unbound antigen. For the UVPD data, the majority 
of amino acids exhibiting suppressed cleavage (colored blue) are located along the 
interface with the Fab region of the antibody in the crystal structure (e.g. the epitope 
regions), whereas for the HCD data there is both suppression and enhancement of 
fragmentation along those regions (Figure 6.16B, 6.16C). When a structure of the 
antibody-antigen complex is lacking, mapping differences in the number of UVPD 
cleavages adjacent to each residue along a high-resolution structure of an unbound antigen 
could help correlate observed changes in photodissociation with structural features of the 
protein and aid in localization of the epitopes. Lastly, plotting the observed fragment ion 
types per residue makes apparent a loss in diversity of observed sequence ions for 
activation of the antibody-antigen complex compared to the unbound antigen (Figure 
6.17). In particular, the full array of UVPD ion types (a/x, b/y, c/z) cover the residues 
involved in the epitope regions upon activation of HA1, yet only b- and y-type ions are 
identified for those same regions upon UVPD of the antibody-antigen complex. 
Comparison of the number and type of sequence ions arising from backbone cleavages 
adjacent to individual residues upon UVPD of unbound antigens and antibody-antigen 
complexes offers an alternative approach for probing unidentified epitopes. 
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Figure 6.16: Heatmaps of the suppression (blue) or enhancement (red) in the number of 
observed sequence ions generated upon backbone cleavages bracketing each 
residue for activation of the Ab•2HA1 complex (29+) compared to the antigen 
alone (10+) using HCD and UVPD shown (A) for the HA1 sequence or (B, 
C) along the crystal structure of the HA1 domain of an HA protomer (H3N2 
A/Texas/50/2012) bound to the antigen binding fragment (Fab) region of the 
S5V2-29 IgG monoclonal antibody (PDB ID: 6E4X). Residues encompassing 
the two epitope regions are shown as spheres, while the light chain (gray) and 
heavy chain (black) of the antibody are labelled in (B). 
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Figure 6.17: Distribution of ion types corresponding to the plots in Figure 6.14 of the 
number of sequence ions originating from backbone cleavages at each residue 
for activation with (A) HCD and (B) UVPD of (1) unbound HA1 and (2) 
antibody-antigen complex. The dashed lines highlight the two epitope 
regions. 
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6.5 CONCLUSION 
Native MS in conjunction with 193 nm UVPD was utilized to probe the antigenic 
determinants of an antibody-antigen complex. Plotting sequence coverage revealed 
suppression of UVPD along the two expected epitope regions and provides an approach 
for elucidation of an unknown antigenic determinant. Moreover, comparing the sequence 
ion types produced upon UVPD of the antigen in the presence and absence of the antibody 
highlighted a loss in diversity of fragment ion types covering the epitope regions for the 
complex. This observation merits future investigation in which utilizing different laser 
wavelengths or intensities could provide insight into the timescales and extent to which 
individual processes govern UVPD. Additional information about the specific factors that 
influence the lack of fragmentation of specific regions of antibody-antigen complexes 
might be obtained by employing supplemental activation prior to and/or after UVPD. When 
integrated with electron activation methods, supplemental activation has proven effective 
for disruption of non-covalent interactions that prevent the separation and release of 
fragment ions.75 
Further experiments are underway to apply this UVPD-MS workflow to a wider 
variety of antibody-antigen complexes to determine if there is an ideal size regime or limit 
for the antigen as well as if targets that exist as higher order oligomers can be probed. 
Additionally, MS analysis can be hampered by the presence of post-translational 
modifications along the antigen, as demonstrated by extensive glycosylation of HA1. 
Nevertheless, leveraging native MS along with structurally sensitive MS/MS techniques 
such as ECD or UVPD could further minimize sample handling and provide a new era of 
MS-based epitope mapping to aid in the discovery of novel therapeutics for use in passive 
immunotherapy or the identification of conserved epitopes for improved vaccine design. 
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Chapter 7: Multistage Ultraviolet Photodissociation Mass Spectrometry 
to Characterize Single Amino Acid Variants of Human Mitochondrial 
BCAT2** 
7.1 OVERVIEW 
Unraveling disease mechanisms requires a comprehensive understanding of how 
the interplay between higher-order structure and protein-ligand interactions impacts the 
function of a given protein. Recent advances in native mass spectrometry (MS) involving 
multi-modal or higher energy activation methods have allowed direct interrogation of intact 
protein complexes in the gas phase, allowing analysis of both composition and subunit 
connectivity. We report a multistage approach combining collisional activation and 193 
nm ultraviolet photodissociation (UVPD) to characterize single amino acid variants of the 
human mitochondrial enzyme branched-chain amino acid transferase 2 (BCAT2), a protein 
implicated in chemotherapeutic resistance in glioblastoma tumors. Native electrospray 
ionization confirms that both proteins exist as homodimers. Front-end collisional activation 
disassembles the dimers into monomeric subunits that are further interrogated using UVPD 
to yield high sequence coverage of the mutated region. Additionally, holo (ligand-bound) 
fragment ions resulting from photodissociation reveal that the mutation causes 
destabilization of the interactions with a bound cofactor. This study demonstrates the 
unique advantages of implementing UVPD in a multistage MS approach for analyzing 
intact protein assemblies. 
                                                 
**Mehaffey, M. R.; Sanders, J. D.; Holden, D. D.; Nilsson, C. L.; Brodbelt, J. S. Multistage Ultraviolet 
Photodissociation Mass Spectrometry to Characterize Single Amino Acid Variants of Human Mitochondrial 
BCAT2. Anal. Chem. 2018, 90, 9904-9911. 
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7.2 INTRODUCTION 
Single amino acid variants that result in altered function are often associated with 
oncogenic potential.1–3 Precision design of small molecule inhibitors or therapeutic 
antibodies to target protein variants and suppress cancer growth relies on a comprehensive 
understanding of the functional impact of the mutation.3,4 Recently a proteogenomic 
screening of glioma stem cells from patient-derived glioblastoma tumors identified the 
T186R sequence variant of the human mitochondrial enzyme branched-chain amino acid 
transferase 2 (BCAT2) as a potential factor of resistance to standard treatments.5 BCAT2 
exists as a 83 kDa homodimer and, along with a pyridoxal phosphate (PLP) cofactor, 
degrades branched chain amino acids into branched chain α-keto acids.6,7 Crystallographic 
experiments suggest R186 in the mutant repulses K59 in the other subunit of the dimer and 
impacts the electrostatic environment near the CXXC (C342 and C345) site. Both are 
perturbations which may destabilize the dimer and alter enzyme kinetics.8 Consequently 
characterization of the structural and functional differences between the wild-type (WT) 
and mutant proteoforms is necessary for further pursuit of the variant as a precision drug 
target in glioblastoma. 
Mass spectrometry (MS) has emerged as a rapid and sensitive approach to 
characterize protein complexes9–11 in a manner complementary to traditional structural 
biology techniques that afford high-resolution three-dimensional structures, such as X-ray 
crystallography and NMR spectroscopy. Native MS experiments involving the transfer of 
intact protein complexes into the gas phase via electrospray ionization of volatile salt 
solutions allow the higher levels of protein organization to be probed, thus providing 
structural information including stoichiometry and spatial arrangement of subunits.9–11 
Traditionally quadrupole time-of-flight (Q-TOF) instruments have been used for native MS 
experiments due to the efficient transmission of high m/z ions.12–16 However, significant 
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inroads in characterization of  protein complexes have occurred with the development of 
extended mass range Orbitrap mass spectrometers.17,18 Both proteoform differentiation and 
measurement of ligand binding to macromolecular complexes are possible owing to the 
increased effective resolution and greater m/z range of these instruments compared to 
previous generations of Orbitrap instruments.19–22 Moreover, disassembling higher-order 
structures using tandem mass spectrometry (MS/MS) techniques can further probe the 
higher-order structures of protein complexes. Electron-based activation methods, such as 
electron transfer dissociation (ETD)23 and electron capture dissociation (ECD)24, yield 
sequence fragment ions from intact protein complexes that correlate with the exposed 
surfaces and provide insight into the higher-order structure. Surface-induced dissociation 
(SID) is another activation method that combined with ion mobility (IM) reveals the 
subunit architecture of protein-protein complexes.15 Although ETD, ECD, and SID have 
not yet been reported on an extended mass range Orbitrap platform, they have been 
demonstrated on other instruments capable of analyzing species over m/z 4000.15,23,24 
Recently ultraviolet photodissociation (UVPD) provided feedback about both quaternary 
and secondary structures of multimeric protein complexes as well as limited primary 
sequence information, based on disassembly of the complexes when irradiated with 193 
nm photons.25–27 Typically, separate bottom-up or top-down proteomics experiments 
involving digestion or denaturation of the protein complexes to further interrogate the 
primary sequence, localize post-translation modifications (PTMs), and identify 
proteoforms are necessary to provide an all-encompassing view into the dynamics and 
functional role of protein complexation in disease mechanisms.28,29 
Efforts to bridge the gap between obtaining primary sequence information and 
deciphering architectures of protein complexes have driven the development of new multi-
modal and/or higher energy activation mass spectrometry methods.30–36 Recently in-source 
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dissociation (ISD), collisional-induced dissociation (CID), and infrared multiphoton 
dissociation (IRMPD) were used in conjunction with ECD on a Fourier-transform ion 
cyclotron resonance (FTICR) MS to yield an integrated native top-down MS/MS 
approach.36 This strategy allowed acquisition of sequence and higher-order structural 
information of native protein complexes. Alternatively, a multistage MS approach on an 
extended mass range Orbitrap platform has been reported that involved introducing intact 
protein complexes into the gas phase by native ESI methods, disassembling protein 
complexes into monomers using front-end collisional activation, referred to as in-source 
trapping (IST), isolating a specific monomer using a quadrupole mass filter, then further 
fragmenting the selected monomeric species with higher energy collisional dissociation 
(HCD). Using this platform, the resulting multiply charged fragment ions were detected at 
high resolution and mass accuracy in an Orbitrap mass analyzer.18,30,32–35 This approach 
has been demonstrated for model protein complexes,30 applied to uncover a novel layer of 
regulation in a key metabolic enzyme,34 and implemented in a high-throughput manner to 
identify endogenous protein complexes.35 While these studies represent a major 
breakthrough, fragmentation efficiency using HCD was found to be low throughout the 
middle of the protein monomer sequences and bottom-up experiments were necessary to 
completely localize PTMs.30,34 In order to enhance sequence coverage in this type of 
advanced multistage strategy, integration with UVPD offers a compelling option. The high-
energy excitation caused by absorption of 193 nm photons has consistently demonstrated 
unsurpassed levels of diagnostic backbone fragmentation for intact monomeric proteins 
sprayed under both denaturing and native conditions.27,37–41 UVPD has demonstrated 
improved retention of labile PTMs, including phosphorylation42 and sulfation43, allowing 
better localization of modifications. Additionally, mapping holo (ligand-bound) fragment 
ions produced during photodissociation of native-like proteins has been used to elucidate 
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regions of interaction with a bound ligand.39,44–46 These properties make UVPD an ideal 
activation method for characterization of protein complexes. 
Here we report the use of a multistage native UVPD-MS approach implemented on 
a modified prototype of an extended mass range Orbitrap mass spectrometer instrument to 
elucidate the oligomeric state, localize a single amino acid mutation, and identify the bound 
cofactor for two single amino acid variants of BCAT2 in a single experiment. Each variant 
was sprayed using native ESI to determine the oligomeric state. In-source trapping was 
used to disassemble the complexes into composing subunits that were isolated with a 
quadrupole mass analyzer and subjected to 193 nm UVPD. A previous top-down study 
combined ETD and CID in a LC-FT-ICR MS at 21 T to confidently localize the BCAT2 
amino acid variant to its position in the sequence.8 In the present study, native ESI confirms 
that both WT and T186R BCAT2 exist as homodimers, even when the proteins are 
combined in solution. Gently activating the complexes in the front-end of the instrument 
using in-source trapping splits the dimers into monomeric subunits that are each non-
covalently bound to a PLP cofactor. UVPD of the monomer affords the highest level of 
sequence coverage compared to HCD of the monomers. Tracking holo ions observed 
during photodissociation of the monomers indicates that the cofactor interacts with the loop 
containing K229 where the cofactor is known to bind.7 
7.3 EXPERIMENTAL 
7.3.1 Sample Preparation 
Human hemoglobin (Sigma-Aldrich, St. Louis, MO), ammonium acetate (Sigma-
Aldrich, St. Louis, MO), acetonitrile (EMD Millipore, Billerica, MA), and formic acid 
(Fisher Scientific, Hampton, NH) were purchased. Recombinant human WT and T186R 
BCAT2 (Figure 7.1) were expressed using purchased plasmids and purified as previously 
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described.8 Protein samples were diluted to 40 µM (hemoglobin) or 20 µM (BCAT2) of 
the complex in 50 mM ammonium acetate at pH 6.8 and desalted using micro bio-spin P-
6 gel columns (Bio-Rad Laboratories Inc., Hercules, CA) for MS analysis. 
 
 
Figure 7.1: (A) Sequences of expressed WT and T186R protein constructs of BCAT2. 
The location of the variant amino acid is highlighted in yellow. The 
numbering system used to refer to the variant (T186R) and PLP binding site 
(K229) accounts for the 27 amino acid transit peptide that is not included in 
the expressed chain. (B) Structure of the pyridoxal phosphate (PLP) cofactor 
necessary for enzymatic action by BCAT2. 
7.3.2 Mass Spectrometry 
Hemoglobin samples at 40 µM in 50 mM ammonium acetate (pH 6.8) and BCAT2 
samples diluted to 10 µM in 50:50 acetonitrile:water with 0.1% formic acid for MS analysis 
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under denaturing conditions were analyzed on a Thermo Scientific Orbitrap Elite mass 
spectrometer (Bremen, Germany) modified to enable photodissociation in the HCD cell 
with a Coherent Excistar 193 nm ArF excimer laser (Santa Cruz, CA), as previously 
described.37 A gold-coated static tip nano-electrospray setup using an applied voltage of 
1.0-1.1 kV and a heated capillary set at 275˚C were used to infuse protein samples. For 
MS1 spectra, sixty scans were averaged at a resolving power of 240K at m/z 400 and an 
automatic gain control setting of 1E6. Ion trap isolation with an isolation width of 15 m/z 
was used to select the 7+ charge states of the α– or β–chain of holo-hemoglobin, and the 
27+ or 37+ charge state of BCAT2 for MS/MS analysis. HCD (15-20% NCE) and UVPD 
(1 pulse at 1.5 or 3 mJ) fragmentation spectra represent the average of 500 scans (over a 
range from m/z 220-4000) using an automatic gain control setting of 5E5 and maximum 
ion time of 2 sec. Three replicates of MS/MS spectra were collected for each protein. 
A schematic of the modified prototype of a Thermo Scientific Q Exactive UHMR 
instrument (Bremen, Germany) used for all multistage experiments is given in Figure 7.2. 
The instrument was built on the basis of a standard Q Exactive Plus (Thermo Scientific, 
Bremen, Germany) and modified to optimize the analysis of ions up to 80,000 m/z, as 
described in references 18 and 22. Briefly, several customized boards to enable lowering 
of the RF frequency in the instrument’s ion guides, a capillary to allow higher bath gas 
pressure in the HCD cell, and an S-lens exit lens with a smaller aperture (1 mm instead of 
2 mm) were installed in place of standard parts. Additionally, pulsing of the electrical 
potentials within the injection flatapole and inter-flatapole lens allows implementation of 
in-source trapping (Figure 7.2).18,22,30,32–35 UVPD was implemented in the HCD cell 
through incorporation of a Coherent Excistar 193 nm ArF excimer laser (Santa Cruz, CA).  
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Figure 7.2: Schematic representation of implementation of UVPD in the HCD cell of a 
prototype of the Thermo Scientific Q Exactive UHMR mass spectrometer. 
Modified electronics allow the ion guides (bent flatapole, quadrupole, transfer 
multipole, C-trap) and HCD cell to operate at lower RF frequencies favoring 
the transmission of higher m/z ions. In-source trapping is enabled in the 
injection flatapole region by raising the bias of the inter-flatapole lens and 
trapping the ions in a potential well created between the S-lens exit lens and 
inject flatapole. The depth and duration of this potential well is set by the 
desolvation voltage and desolvation time, respectively. 
Implementation of UVPD on the prototype Q Exactive Plus UHMR instrument 
required removal of the charge detector (electrometer, routinely used to aid in automatic 
gain control) to incorporate a fused silica optical window (Kurt J. Lesker Company, 
Hustings, England) and allow introduction of the laser beam concentric with the HCD cell. 
Removal of the electrometer breached the vacuum seal between the back of the HCD cell 
and high-vacuum chamber, causing increased flow of collision gas from the cell. To 
mitigate the resulting loss of pressure, a stainless steel tube (2 cm O.D × 13 cm long) with 
O-rings affixed to either end was inserted through a hole in a custom built vacuum flange 
so that it made contact with a Teflon washer mounted to the back of the HCD cell, thus 
preventing gas from leaking out. The fused silica window was mounted to the other end of 
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the tube using a custom-built holder. An optical periscope (Thorlabs, Newton, NJ) 
equipped with two 25 mm UV mirrors (Edmund Optics, Barrington, NJ) mounted at 45˚ 
with micropositioners was used to elevate and guide the laser beam coaxial to the HCD 
cell. Emission of the laser was triggered by a rise in the HCD multipole DC offset so that 
the laser was triggered after ions had cooled in the HCD and just prior to sending them to 
the C-trap. To bring the offset signal down to a 0-5 V range, it was modulated by a series 
of voltage dividers and diodes assembled in house. Following voltage division this signal 
was used to gate an Arduino Uno microcontroller programmed with a custom script to 
generate one or more TTL pulses, corresponding to the desired number of laser shots 
specified by the user, to trigger the laser. 
A nano-electrospray setup with gold-coated borosilicate emitters operated at 1.0-
1.2 kV was used to infuse protein solutions. A heated inlet capillary set at 200˚C aided in 
desolvation. The modified electronics on the instrument enabled transmission of higher m/z 
ions by operating at lower RF frequencies for the bent flatapole (1.1 MHz), transfer 
multipole (770 kHz), C-trap (2.1 MHz), and HCD cell (770 kHz). Additionally, control of 
the nitrogen bath gas pressure was adjusted during collection of MS1 (UHV pressure of 
1.09E-9 mbar), in-source trapping (UHV pressure of 4.09E-10 mbar), HCD MS/MS (UHV 
pressure of 4.09E-10 mbar), UVPD MS/MS (UHV pressure of 1.28E-10 mbar) spectra to 
optimize signal intensity.  
In-source trapping was enabled in the region of the injection flatapole. Specifically, 
the inter-flatapole lens is operated at an increased positive potential compared to the normal 
operating value to block the ions from exiting the injection flatapole. Simultaneously the 
injection flatapole is maintained at a negative voltage (up to -300 V), referred to as the 
desolvation voltage (Figure 7.2). During trapping, as ions exit the S-lens region they 
collide with background gas and settle at the bottom of a potential well created by the S-
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lens exit lens and injection flatapole for a set amount of time termed the desolvation time 
(4 ms – 10 ms) (Figure 7.2). A 200 µs release event returns the inject flatapole and inter-
flatapole lens biases to their set operating values (given in Table 7.1). Depending on 
protein size and flexibility, lower desolvation voltage values (-50 to -150 V) typically leave 
complexes intact and simply aid in desolvation while higher desolvation voltages (> -150 
V) result in complex disassembly into constituent subunits.  
Given that implementation of UVPD required removal of the electrometer, the 
automated gain control was turned off for all experiments. Instead the maximum inject time 
was optimized to control the number of ions analyzed. Table 7.1 summarizes all other 
instrumental parameters used for each scan type: MS1, in-source trapping, and MS/MS. 
For MS1 and in-source trapping spectra, fifty scans were averaged while the MS/MS 
spectra represent the average of 500 scans. During collection of in-source trapping and 
MS/MS spectra, the RF amplitude of the bent flatapole and injection flatapole were 
dropped from 990 Vpp to 300 Vpp to favor the transfer of lower mass ions. For MS/MS 
analysis, the most intense monomeric charge state was selected after in-source trapping 
with an isolation width of ±15 m/z using a segmented quadrupole mass filter with a 
modified electronic board that featured a decreased RF frequency (278 kHz) allowing a 
mass-selection limit of up to 40,000 m/z. During MS/MS analysis, HCD collision energy 
was set to 225 eV or 160 eV for the activation of dimers and monomers, respectively. For 
UVPD MS/MS spectra, ions were activated by exposure to a single 1 mJ or 3 mJ pulse. 
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Table 7.1: Summary of instrumental parameters used for analysis of BCAT2 solutions. 
Parameter 
Scan Type 
MS1 IST MS/MS 
Source Fragmentation (eV) 20 50 50 
Desolvation Voltage (V) -100 -250 -250 
Desolvation Time (ms) 4 6 6 
Source DC Offset (V) 3 3 3 
Injection Flatapole DC (V) 10 9 9 
Inter-Flatapole Lens (V)  8 8 8 
Bent Flatapole DC (V) 7 7 7 
Auto Transfer Multipole DC (V) 6.5 5.0 5.0 
Auto C-Trap Entrance Lens Inject (V) 5.0 3.5 3.5 
Resolving Power (at m/z 200) 10K 15K 140K 
Max Inject Time (ms) 25 50 500 
Scan Range (m/z) 1000-10000 1000-10000 500-8000 
 
A Dionex LC system interfaced to the modified Thermo Scientific Q Exactive 
UHMR instrument described above was used to perform all size exclusion chromatography 
experiments. For each run, 5 µg of protein complex (5 µL injection volume) in 50 mM 
ammonium acetate (pH 6.8) was injected onto a 2.1 mm × 30 cm Zenix-C column with an 
80 Å pore size and 3 µm particle size (Sepax Technologies, Newark, DE). An isocratic 
mobile phase comprised of 50 mM ammonium acetate at pH 6.8 was applied at a flow rate 
of 80 µL min-1. A HESI source with an applied voltage of 4 kV was used to introduce the 
LC effluent into the MS. Data was collected using the parameters for MS1 spectra 
described above in Table 7.1. 
7.3.3 Data Analysis 
Intact molecular masses of protein complexes from MS1 and in-source trapping 
mass spectra were determined by taking the apex of the most abundant peak in the charge 
state distribution, manually calculating the charge state based on the spacing of the peaks, 
and calculating the molecular mass from the assigned charge state. All MS/MS spectra 
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were de-charged and de-isotoped using Xtract with a signal-to-noise ratio of 3, fit factor of 
44%, and remainder of 25%. ProSight Lite v1.4 software was used to search monoisotopic 
fragment ions against the sequence of hemoglobin or BCAT2 and identify fragment ions 
(± 10 ppm) produced by HCD (b, y) or UVPD (a, a•, b, c, x, x•, y, y-1, z). Sequence coverage 
maps shown were created using ProSight Lite according to the following legend: a/x-type 
ions (green), b/y-type ions (blue), and c/z-type ions (red). Holo fragment ions resulting 
from UVPD were identified by searching the spectra for a mass shift corresponding to the 
heme in hemoglobin (615.170 Da) or PLP in BCAT2 (247.025 Da) fixed at the N- and C-
terminus. For all MS/MS spectra, three replicates were collected. Only fragment ions (apo 
and holo) identified in all three replicates were considered confidently identified. All raw 
spectra are archived and available at: https://repository.jpostdb.org/ and accession numbers 
are PXD009447 for ProteomeXchange and JPST000410 for jPOST. 
7.4 RESULTS AND DISCUSSION 
7.4.1 Multistage Native UVPD-MS for Complete Protein Complex Characterization 
The recent development of Orbitrap mass spectrometers with extended mass range 
capabilities has enabled improved resolution and sensitivity in the analysis of protein 
complexes.17–22,30–35 Specifically modification of the quadrupole RF drive allows selection 
of higher m/z species and implementation of a “trap and release” approach to convert the 
inject flatapole into a linear quadrupole trap affords high-efficiency desolvation and 
improved dissociation of assemblies into subunits.18,30,32–35 By leveraging these key 
upgrades in instrumentation, we have further advanced the utility of a multistage approach 
for analysis of protein complexes by implementing UVPD for activation/fragmentation 
after disassembly of the complexes. To optimize and characterize the performance of this 
multistage approach, we first analyzed the heterotetramer hemoglobin (64 kDa). 
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Electrospray ionization of hemoglobin in a solution containing the volatile salt 
ammonium acetate allows efficient transfer of the intact heterotetramer into the gas phase 
(Figure 7.3). The 15+, 16+, and 17+ charge states of a complex comprised of two α-chains 
and two β-chains with each subunit non-covalently bound to a heme ligand were observed 
in the MS1 spectrum (Figure 7.3A). Increasing the applied desolvation voltage allows in-
source trapping, resulting in dissociation of the tetramer into its constituent α- and β-chain 
monomers as well as some low abundance dimeric species (Figure 7.3B). Interestingly, 
the non-covalently bound heme is retained during this front-end low energy collisional 
activation, yielding the 7+ charge states of the α– and β–chains that can be selectively 
isolated using the quadrupole (Figure 7.3C, 7.3D) and subsequently activated with HCD 
or UVPD. The fragmentation patterns observed for the α- and β-chain monomers activated 
with HCD or 193 nm UVPD are shown in Figure 7.4. Important benchmark performance 
comparisons are facilitated by comparison of the sequence information obtained by this 
multistage approach (which allows dissection of multimers) to the sequence information 
obtained directly from monomeric forms of the protein. As extended mass range 
instruments are designed for analysis of large, multimeric complexes, the higher mass 
range is optimized at the expense of the lower mass range. To ensure this did not impede 
the efficient transmission of monomeric proteins, the sequence analysis of hemoglobin was 
undertaken using similar native MS conditions on a standard Orbitrap instrument (without 
extended mass range) outfitted with UVPD to enable direct analysis of monomers.25,37–
40,44–46 The 7+ charge state of α- and β-chain monomers were observed in the MS1 spectrum 
obtained on the Elite mass spectrometer, each of which could be isolated using the ion trap 
and activated with HCD or UVPD (Figure 7.4). Identifying the fragment ions and mapping 
these along the sequences confirms that the multistage approach on the extended mass 
range Orbitrap instrument yields comparable or higher sequence coverage of the α- and β-
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chains of hemoglobin for both HCD and UVPD (Figure 7.4). Additionally, holo (ligand-
bound) fragment ions originated from the same regions of the protein using the multistage 
approach on the mass spectrometer with the extended mass range compared to the direct 
analysis of monomers on the standard Orbitrap mass spectrometer, suggesting that 
sufficient electrostatic contacts between the ligand and protein side-chains are maintained 
during in-source trapping to allow retention of binding site information. This optimized 
multistage approach involving native MS, in-source trapping, and UVPD provides an ideal 
platform to interrogate the differences in fragmentation of dimeric BCAT2 complexes 
containing the WT and T186R variants. 
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Figure 7.3: (A) ESI mass spectra (m/z 500-10,000) of hemoglobin sprayed in 50 mM 
ammonium acetate (pH 6.8). Each species observed is identified by colored 
circles. (B) IST ejects the 7+ monomers of the α and β chains in which the 
heme is retained. (C, D) Using the quadrupole, each chain can be selectively 
isolated for MS/MS analysis. 
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Figure 7.4: Direct comparison of (1) HCD and (2) UVPD mass spectra of the 7+ charge 
state of the monomeric (A) α and (B) β chains of holo hemoglobin collected 
on the Q Exactive UHMR (left) and Orbitrap Elite (right). The precursor 
species was observed after IST on the UHMR and in the MS1 spectra on the 
Elite. Surviving precursors are indicated with a star in the MS/MS spectra and 
the ejected heme is identified with a red pentagon. Sequence coverage maps 
for HCD and UVPD (apo and holo fragment ions separately) of the α and β 
chains are shown beneath the spectra (± 10 ppm tolerance). Holo fragment 
ions were identified by searching for a +615.170 Da shift fixed at the N- and 
C-terminus to encompass all mass-shifted product ions. The holo ions 
observed for both chains are similar for each mass spectrometer. The heme is 
known directly interact with H58 and H87 for the α-chain, and H63 and H92 
for the β-chain. 
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7.4.2 Native MS1 and Size-Exclusion Chromatography of BCAT2 
Spraying WT and T186R BCAT2 under native conditions provides insight into the 
oligomeric state of each variant, thus revealing the highest level of protein structure. The 
MS1 spectra of WT and T186R BCAT2 indicate that each protein exists as a homodimer 
(Figure 7.5A, 7.5B). Although previous crystallographic experiments8 indicate that R186 
in the mutant repulses K59 in the other subunit, this effect is insufficient to completely 
destabilize the dimer. Heterodimers were not observed after simply mixing the variants; a 
co-folding experiment would be necessary to investigate more explicitly the potential 
formation of WT and T186R heterodimers (Figure 7.5C). The observed masses of the 
dimers were 497 Da greater than the theoretical masses (Figure 7.5), suggesting that one 
or more ligands are non-covalently bound to the proteins. Conversely, when the proteins 
are sprayed from denaturing solutions, no mass shift is observed for the unfolded 
monomeric proteins (Figure 7.6). Sequence coverages were 11% (27+, denatured) and 7% 
(37+, denatured) from HCD, and 36% (27+, denatured) and 34% (37+, denatured) from 
UVPD for WT and T186R BCAT2, respectively. The mass shift for the dimers is attributed 
to the non-covalent binding of one PLP cofactor (247.025 Da) to each subunit of the dimer. 
A PLP cofactor is necessary for the enzymatic action of the protein.7 On-line size-exclusion 
chromatography was used to confirm the results observed for the MS1 spectra (Figure 
7.7). The proteins were injected individually and as a mixture after incubation for 120 
minutes. Each variant eluted as a homodimer containing two molecules of PLP. Extracted 
ion chromatograms confirmed that no heterodimers were observed, nor were any dimers 
containing a single or no cofactors (Figure 7.7). 
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Figure 7.5: ESI mass spectra (m/z 1,000-10,000) of (A) WT, (B) T186R, and (C) 
WT+T186R BCAT2 sprayed in 50 mM ammonium acetate (pH 6.8). Each 
species observed is identified by colored circles in an expanded view (insets) 
of the 17+ charge state of the homodimer (m/z 4,850-4,950). The peaks 
denoted by diamonds (♦) represent the corresponding Na-adducted species. 
The experimentally measured masses are 497 Da larger than the expected 
masses for both WT and T186R BCAT2. This mass shift is attributed to a 
PLP cofactor bound to each subunit of the dimer. As demonstrated in (C), 
combining the protein variants in solution only yields homodimers. SEC 
confirms that these are the oligomeric states that exist in solution (Figure 7.7). 
The table in (D) summarizes theoretical and measured masses for the dimers. 
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Figure 7.6: (A) ESI mass spectra collected on the Orbitrap Elite (m/z 600-1,800) of (1) 
WT and (2) T186R BCAT2 sprayed under denaturing conditions (50:50 
ACN:H2O w/ 0.1% formic acid). (B) Deconvoluted ESI mass spectra of (1) 
WT and (2) T186R BCAT2 confirming that the intact masses are within 2 
ppm of the expected masses for both protein variants without any cofactor 
bound. Combined HCD (15% NCE) or UVPD (1 pulse at 2 mJ) sequence 
coverage maps of the 27+ and 37+ charge states of each variant are shown 
beneath the spectra. Sequence coverages were 11% and 7% from HCD, and 
36% and 34% from UVPD for WT and T186R BCAT2, respectively. 
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Figure 7.7: (A-C) SEC base peak LC traces of (A) WT, (B) T186R, and (C) WT+T186R 
BCAT2. For the combined sample in (C), XIC traces of the m/z values 
corresponding to the homodimer of each variant are shown. (D, E) ESI mass 
spectra (m/z 2,000-6,000) collected at RT 6.60 min in (A) and 6.95 min in (B) 
confirm that both variants exist as homodimers in solution with each subunit 
bound to a PLP cofactor. 
7.4.3 In-Source Trapping and UVPD for Improved Localization of T186R Mutation 
in BCAT2 
Identification of the protein sequences requires activation and disassembly of the 
dimeric complexes. Irradiation of protein complexes in the gas phase with 193 nm photons 
has been demonstrated to release the constituent subunits as well as diagnostic backbone 
fragment ions.25,26 Isolation and activation of the homodimers of WT and T186R BCAT2 
(17+ charge state with two PLP cofactors per dimer) by HCD or UVPD produces the 
MS/MS spectra shown in Figure 7.8. Both activation methods result in backbone cleavages 
 260 
that result in production of diagnostic sequence ions (Figure 7.8). UVPD outperforms 
HCD for both protein variants, yielding higher sequence coverage deeper into the protein 
sequence. Sequence coverages were 12% and 16% from HCD, and 21% and 28% from 
UVPD for WT and T186R BCAT2, respectively. This improved coverage is attributed to 
the access to excited electronic states and thus higher energy fragmentation pathways upon 
absorption of 193 nm photons.25,26,37,38,41 Additionally, the pressure of the nitrogen bath gas 
in the trapping cell used for ion activation was significantly reduced during UVPD, 
resulting in a slower transient decay and higher resolution frequency measurements and 
improved sensitivity as a result of fewer collisions during ion ejection from the C-trap into 
the mass analyzer and during analysis in the Orbitrap.47,48 The use of reduced pressure has 
no impact on the fragmentation efficiency of UVPD but is detrimental for the performance 
of HCD. 
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Figure 7.8: HCD and UVPD mass spectra of the 17+ charge state of the homodimer of 
(A) WT and (B) T186R BCAT2. Expanded views (m/z 1,255-1,280) in panel 
(A) show selected fragment ions labelled. The precursors are indicated with a 
star in the MS/MS spectra. Sequence coverage maps for (1) HCD and (2) 
UVPD of (A) WT and (B) T186R BCAT2 are shown beneath the spectra. 
Sequence coverages were 12% and 16% from HCD, and 21% and 28% from 
UVPD for WT and T186R BCAT2, respectively. The Thr residue mutated to 
an Arg is shaded in gold in panel (B). 
When protein complexes are subjected to UVPD, sequence ions that retain the PLP 
cofactor or portions of other subunits are produced, in addition to the diagnostic apo 
(ligand-free) fragment ions. The formation of such holo (ligand-bound) fragment ions has 
been observed previously for UVPD.39,44–46 Conversely, HCD causes ejection of ligands 
and results exclusively in formation of apo fragment ions. In the case of the BCAT2, the 
sequence coverage achieved with UVPD would be even further improved if the holo 
fragment ions bound to the PLP cofactor could be identified and contribute in a meaningful 
way to the net sequence coverage. Confident identification of holo ions at this time is 
challenging for a protein complex of this size given the nearly unlimited array of possible 
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fragment ion assignments that can arise from combinations of partial protein sequence 
segments and the PLP cofactor. In essence, “mass shifted” fragment ions could be falsely 
attributed to the presence of the PLP cofactor when in reality the mass shift arises from a 
portion of the protein from the other subunit with the same exact mass as the cofactor. By 
utilizing a multistage approach, however, monomers can be separated from the dimeric 
complexes at the front-end of the mass spectrometer prior to MS/MS analysis, thus 
alleviating the ambiguity in the origin and identities of holo fragment ions.30,32–35  For 
implementation of the multistage strategy, the in-source trapping parameters were 
optimized to cause subunit ejection and yield the mass spectra shown in Figure 7.9. The 
bound PLP ligands are retained as the subunits are disassembled. A mass shift of +249 Da 
corresponding to a single PLP cofactor bound to a monomeric subunit of the protein is 
observed for both variants. In-source trapping of the solution containing both the WT and 
T186R proteins yields PLP-bound monomers of each (Figure 7.9C).  
The 12+ charge state monomer of each variant bound to a PLP cofactor resulting 
from in-source trapping of the observed homodimer was selectively isolated and activated 
with HCD or UVPD, resulting in the MS/MS spectra in Figure 7.10. Identified sequence 
ions are mapped on to the known protein sequences (Figure 7.10). As evident in the UVPD 
spectra, lower energy laser pulses (1 mJ) yielded larger fragments corresponding to 
cleavage in the central region of the protein. Conversely, using a higher energy per laser 
pulse (3 mJ) resulted in smaller fragments originating from the termini of the protein. The 
UVPD sequence maps shown in Figure 7.10 represent the combined coverage for 
identified apo and holo (ligand-bound) fragment ions for the spectra collected using 1 mJ 
and 3 mJ per pulse. For comparison, Figure 7.11 gives sequence coverage maps based 
solely on the apo fragment ions obtained from UVPD. 
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Figure 7.9: In-source trapping mass spectra (m/z 1,000-10,000) of (A) WT, (B) T186R, 
and (C) WT+T186R BCAT2. Each species observed is identified by colored 
circles in an expanded view (insets) of the 12+ charge state of the monomer 
(m/z 3,420-3,500). The experimentally measured monomeric masses are 249 
Da larger than the expected masses for both WT and T186R BCAT2. This 
mass shift is attributed to a PLP cofactor bound to each monomer. Given that 
in-source trapping occurs at the front of the instrument, each monomeric 
species of interest can be isolated and subjected to MS/MS analysis (Figure 
7.10). The table in (D) summarizes theoretical and measured masses for the 
monomers. 
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Figure 7.10: HCD and UVPD mass spectra of the 12+ charge state monomer of (A) WT 
and (B) T186R BCAT2 observed after in-source trapping. Expanded views 
(insets) in panel (A) show selected fragment ions labelled. Holo fragment ions 
that contain the PLP cofactor are denoted by a diamond. The precursors are 
indicated with a filled star in the MS/MS spectra. The unfilled star denotes 
the charge-reduced precursor (11+) as the PLP cofactor is ejected during 
HCD. Sequence coverage maps for (1) HCD and (2) UVPD of (A) WT and 
(B) T186R BCAT2 are shown beneath the spectra. The UVPD sequence maps 
represent the combined coverage for identified apo and holo fragment ions 
for the spectra collected using 1 mJ and 3 mJ per pulse. Apo ion only sequence 
coverage maps are given in Figure 7.11. Sequence coverages were 13% and 
18% from HCD, and 45% and 37% from UVPD for WT and T186R BCAT2, 
respectively. The Thr residue mutated to an Arg is shaded in gold in panel 
(B). 
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Figure 7.11: Sequence coverage maps based on apo fragment ions only produced by 
UVPD using 1 pulse at (1) 1 mJ or (2) 3 mJ of the 12+ monomer of (A) WT 
and (B) T186R BCAT2. Sequence coverages were 18% and 10% using 1 mJ 
pulses, and 15% and 14% using 3 mJ pulses for WT and T186R BCAT2, 
respectively. The Thr residue mutated to an Arg is highlighted in yellow in 
panel (B). 
UVPD affords higher sequence coverage (45% and 37% for WT and T186R 
BCAT2, respectively) compared to HCD (13% and 18% for WT and T186R BCAT2, 
respectively) and more effectively spans the central region of the protein where the 
mutation is located.  These sequence coverages obtained by UVPD are higher than or 
comparable to those found for denatured BCAT proteins, as reported above for the 27+ and 
37+ charge states. HCD of the monomers ejected from the dimeric complexes afforded 
only a 1-2% increase in sequence coverage compared to HCD of the dimers. UVPD of the 
monomers ejected from the dimers give significantly higher sequence coverage compared 
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to UVPD of the intact dimers (e.g. increasing from 21% to 45% for WT BCAT2). The holo 
(PLP-containing) sequence ions contributed significantly to the gain in sequence coverage 
achieved by UVPD. Figure 7.12 summarizes the sequence coverage afforded by HCD and 
UVPD. In general, substantial improvements in sequence coverage and localization of the 
mutation in BCAT2 were obtained by disassembling the dimer and selecting a single 
charge state of the monomer for subsequent UV photoactivation. 
 
 
Figure 7.12: Graphs summarizing the sequence coverage afforded by HCD and UVPD 
(apo and holo ions) for activation of the monomer ejected by IST vs. direct 
interrogation of the intact dimer for (A) WT and (B) T186R BCAT2. 
7.4.4 Mapping UVPD Holo Fragment Ions to Examine the Cofactor Binding Site 
along BCAT2 
Identifying PLP-bound holo ions produced upon photodissociation not only adds 
to the sequence coverage but also sheds light on the binding site based on the pattern of 
apo versus holo fragment ions. The high energy deposited during absorption of 193 nm 
photons by the protein backbone favors preferential cleavage of backbone bonds rather 
than disruption of the electrostatic interactions with a bound ligand.39,44–46 Figure 7.13 
 267 
gives the sequence of BCAT2 with the regions of the protein demarcated where backbone 
cleavages occurred to produce holo fragment ions upon UVPD. For both variants, the 
majority of holo ions are bi-directional (i.e. holo ions for which both N-terminal and C-
terminal fragment ions retain the ligands and share overlapping residues) and cover regions 
in the middle (V205-Y233) of the protein. Those residues which are consistently included 
in bi-directional holo fragment ions expected to be those that interact with the cofactor.39,44–
46,49 To aid in visualization, space-filling models of the crystal structures of WT (PDB ID: 
5CR5)50 and T186R (PDB ID: 5MPR)8 BCAT2 with the residues corresponding to holo 
fragment ions produced by UVPD represented as colored spheres are shown in Figure 
7.13. 
 
 
 268 
 
Figure 7.13: (A) Sequence of BCAT2 (X160 = T for WT or R for T186R in bold font) with 
the observed N-terminal (blue), C-terminal (red), and bi-directional (green) 
PLP cofactor-bound holo fragment ions observed during UVPD of the 12+ 
monomer (combined from 1 mJ and 3 mJ) mapped above for WT (solid line) 
and T186R (dotted line). Bi-directional fragmentation indicates 
complementary N- and C-terminal ions occurring at the same backbone 
position. The known binding site of the PLP cofactor is K229 shown 
highlighted in yellow. Note that the numbering system used to refer to the 
variant (T186R) and PLP binding site (K229) accounts for the 27 amino acid 
transit peptide that is not included in the expressed chain. (B, C) Space-filling 
models of the crystal structures of WT (PDB ID: 5CR5) and T186R (PDB ID: 
5MPR) BCAT2 with the residues corresponding to holo fragment ions 
produced by UVPD represented as colored spheres. The PLP cofactor 
(purple) and residue K229 (orange) are shown as sticks and labelled in (C). 
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BCAT2 is dependent on a PLP cofactor to catalyze the transfer of an amino group 
from the donor branched-chain amino acid to α-ketoglutarate. This ligand is known to bind 
at active site residue K229.7 The observation that the bi-directional holo ions generally 
contain K229 is consistent with the prevailing understanding of the structure of BCAT2. 
Furthermore, the N-terminal holo ions are only observed C-terminal to the first loop that is 
in proximity to K229 (F29-H37) and the active site (Figure 7.13B, 7.13C). Both variants 
yielded holo ions from the same regions with the exception of P144-L146 and P158-A161 
which were only observed for the wild-type protein. The T186R substitution occurs in this 
region suggesting that the mutation may destabilize electrostatic interactions between 
amino acids along that area of the protein and the PLP cofactor, a hypothesis that merits 
further confirmation using ancillary structural and biophysical methods, as well additional 
supporting examples from future UVPD-MS studies. This finding agrees with previous 
electrostatic free energy calculations suggesting that the substitution of Thr for Arg at 
residue 186 induces a sufficiently large pKa shift of nearby Cys residues in the other 
subunit of the dimer that influences the Cys protonation state, and prevents the substrate 
and PLP cofactor from orienting correctly.5 Obtaining this type of insight on the ligand 
binding sites by mapping holo fragment ions is an advantage of UVPD in a multistage MS 
approach. 
7.5 CONCLUSION 
In addition to establishing T186R BCAT2 exists as a dimer in solution and 
identifying a bound PLP cofactor, our study demonstrates the general utility of 
incorporating 193 nm UVPD into a multistage MS approach for complete characterization 
of protein complexes from the oligomeric state down to the primary sequence. The first 
stage (MS1) provided a comprehensive view of the oligomeric state adopted by each 
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BCAT2 protein and aided in the identification of a bound PLP cofactor based on the 
measured intact mass. Direct interrogation of the BCAT2 dimers by UVPD afforded 
moderate sequence coverage and yielded holo product ions that could not be confidently 
assigned owing to the large number of possible compositional combinations. To mitigate 
the ambiguous identification of key PLP-containing holo fragment ions, in-source trapping 
was used to eject a PLP-bound BCAT2 monomer which was subsequently subjected to 
UVPD. The ability to confidently identify holo ions contributed significantly to the 
sequence coverage achieved, and mapping the origin of observed holo ions along the 
sequence provided insight into the binding of PLP in the T186R mutant of BCAT2 
compared to the WT protein. In summary, by increasing the diversity of sequence ions 
observed and producing assignable holo ions that reveal information about bound ligands, 
the incorporation of UVPD advances the utility of a multistage MS approach for complete 
characterization of intact protein complexes. 
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Chapter 8: Uniting Native Capillary Electrophoresis and Multistage 
Ultraviolet Photodissociation Mass Spectrometry for On-line Separation 
and Characterization of E. Coli Ribosomal Proteins and Protein 
Complexes 
8.1 OVERVIEW 
With an overarching goal of characterizing the structure of every protein within a 
cell, identifying its interacting partners, and quantifying the dynamics of the states in which 
it exists, key developments are still necessary to achieve comprehensive native proteomics 
by mass spectrometry. In practice, much work remains to optimize reliable on-line 
separation methods that are compatible with native mass spectrometry (MS), as well as 
improve tandem MS (MS/MS) approaches with respect to when and how energy is 
deposited into proteins of interest. Herein we utilize native capillary zone electrophoresis 
(CE) coupled with MS to characterize the proteoforms in the E. coli 70S ribosome. The 
capabilities of 193 nm ultraviolet photodissociation (UVPD) to yield informative backbone 
sequence ions are compared to those of higher-energy collisional dissociation (HCD). To 
further improve sequence coverage values, a multistage MS/MS approach is implemented 
involving front-end collisional activation to disassemble protein complexes into 
constituent subunits that are subsequently individually isolated and activated by HCD or 
UVPD. In total, 48 of the 55 known E. coli ribosomal proteins are identified as 84 unique 
proteoforms included 22 protein-metal complexes and 10 protein-protein complexes. 
Additionally, mapping metal-bound holo fragment ions resulting from UVPD of protein-
metal complexes offers insight into the metal binding sites. 
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8.2 INTRODUCTION 
Owing to the prevalence of noncovalent interactions between proteins and metals, 
ligands, or other proteins, the definition of such networks is necessary to fully understand 
cellular processes or elucidate disease mechanisms.1 Preservation of such interactions and 
characterization of the protein-protein and protein-ligand partners poses a significant 
problem, especially in the quest to analyze more elaborate mixtures of proteins that are 
better representative of a biological system. Numerous strategies have been developed to 
evaluate protein interactions, ranging from spectroscopic to microscopic to mass 
spectrometric to other molecular biology methods.2,3 Mass spectrometry (MS) in particular 
offers the potential both to identify individual proteins via various proteomic techniques 
and to characterize interactions via application of native-MS methods that allow 
preservation of non-covalent interactions of the protein-protein and protein-ligand 
partners.4–6 However, despite substantial inroads in the performance of mass spectrometric 
methods, characterization of mixtures of protein complexes remains challenging. Bottom-
up MS-based proteomics provides a robust method for characterization of the primary 
sequences of proteins but is less suitable for mapping protein interactions due to the use of 
denaturing conditions and proteolytic digestion of proteins into peptides.7 Alternative top-
down methods enable direct analysis of intact proteins, now successfully demonstrated 
even for complex mixtures.8 As such top-down proteomics uniquely offers the potential to 
derive a complete picture of all of the combinations of molecular forms in which a protein 
resulting from a single gene exists (i.e. caused by genetic variation, alternative splicing, 
and PTM), referred to as proteoforms.9 However, the wealth of information related to 
noncovalent interactions is typically not retained owing to the use of denaturing solvents 
that facilitate conventional reversed phase liquid chromatography necessary for efficient 
protein separations but disrupt all levels of higher order structure. An alternative approach, 
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native MS, involves the use of volatile salts during electrospray ionization (ESI) to 
efficiently transfer proteins into the gas phase while maintaining noncovalent interactions. 
This method allows analysis of multi-protein complexes that retain both metals and ligands 
with higher order structures reminiscent of those adopted in solution.4–6 While this 
technique has become widely used in studies aimed at probing secondary, tertiary, and 
quaternary protein structure, it is generally limited to highly purified single proteins or 
simple protein mixtures.10,11 Achieving more comprehensive characterization of the 
proteoforms present in multimeric macromolecules in complex biological mixtures 
requires technical advances in two primary areas: (1) robust, high-resolution separation 
methods compatible with the volatile salts necessary for native MS, and (2) MS 
instrumentation capable of detecting high m/z species as well as enabling proficient tandem 
mass spectrometry to allow identification of the constituent proteins. 
Several separation techniques have been adapted to be compatible with native MS 
conditions, including size exclusion chromatography (SEC),12–14 ion exchange 
chromatography (IEX),15,16 hydrophobic interaction chromatography (HIC),17 and 
electrophoresis methods.18–24 While SEC is routinely used to separate higher order 
structure variants or aggregates of antibodies under native MS conditions,12–14 the 
simplicity of this method often yields relatively low-resolution separations insufficient to 
distinguish the subtle differences between various proteoforms of a single protein. IEX and 
HIC have demonstrated superior resolving powers in the analysis of computationally 
designed oligomers,15 biopharmaceutical protein products,16 and antibody-drug 
conjugates.17 However, both of these methods operate on principles requiring relatively 
high salt concentrations which can cause disruption of weak noncovalent interactions. 
Additionally, the amenability of these separation methods (SEC, IEX, HIC) to nanoscale 
flow rates has yet to be demonstrated. In this regard, they require significantly larger 
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sample quantities, may cause sample dilution, and ultimately result in lower sensitivity 
compared to conventional reversed-phase LC approaches used for bottom-up and top-down 
proteomics. In contrast to such techniques that rely on interactions of analytes with a solid 
phase, electrophoresis methods utilizing a high electric field to separate molecules based 
on charge and size have become attractive options for performing native separations.18–24 
Isoforms and subcomplexes of relatively stable protein-protein complexes have been 
separated by capillary isoelectric focusing (cIEF).18,19 However, this method requires 
denaturing sheath flow buffers to maintain stable ESI, potentially causing protein 
unfolding. Additionally, native gel-eluted liquid fraction entrapment electrophoresis 
(GELFrEE) has been used for off-line separation of endogenous protein complexes but has 
not yet been coupled on-line to a mass spectrometer owing to the use of non-MS compatible 
detergents and salts.20,21 Stemming from its ability to achieve high-resolution separations 
using negligible quantities of sample and buffer under both denaturing and native 
conditions, capillary zone electrophoresis (CE) has emerged as a top contender for 
facilitating analysis of protein complexes in conjunction with native MS.22–27 Although 
non-MS compatible buffers are typically used as the background electrolyte (BGE) in CE, 
volatile salts such as ammonium acetate or ammonium formate are easily substituted. 
Additionally, commercially available MS sources (both sheath flow and sheathless) 
circumvent initial issues with completing the electrical circuit for separation while 
simultaneously maintaining appropriate voltages necessary for ESI.28,29 
Two key features of native MS, the deposition of less charge during the ESI process 
and the retention of noncovalent interaction partners, result in the production of high m/z 
ions that demand mass analyzers with extended mass ranges. This is why initial native MS 
studies were generally limited to time-of-flight (TOF) or Fourier-transform ion cyclotron 
resonance (FT-ICR) instruments.30–33 More recently the development of Orbitrap 
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instruments with ultra-high mass range (UHMR) capabilities has provided a new high 
performance platform for native MS.34 With respect to MS/MS capabilities, collisional 
activation, including collisional-induced dissociation (CID) and higher-energy collisional 
dissociation (HCD), has proven proficient for disassembly of protein complexes into 
subunits or even monomeric proteins, but the low degree of backbone cleavages results in 
limited sequence coverage of proteins, impeding both identification and characterization.35 
Several ion activation methods based on alternative mechanisms and/or offering higher 
energy deposition have been developed for the characterization of intact protein 
complexes.36 Electron-based methods, including electron-transfer dissociation (ETD), 
electron-capture dissociation (ECD), and electron ionization dissociation (EID), offer 
improved sequence coverage of the proteins within protein complexes.37–40 Conversely 
surface-induced dissociation (SID) mainly causes disruption of multimeric complexes into 
constituent protein subcomplexes and individual subunits, thus affording a remarkable new 
strategy for probing architectures of protein assemblies.41 Another high energy activation 
method, ultraviolet photodissociation (UVPD), produces both intact subunits and extensive 
series of sequence ions resulting from backbone cleavages.42–44 In addition to returning 
unsurpassed sequence coverages and retention of labile PTMs even for high-throughput 
workflows,45–48 UVPD maintains non-covalent interactions, thus resulting in metal- or 
ligand-bound holo fragment ions that offer insight into binding sites.49  
While these alternative MS/MS methods provide high sequence coverages and 
impressive characterization of increasingly large protein complexes,50 signal averaging of 
several minutes may be required to achieve sufficient resolution and signal-to-noise 
necessary for identifying backbone cleavage sites. Thus, the amenability to high-
throughput workflows is limited. Several recent studies posit a multistage MS approach in 
which an initial stage of collisional activation of intact protein complexes (referred to as 
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in-source trapping (IST)) is used to disassemble oligomeric proteins into constituent 
monomeric subunits.51,52 The resulting monomeric species are then individually isolated 
and activated using HCD or UVPD. These successful multistage MS/MS approaches (IST-
HCD or IST-UVPD) have afforded higher sequence coverages compared to single step 
activation methods and improved characterization of model protein complexes,51 enzymes 
implicated in either metabolism53 or chemotherapeutic resistance of glioblastoma tumors,54 
and protein complexes in a human cell lysate pre-fractionated off-line.21 More recently, 
endogenous lipids bound to membrane proteins were identified using a strategy that 
integrated native MS of intact protein-lipid complexes, collisional activation to separate 
the lipids from the protein, and subsequent HCD or 213 nm UVPD of the lipids.55  
Here we unite CE with a multistage IST-UVPD approach to characterize the 
proteins comprising the E. coli 70S ribosome. The tolerance for high salt concentrations 
characteristic of CE allows up to 500 μM magnesium acetate to be included in the 
background electrolyte (BGE) solution and results in the observation of the intact 30S and 
50S subunits. By strategically reducing the magnesium concentration in the BGE and 
removing the ribosomal RNA, subcomplexes and/or single proteins are generated for 
subsequent MS/MS characterization. HCD and UVPD as well as multistage IST-HCD and 
IST-UVPD methods are used to characterize the ribosomal proteins and protein complexes. 
PTMs, including methylation, acetylation and phosphorylation, are identified in addition 
to noncovalently bound metal cofactors (Mg2+ and Zn2+). UVPD consistently yields higher 
sequence coverages of the ribosomal proteins, protein-metal, and protein-protein 
complexes compared to HCD. Incorporating front-end collisional activation (IST-UVPD) 
further improves the protein characterization capabilities of UVPD, yielding significantly 
higher sequence coverage and offering insight into metal-binding sites based on mapping 
holo fragment ions. The demonstration of CE in conjunction with a multistage MS/MS 
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approach represents a significant advance in establishing a robust pipeline for native 
proteomics studies. 
8.3 EXPERIMENTAL 
8.3.1 Ribosomal Sample Preparation 
E. coli 70S ribosomes were purchased from New England BioLabs (Ipswich, MA) 
and exchanged into 25 mM ammonium acetate (pH 6.8) containing 1 mM magnesium 
acetate using 10 kDa molecular weight cutoff filters (MilliporeSigma, Burlington, MA) for 
CE-MS analysis using a BGE containing a high magnesium concentration. Alternatively, 
ribosomal nucleic acids were precipitated as previously described.56 Briefly, 1:4 (v:v) 100 
mM magnesium acetate:ribosome and 1:1 (v:v) glacial acetic acid:ribosome were added to 
the ribosome suspension. The sample was incubated at 4 °C for 1 hr before centrifugation 
at 10000 RPM for 5 min. The resultant supernatant was removed and exchanged into 25 
mM ammonium acetate (pH 6.8) containing 0 or 100 μM magnesium acetate for CE-MS 
analysis. 
8.3.2 Native Capillary Electrophoresis 
Ribosomal samples prepared at ~30 μg/μL were hydrodynamically injected at 5 psi 
for 30-45 sec using a CMP Scientific (Brooklyn, NY) ECE-001 capillary electrophoresis 
autosampler into a 100 cm capillary (50 µm inner diameter) coated with linear 
polyacrylamide (LPA) as previously described.24 In short, a bare fused silica was flushed 
successively with 1 M hydrochloric acid, water, 1 M sodium hydroxide, water, and 
methanol prior to exposure to 3-(trimethoxysilyl) propyl methacrylate to introduce carbon-
carbon double bonds along the capillary wall. An aqueous acrylamide solution containing 
ammonium persulfate was used to fill the treated capillary before incubation at 50 °C for 2 
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hrs. Extensive flushing with water removed unreacted reagents, and introduction of the 
background electrolyte (BGE) solution (25 mM ammonium acetate, pH 6.8, containing no, 
100, or 500 μM magnesium acetate) conditioned the capillary. CE separations were 
achieved using a +30 kV separation voltage with 0.5 psi of pressure applied throughout the 
separation. An electrokinetically pumped sheath flow interface (CMP Scientific, Brooklyn, 
NY) allowed coupling of the CE capillary with the mass spectrometer. ESI emitters (~20 
μm tip opening, 4 cm length) were fabricated using a Sutter Instrument (Novato, CA) P-
1000 micropipette puller from borosilicate capillaries (1.0 mm outer dimeter, 0.75 mm 
inner diameter) for the CE-MS interface. Following CE separation, on-line ionization of 
proteins was carried out using ESI spray voltages of 2.4-2.6 kV. 
8.3.3 Mass Spectrometry 
A Thermo Scientific Q Exactive UHMR mass spectrometer (Bremen, Germany) 
previously modified54 to perform UVPD in the HCD cell by a Coherent ExciStar XS 500 
(Santa Clara, CA) pulsed excimer laser operating at 193 nm (ArF gas) was used for all CE-
MS experiments. The source temperature was set at 200 °C, and all ion optics were 
optimized for the transmission of species of interest. Specifically, for CE conditions with 
high magnesium acetate concentrations (100 and 500 μM), values were tuned to transfer 
higher m/z species, whereas for CE-MS without magnesium acetate present in the BGE 
solution, parameters were adjusted for lower m/z species. During ribosomal analysis, ESI 
mass spectra, without and with IST, were collected at a resolving power of 6250. MS/MS 
spectra were acquired at a resolving power of 140K for the top three most abundant 
precursors in a data dependent manner. For all spectra, the ion population was controlled 
by the ion time (IT) as automated gain control (AGC) was turned off during CE-MS 
analysis. MS spectra represent two averages using an IT of 20 ms, and MS/MS spectra are 
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based on 10 averages with an IT of 300 ms. HCD spectra were collected using collision 
energies of 200-250 eV/q, and a single laser pulse at 3 mJ was used for UVPD spectra. For 
multistage analyses (IST-HCD and IST-UVPD), the desolvation voltage was increased 
from -25 V to -225 V (i.e. resulting in disassembly of protein complexes instead of simply 
desolvation). The nitrogen bath gas pressure of the HCD cell was lowered for CE-MS 
analysis using none or 100 μM in the BGE solution. Specifically, the value was adjusted 
from a pressure corresponding to 1E-9 to 4E-10 mbar or 1E-10 mbar in the ultra-high 
vacuum (UHV) region for HCD and UVPD, respectively. 
8.3.4 Data Analysis 
Triplicate CE-MS runs were collected each using HCD, UVPD, IST-HCD and IST-
UVPD for solutions containing no and 100 μM magnesium acetate in the BGE. ProSight 
Native was used to de-charge low resolution ESI and IST mass spectra and deconvolute 
corresponding high resolution MS/MS spectra. Lists of the average masses observed in the 
ESI mass spectra (acquired with and without IST) were assigned as 70S ribosomal proteins 
or protein-protein complexes within ±3 Da. Searches included methylation (+14.0 Da), 
acetylation (+42.0 Da), and phosphorylation (+80.0 Da) as possible PTMs. The presence 
of metal cofactors was identified by a mass difference corresponding to Mg2+ (+22.3 Da) 
or Zn2+ (+63.4 Da). Fragment ion matches were made using a tolerance of ±15 ppm. For 
HCD mass spectra, only b- and y-type ions were considered, whereas for UVPD mass 
spectra, nine ion types were searched (a, a+1, b, c, x, x+1, y, y-1, z). Table 8.1 summarizes 
the observed average mass, sequence coverage, and P-score (Poisson-based score) for each 
identified ribosomal protein and protein complex based on CE-MS analysis in the absence 
of magnesium acetate ((-) Mg2+) or containing 100 μM magnesium acetate in the BGE. 
Holo fragment ions (bound to Mg2+ or Zn2+) produced upon UVPD were identified by 
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inclusion of the corresponding mass shifts at the N- and C-terminus. All reported sequence 
coverages derived from UVPD include both holo (metal-bound) and apo (metal-free) 
fragment ions. Only holo fragment ions identified in all three replicates at a given 
magnesium acetate concentration in the BGE were considered confidently identified and 
reported. 
 
Table 8.1:  List of all proteoforms identified by CE-MS in conjunction with HCD, 
UVPD, IST-HCD, or IST-UVPD using no (turquoise) or 100 μM (orange) 
magnesium acetate in the background electrolyte (BGE) solution. In addition 
to individual proteins (unmodified or post-translationally modified), several 
protein-metal and protein-protein complexes were characterized. For each 
identified proteoform the protein name, Uniprot protein accession number, 
sequence (accounting for initiator Met removal), covalent modifications (Me 
= methylation (+14.0 Da), Ac = acetylation (+42.0 Da), Ph = phosphorylation 
(+80.0 Da)) with the localized site in parenthesis, theoretical average mass 
(accounting for covalent modifications), attached metal cofactors, observed 
average mass, difference in observed and theoretical average mass (+22 Da 
corresponds to a Mg2+ cofactor and +64 Da results from a Zn2+ cofactor), 
sequence coverage (resulting from HCD, UVPD, IST-HCD, or IST-UVPD), 
and the corresponding Poisson-based P-score value (lower values indicate 
better characterization of a given proteoform). Identified protein-protein 
complexes are listed in the furthest left column with the observed average 
mass of the intact complex listed. Blank spaces indicate that a given 
proteoform was not identified using that combination of BGE solution 
conditions (no or 100 μM magnesium acetate) and MS/MS method (HCD, 
UVPD, IST-HCD, or IST-UVPD). 
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8.4 RESULTS AND DISCUSSION 
8.4.1 Separation of Ribosomal Proteins by Native CE using Various Mg2+ 
Concentrations 
Comprised of 55 proteins held together by three ribosomal RNA strands, the E. coli 
70S ribosome requires a minimum concentration (10 mM) of Mg2+ to maintain its intact 
2.3 MDa structure.57,58 At lower concentrations (< 1 mM), this macromolecular complex 
dissociates into 50S (1.4 MDa, composed of 33 proteins) and 30S (850 kDa, consisting of 
22 proteins) subunits.59 The dependence of subunit association and activity on the presence 
and concentration of Mg2+ suggests this metal cofactor intricately governs the dynamics of 
the ribosome by controlling the balance between flexibility and stability.60,61 The Mg2+-
dependent reorganization of the ribosome has been studied by hydrogen/deuterium 
exchange (HDX) and MALDI TOF-MS to localize regions impacted by varying 
magnesium concentrations.62,63 Additionally, intact E. coli ribosomes have been previously 
detected by native MS64 and the heterogeneity of such macromolecules studied using 
various concentrations of magnesium acetate in the ESI spray solution.65 Similarly, native 
MS in conjunction with top-down and bottom-up MS methods have been used to dissect 
ribosomal protein complexes and define the ribosomal proteoforms present across the 
kingdoms of life, including bacteria, plants, and humans.66 These prior studies relied on 
denaturation of the ribosomal proteins to delineate the proteoforms present based on 
application of bottom-up or top-down MS techniques. In the present study, the use of CE 
for front-end separation facilitates the characterization of the ribosomal proteins and 
protein complexes present at various magnesium concentrations under native conditions. 
Base peak electropherograms for the CE-MS analysis of ribosomal proteins with 
various concentrations of magnesium acetate (no, 100, and 500 μM) in the BGE solution 
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are shown in Figure 8.1. Although CE is typically tolerant of salts, inclusion of greater 
than 500 μM magnesium acetate in the BGE resulted in poor spray stability and low MS 
signal. Nevertheless, two dominant multimeric species were observed in the presence of 
500 μM magnesium acetate (Figure 8.1A). Intact masses in the ESI mass spectra shown 
in Figure 8.1B allow these species to be identified as the 30S (RT 53.72 min, 850.1 ± 0.2 
kDa) and 50S (RT 65.41 min, 1450.4 ± 0.9 kDa) subunits. Decreasing the magnesium 
concentration of the BGE alone failed to result in production and detection of significantly 
more subcomplexes or individual proteins. However, removal of the ribosomal RNA by 
precipitation, as described in the Experimental section, yielded the electropherograms in 
Figure 8.1C and 8.1D. After removal of the nucleic acids scaffolding the complex, a 
variety of proteins and protein complexes were present in solution for characterization by 
MS/MS methods. 
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Figure 8.1: (A) Base peak electropherogram of E. coli ribosomal proteins containing 500 
μM magnesium acetate in the background electrolyte solution. (B) 
Experimental masses of the dominant species in the ESI mass spectra 
collected at retention times of (1) 53.72 and (2) 65.41 min with a high Mg2+ 
concentration (500 μM) correspond to the theoretical masses of intact 30S and 
50S subunits. Extracted ion chromatograms for observed m/z values of the 
30S (turquoise) and 50S (orange) subunits are overlaid with the base peak 
electropherogram in (A). Removal of ribosomal RNA (rRNA) allowed 
separation of smaller subcomplexes and individual proteins shown as the base 
peak electropherograms in (C) no Mg2+ and (D) 100 μM Mg2+ in the BGE. 
Table 8.1 summarizes all species identified under these latter two conditions. 
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8.4.2 MS/MS Methods for the Analysis of Ribosomal Proteins 
The absorption of 193 nm photons by the protein backbone results in direct 
dissociation from excited states and allows access to more fragmentation pathways during 
UVPD compared to collisional activation methods.44 Owing to its higher energy 
deposition, UVPD has consistently yielded greater levels of sequence coverage for intact 
proteins under denaturing45–48 and native42,43,50,54 conditions alike. For proteomics 
applications, higher sequence coverage generally affords better characterization of the 
various proteoforms present.47 HCD and UVPD mass spectra were collected in a data 
dependent manner after CE separation of ribosomal proteins with no or 100 μM magnesium 
acetate present in the BGE solution. Additionally, increasing the in-source trapping (IST) 
voltage enabled implementation of a multistage MS/MS approach (referred to as IST-HCD 
and IST-UVPD) for protein characterization.  
Table 8.1 summarizes the sequence coverage values and P-scores for all identified 
proteoforms using each of the four activation methods (HCD, UVPD, IST-HCD, and IST-
UVPD) obtained for both CE separation conditions (e.g., no and 100 μM magnesium 
acetate). Representative MS and MS/MS spectra are shown in Figure 8.2 for three 
proteoforms containing covalent modifications (RL7 (Me, Ph) • Mg2+, RS16 (Ac) • Mg2+, 
and RS11 (Me)) confidently identified and characterized using IST-UVPD. Identified 
proteoforms are categorized into three groups: individual proteins, protein-metal 
complexes, and protein-protein complexes (Figure 8.3). In the absence of magnesium 
acetate during CE separation, HCD and IST-HCD resulted in the identification of the same 
54 proteoforms, whereas UVPD alone confirmed the presence of 61 proteoforms and IST-
UVPD allowed assignment of 62 proteoforms. Almost half of the species identified by both 
HCD and UVPD corresponded to protein-metal complexes with only 3 protein-protein 
complexes confirmed by each of the four MS/MS approaches. As expected, inclusion of 
 290 
100 μM magnesium acetate in the BGE for the CE separation resulted in the identification 
of significantly more protein-protein complexes (10 each for HCD and UVPD). The 
identification of an overall lower number of proteoforms for CE-MS with 100 μM 
magnesium acetate in the BGE solution compared to no magnesium acetate is attributed to 
the signal suppression and MS peak broadening caused by the presence of a high 
concentration of Mg2+, a trend commonly noted in native MS studies.65,67 
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Figure 8.2: (A) Base peak electropherogram for IST-UPVD analysis of E. coli ribosomal 
proteins containing no magnesium acetate in the background electrolyte 
solution. Extracted ion chromatograms are shown in (A) for m/z values 
corresponding to (B) RL7 (Me, Ph) • Mg2+ (m/z 2457, turquoise), (B) RS16 
(Ac) • Mg2+ (m/z 2315, orange), and (C) RS11 (Me) (m/z 1962, green). (B-D) 
For each of these three identified proteoforms containing covalent 
modifications the (1) in-source trapping MS spectrum, (2) UVPD mass 
spectrum, and (3) deconvoluted UVPD mass spectrum are shown. Observed 
charge states of the identified proteoforms are labelled in each IST-MS 
spectrum. UVPD mass spectra are the result of activating the most abundant 
charge state of the corresponding proteoform in (1) (5+ for RL7 (Me, Ph) • 
Mg2+, 4+ for RS16 (Ac) • Mg2+, and 7+ for RS11 (Me)). Select identified 
fragment ions are labelled in (2) and (3) with retention of the covalent 
modifications denoted as (○) for methylation, (◊) for acetylation, and (Δ) for 
phosphorylation. Additionally, metal-bound holo fragment ions containing 
Mg2+ are labelled as such. Surviving precursor is indicated as a filled circle in 
(3). UVPD sequence coverage maps and values (accounting for both apo and 
Mg2+-bound holo fragment ions) are shown at the bottom with the fragment 
ion types indicated as: a/x (green), b/y (blue), and c/z (red). Residues with 
localized covalent modifications are highlighted in yellow including (B) 
phosphorylation (+80.0 Da) at S15 and methylation (+14.0 Da) at K82, (C) 
acetylation (+42.0 Da) at K46, and (D) methylation (+14.0 Da) at A2. 
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Figure 8.3: Graph displaying the total number of E. coli ribosomal proteoforms identified 
using HCD, IST-HCD, UVPD, or IST-UVPD to activate proteins after CE 
separation with no (left) or 100 μM (right) magnesium acetate present in the 
background electrolyte solution. Identified proteoforms are divided into three 
categories: protein (turquoise), protein-metal complex (orange), or protein-
protein complex (tan). A complete list of identified proteoforms is shown in 
Table 8.1. 
While there is significant agreement between the overall number of proteoforms 
identified by HCD and UVPD (Figure 8.4), examination of sequence coverage values 
confirm that UVPD generally offers better characterization of a given proteoform. Figure 
8.5A displays the sequence coverages obtained by HCD and UVPD for all identified 
proteoforms for the CE-MS analysis of the ribosome containing no magnesium acetate. 
Corresponding bar graphs for IST-HCD vs. IST-UVPD in the absence of magnesium 
acetate in the BGE solution and all activation methods (HCD vs. UVPD and IST-HCD vs. 
IST-UVPD) for CE-MS using 100 μM magnesium acetate are shown in Figure 8.6. With 
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the exception of a proteoforms of lower molecular weight (< 10 kDa), UVPD resulted in 
higher sequence coverage values across the board. Plots of the differences in sequence 
coverages for HCD vs. UVPD and IST-HCD vs. IST-UVPD for both CE conditions (no 
and 100 μM magnesium acetate) highlight this trend (Figure 8.5B). A list detailing the 
ranked proteoform pairs is shown in Table 8.2. The orange dots and triangles indicate those 
proteoforms in common for which greater sequence coverage (> 2%) was afforded by 
UVPD or IST-UVPD compared to HCD or IST-HCD. The turquoise dots and triangles 
denote the opposite outcome with higher sequence coverages for HCD or IST-HCD 
compared to UVPD or IST-UVPD. Under both CE conditions (no and 100 μM magnesium 
acetate in the BGE), over 75% of the dots/triangles are orange which suggests sequence 
coverages produced by UVPD and IST-UVPD are consistently higher than those resulting 
from HCD and IST-HCD for native protein complexes analyzed in a high-throughput 
manner by CE-MS. Greater sequence coverages of E. coli ribosomal proteins (unmodified 
or carbamylated) by UVPD compared to HCD have also been previously using denaturing 
LC-MS/MS for analysis.46,68 In general, UVPD sequence coverages reported here using 
native CE-MS are somewhat lower (by ~10-15%) than six similar ribosomal proteins 
reported in a previous study (RS19, RL15, RL18, RL24, RL34, RL36),68 an outcome 
attributed to the fact the MS parameters in the present study were optimized for 
identification of multimeric protein complexes (i.e., higher m/z species).  
A comparison of the sequence coverage values associated with UVPD and IST-
UVPD is also shown for both CE conditions (no and 100 μM magnesium acetate in BGE) 
in Figure 8.5C. Again, orange dots denote proteoforms in common whose sequence 
coverages using IST-UVPD were higher compared to UVPD, while turquoise dots and 
triangles indicate higher sequence coverage values resulting from UVPD compared to IST-
UVPD. In the absence of magnesium acetate, there is minimal improvement in sequence 
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coverage when using the multistage approach (IST-UVPD) relative to UVPD. However, 
at a magnesium acetate concentration of 100 μM (favoring the survival of more multimeric 
protein-protein complexes), IST-UVPD resulted in higher sequence coverage than UVPD 
for over two-thirds of the proteoforms. 
 
 
Figure 8.4: Venn diagrams showing the overlap in identified proteoforms (including 
individual proteins, protein-metal complexes, and protein-protein complexes) 
between (1) HCD and UVPD or (2) IST-HCD and IST-UVPD for CE-MS 
analysis of ribosomal proteins using (A) no or (B) 100 μM magnesium acetate 
in the BGE solution.  
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Figure 8.5: (A) Bar graph depicting sequence coverages afforded by HCD (turquoise) and 
UVPD (orange) for each E. coli ribosome proteoform identified after CE 
separation with no magnesium acetate in the background electrolyte solution. 
The floating labels correspond to the proteoforms of the subunits comprising 
the identified protein-protein complexes. Corresponding graphs for IST-HCD 
and IST-UVPD as well as for the separation containing 100 μM magnesium 
acetate using each activation method are shown in Figure 8.6. The differences 
in sequence coverage of proteoforms identified in common are shown for (B) 
HCD vs. UVPD (dots) and IST-HCD vs. IST-UVPD (triangles), and (C) 
UVPD vs. IST-UVPD. Proteoforms were ranked by increasing difference in 
coverage. Lists of ranked proteoform pairs are included in Table 8.2. In (B), 
orange indicates proteoforms for which UVPD (dots) or IST-UVPD 
(triangles) generated greater sequence coverage than HCD (dots) or IST-HCD 
(triangles) by more than 2%, turquoise highlights proteoforms for which HCD 
(dots) or IST-HCD (triangles) yielded higher sequence coverage than UVPD 
(dots) or IST-UVPD (triangles) by more than 2%, and tan indicates 
proteoforms for which the sequence coverage differed by less than 2%. 
Similarly, in (C) orange denotes proteoforms for which IST-UVPD afforded 
greater sequence coverage than UVPD (> 2%), turquoise indicates 
proteoforms for which UVPD resulted in higher sequence coverage than IST-
UVPD (> 2%), and tan identifies proteoforms for which the sequence 
coverage differed by less than 2%. Note that the y-axis for (1) (-) Mg2+ and 
(2) 100 μM Mg2+ in (C) is scaled differently than (B) (maximum value of 35% 
instead of 55%) since the differences in sequence coverages between UVPD 
and IST-UVPD for corresponding proteoforms were smaller. Sequence 
coverages for all identified proteoforms are listed in Table 8.1. 
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Figure 8.6: Bar graphs illustrating sequence coverages afforded by HCD or IST-HCD 
(turquoise) and UVPD or IST-UVPD (orange) for each E. coli ribosome 
proteoform identified after CE separation with (A) no or (B, C) 100 μM 
magnesium acetate in the background electrolyte solution. Identified protein-
protein complexes are labelled above the bars of corresponding proteoforms. 
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Table 8.2: Table detailing the ranked proteoform pairs (for HCD vs. UVPD (and IST-
HCD vs. IST-UVPD), and UVPD vs. IST-UVPD using no (turquoise) or 100 
μM (orange) magnesium acetate in the BGE solution during CE-MS) 
corresponding to Figure 8.5B, 8.5C. Covalent modifications are included (Me 
= methylation, Ac = acetylation, and Ph = phosphorylation) as well as 
noncovalently bound metals (Mg2+ or Zn2+). Subunits constituting 
oligomeric protein-protein complexes are labelled as such. 
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8.4.3 Multistage MS/MS Approach for the Improved Characterization of Ribosomal 
Protein Complexes 
As demonstrated in Figure 8.5C, a multistage MS/MS approach is particularly 
beneficial for improved characterization of protein-protein complexes compared to HCD 
or UVPD alone. Closer examination of the largest protein-protein complex (66.4 kDa) 
identified at no or 100 μM magnesium concentrations further demonstrates this trend. The 
heteropentameric RL8 complex (consisting of RL10(RL7/RL12)4) comprises the stalk of 
the ribosomal complex.69 Owing to its role in promoting translation factors to the ribosome, 
it remains highly mobile and is absent from most crystal structures of the ribosome.57,58,69 
As such, the development of alternative structural biology methods in which this protein 
complex can be reliably detected as part of the ribosome are important. While 
subcomplexes of this assembly were detected in the absence of magnesium acetate in the 
BGE during CE separation (i.e., (RL7/RL12)2, (RL7/RL12)4, and RL10(RL7/RL12)2), the 
intact complex was only identified at the higher magnesium acetate concentration (100 
μM). The ESI mass spectra collected at a retention time of 61.81 min during the CE 
separation performed with 100 μM magnesium acetate in the BGE (Figure 8.1D) is shown 
in Figure 8.7A. The 14+ – 16+ charge states of the pentameric RL10(RL7/RL12)4 complex 
bound to four equivalents of Mg2+ (observed average mass: 66325 ± 9 Da; theoretical 
average mass: 66409.7 Da) were detected. Increasing the desolvation voltage (-225 V) for 
a multistage MS/MS approach yields the in-source trapping (IST) mass spectrum displayed 
in Figure 8.7B in which the monomeric subunits corresponding to each individual protein 
are observed (6+, 7+ charge states of RL7/RL12 • Mg2+; 5+, 6+ charge states of RL7/RL12 
(Ac) • Mg2+; and 6+ – 8+ charge states of RL10).  
The UVPD mass spectrum of the 15+ charge state of the pentameric 
RL10(RL7/RL12)4 complex and IST-UVPD mass spectra of each individual subunit (7+ 
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charge state of RL7/RL12 • Mg2+, 6+ charge state of RL7/RL12 (Ac) • Mg2+, 7+ charge 
state of RL10) and the corresponding deconvoluted MS/MS spectra are shown in Figure 
8.8. The sequence coverage maps and sequence coverages corresponding to each of the 
three proteins contained in the complex demonstrate several remarkable features (Figure 
8.7C). First, UVPD (without IST) of the pentameric complex yields a modest number of 
diagnostic fragment ions of each of the constituent proteins, yielding 11% to 16% sequence 
coverage. More notably, the multistage IST-UVPD approach results in significantly better 
characterization of the proteoforms constituting this complex (Figure 8.7C-2). In 
particular, sequence coverage values using IST-UVPD increased to 43% for RL7/RL12 • 
Mg2+, 43% for RL7/RL12 (Ac) • Mg2+, and 35% for RL10. These improvements are 
attributed to the simplification of the UVPD spectra owing to disassembly of the pentamer 
and activation of the subunits individually instead of activation of the pentameric complex. 
Fewer averages are necessary to achieve quality MS/MS spectra for the subunits than the 
multi-protein complex making the multistage approach more amenable for the high-
throughput analysis of protein-protein complexes. 
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Figure 8.7: (A) ESI mass spectrum collected at a retention time of 61.81 min during on-
line CE separation of E. coli ribosomal proteins using a background 
electrolyte solution containing 100 μM magnesium acetate (base peak 
electropherogram shown in Figure 8.1D). The 14+ – 16+ charge states of the 
pentameric RL10(RL7/RL12)4 • 4Mg
2+ complex are labelled. (B) In-source 
trapping spectrum, collected at a retention time of 61.27 min during CE 
separation with 100 μM magnesium acetate in the BGE, resulting from 
disassembly of the protein-protein complex observed in (A) into its 
constituent monomeric subunits: RL7/RL12 • Mg2+ (6+, 7+ charge states 
labelled in turquoise), RL7/RL12 (Ac) • Mg2+ (5+, 6+ charge states labelled 
in orange), and RL10 (6+ – 8+ charge states labelled in tan). (C) Maps and 
sequence coverage values for each protein comprising the complex afforded 
by (1) UVPD of the 15+ charge state of the pentamer or (2) IST-UVPD of 
each individual subunit (7+ charge state of RL7/RL12 • Mg2+, 6+ charge state 
of RL7/RL12 (Ac) • Mg2+, 7+ charge state of RL10). Observed fragment ion 
types are labelled as: a/x (green), b/y (blue), and c/z (red). MS/MS spectra for 
each of the maps shown in (C) are included in Figure 8.8. 
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Figure 8.8: (1) MS/MS spectrum and (2) deconvoluted MS/MS spectrum resulting from 
(A) UVPD of the 15+ charge state of the RL8 stalk complex 
(RL10(RL7/RL12)4 • 4Mg
2+)  or IST-UVPD of (B) the 7+ charge state of 
RL7/RL12 • Mg2+, (C) the 6+ charge state of RL7/Rl2 (Ac) • Mg2+, and (D) 
the 7+ charge state of RL10 collected during CE-MS analysis of E. coli 
ribosomes using 100 μM magnesium acetate in the background electrolyte. 
The ESI-MS and IST-MS spectra are shown in Figure 8.7. In (A), intact 
subunits are observed and the corresponding charge states are labelled for 
RL7/RL12 • Mg2+ (turquoise), RL7/Rl2 (Ac) • Mg2+ (orange), and RL10 
(tan). Representative apo and holo (Mg2+-bound) fragment ions are labelled 
in (2) for (B-C) with fragment ions retaining the acetylation in (C) indicated 
by ◊ and any surviving precursor denoted with a filled circle. Corresponding 
sequence coverage maps and values are shown in Figure 8.7. 
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8.4.4 Mapping UVPD Holo Fragment Ions to Examine Metal Cofactor Binding to 
Ribosomal Proteins 
In addition to higher sequence coverages, the accessibility to higher energy 
fragmentation pathways allows the preservation of non-covalent interactions between the 
protein and metals or ligands during cleavage of covalent backbone bonds of the protein, a 
phenomenon reported for UV photoactivation of protein-metal and protein-ligand 
complexes.49,54,70–72 This counter-intuitive outcome is rationalized by the fast cleavage of 
the polypeptide backbone occurring from ions in excited states prior to vibrational energy 
redistribution which favors disruption of lower energy covalent or noncovalent bonds.44 In 
practice, mapping these ligand- or metal-retaining holo fragment ions generated during 
UVPD has offered insight into the residues involved in ligand binding for a wide variety 
of protein-ligand complexes such as an NADPH cofactor and inhibitor methotrexate bound 
to dihydrofolate reductase (DHFR),70 GDP or a GTP-analogue within the oncogenic rat 
sarcoma protein K-Ras,71 adenosine phosphate ligands interacting with the 
phosphotransferase enzyme adenylate kinase,72 and a PLP cofactor pulled down with 
branched-chain amino acid transferase 2 (BCAT2).54  
Two specific examples of UVPD holo fragment ion mapping are shown in Figure 
8.9 for the protein-metal complexes RL29 • Mg2+ and RL31 • Zn2+ identified by IST-UVPD 
in the CE separation of ribosomal proteins with no magnesium acetate present in the BGE. 
The backbone cleavage sites that lead to holo fragment ions are represented either as lines 
above the protein sequence or colored along the corresponding crystal structure of the 
proteins (PDB ID: 4V4Q).73 Backbone cleavages that result in N-terminal-containing holo 
fragment ions (a, b, c) are colored turquoise, C-terminal-containing holo fragment ions (x, 
y, z) are shaded orange, and backbone cleavages that produce complementary N-terminal- 
and C-terminal-containing ions (“bi-directional” holo fragment ions) are shown in dark 
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red. Corresponding IST-MS spectra and IST-UVPD MS/MS spectra for both protein-metal 
complexes are shown in Figure 8.10. For RL29, the Mg2+ ion is expected to interact with 
acidic residues (D or E) which correlates with the interaction site identified by mapping 
holo fragment ions (L22-Q25). Similarly, the putative binding site of Zn2+ in RL31 is C16. 
This aligns with the binding region elucidated from tracking the holo fragment ions (S15-
N20). These types of holo ions are not generally created upon HCD as collisional activation 
tends to disrupt electrostatic interactions preferentially relative to cleavage of backbone 
bonds of the protein. 
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Figure 8.9: Backbone cleavage sites of holo (Mg2+- or Zn2+-containing) fragment ions 
observed upon IST-UVPD of (A) RL29 • Mg2+ and (B) RL31 • Zn2+ following 
on-line CE separation of E. coli ribosomal proteins using no magnesium 
acetate in the background electrolyte solution represented as lines above the 
corresponding sequences or colored along a crystal structure of the protein 
(PDB ID: 4V4Q). Cleavage that results in N-terminal holo fragment ions (a, 
b, c) are colored turquoise, C-terminal holo fragment ions (x, y, z) are shaded 
orange, or complementary N-terminal and C-terminal ions (bi-directional 
holo fragment ions) are shown in pink. Corresponding ESI-MS spectra, 
UVPD MS/MS spectra, and sequence coverage maps including apo (metal-
free) fragment ions are shown in Figure 8.10. 
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Figure 8.10: (1) In-source trapping mass spectrum, (2) IST-UVPD mass spectrum, and (3) 
deconvoluted IST-UVPD mass spectrum for (A) RL29 • Mg2+ and (B) RL31 
• Zn2+ collected during CE-MS analysis of E. coli ribosomes using no 
magnesium acetate in the background electrolyte solution and IST-UVPD for 
ion activation (at retention times of 27.57 min (RL29 • Mg2+) and 28.31 min 
(RL31 • Zn2+) in Figure 8.1C). Observed charge states are labelled in the 
respective IST-MS spectra. Activation of the most abundant charge state of 
each protein in (1) resulted in the UVPD mass spectra shown in (2) (5+ for 
RL29 • Mg2+ and 5+ for RL31 • Zn2+). Zoom views in (2) show an example 
apo (metal-free) and holo (bound to Mg2+ or Zn2+) fragment ion. Several 
identified apo and holo fragment ions are labelled in (3). The surviving 
precursor is denoted with a filled circle in (3). Sequence coverage maps and 
values (accounting for both apo and metal-bound holo fragment ions) are 
shown at the bottom (fragment ion types are indicated as a/x (green), b/y 
(blue), and c/z (red)). Corresponding maps of holo fragment ions only are 
shown in Figure 8.9. 
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8.5 CONCLUSION 
Characterization of E. coli 70S ribosomes at various Mg2+ concentrations is 
successfully accomplished by coupling native CE with a UHMR mass spectrometer 
equipped with UVPD. The capabilities of this instrument for detecting high m/z species 
mitigates bias evident in previous studies towards the identification of lower mass 
complexes (< 30 kDa) and enables identification of protein-protein complexes (up to 66.4 
kDa) larger than previously reported using a native high-throughput workflow.23,24 
Additionally, the ability to access different structural states of a macromolecular complex 
through adjustment of the salt concentration of the BGE solution posits CE as a versatile 
separation partner for MS. Four different MS/MS approaches are compared, with UVPD 
consistently outperforming HCD in the characterization of ribosomal proteoforms across 
individual protein, protein-metal complexes, and protein-protein complexes. Incorporation 
of a multistage approach (IST-HCD and IST-UVPD) further increases observed sequence 
coverage values, particularly for protein-protein complexes owing to the simplification of 
the precursor species. Although previous studies using native MS in conjunction with 
denaturing top-down and bottom-up LC-MS/MS66 or CE-MS/MS under denaturing and 
native conditions23 to analyze E. coli 70S ribosomes both resulted in the identification of 
more proteoforms, the current study was designed specifically to improve the 
characterization of intact protein-protein complexes (higher m/z species). Additionally, 
mapping holo fragment ions generated by UVPD offers further confirmation of putative 
binding sites for protein-metal complexes. Such fragment ions provide another layer of 
information relevant for deciphering the organization of protein complexes containing 
metals or small molecule ligands. As this multistage native CE/UVPD-MS approach is 
further scaled up, the high-throughput analysis of more complex samples such as the 
endogenous proteins in cell lysates represents the next frontier. 
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Chapter 9: Conclusions 
9.1 SUMMARY OF CHAPTERS 
Significant advances with regards to covalent labeling workflows, instrumentation, 
and ion activation methods have already solidified a spot for MS in the structural biology 
toolbox as a rapid, sensitive alternative to supplement traditional methods in defining the 
higher order structures of biomolecules. Nevertheless, many opportunities to extend the 
versatility of MS approaches for structural biology applications still remain. Specifically, 
the work presented in this dissertation sought to further develop native MS and 193 nm 
UVPD for probing conformational changes in protein-ligand and protein-protein 
complexes, as well as lay the groundwork for scaling up this analysis to more complex 
biological samples in a high-throughput workflow. 
Although the capabilities of UVPD-MS for elucidating ligand binding sites and 
detecting changes in secondary/tertiary structure resulting from enzymatic processes, 
ligand exchange, or single point mutation in protein-ligand complexes had been previously 
established, further studies were still necessary to establish the sensitivity of this approach 
and demonstrate applicability to larger protein complexes. Tracking variations in UVPD 
backbone cleavage efficiency for the phosphotransferase AK throughout its catalytic cycle, 
as described in Chapter 3, highlighted the utility of this approach for offering information 
on how structural dynamics, metal cofactors, and side-chain chemistries each contribute to 
enzyme catalysis. Specifically, UVPD-MS pinpointed five main regions (three α-helices 
of the AMP binding domain and the adenosine binding regions of AMP and ATP) 
undergoing such movements to facilitate a global open-to-closed transition and optimize 
the environment for phosphoryl transfer. As such, this study demonstrated the application 
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of UVPD-MS to detect structural changes on several different scales ranging from global 
movements down to conformational fluctuations of single residues for active enzymes.  
In Chapter 4, UVPD-MS offered critical insights into structural variations induced 
by inhibitor binding or mutation of the MBL enzyme NDM that have remained elusive 
using other biochemical techniques. Both Lys and Cys specific covalent inhibitors were 
studied in addition to clinical single amino acid variants, demonstrating the versatility of 
UVPD-MS. The detection of the closure of a beta-hairpin loop near the active site upon 
inhibitor binding and elucidation of the individual contributions to metal affinity of the six 
Zn-binding residues in clinical variants are both important to designing potent inhibitors of 
this enzyme. Previous spectroscopic studies aimed at studying NDM-inhibitor complexes 
relied on labelling the protein or using non-native metalloforms both of which can 
artificially perturb the system. Studies such as this further establish UVPD-MS as a 
sensitive and versatile structural biology tool. 
Owing to the fact that an estimated 86% of proteins exist as higher order oligomers, 
scaling up the UVPD-MS approach to protein-protein complexes was necessary to exhibit 
utility in establishing a comprehensive picture of interaction networks and disease 
mechanisms. Previously published UVPD studies of protein-protein complexes utilized 
model proteins and focused on defining favored dissociation pathways. Instead, Chapter 5 
detailed structural changes resulting from the most common genetic alterations in human 
cancers, G12X mutations in the GTPase enzyme K-Ras. Probing complexes formed 
between K-Ras variants and the downstream effector protein Raf revealed hydrogen-
bonding substitutions resulted in a stabilized β-interface of the Ras-Raf heterodimer, 
whereas a bulky, hydrophobic mutation yielded tighter helical bundles instead along the α-
interface.  
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Another important subset of protein-protein complexes was analyzed by UVPD-
MS in Chapter 6, antibody-antigen complexes. Specifically, the epitope mapping 
capabilities of UVPD were demonstrated for hemagglutinin (HA), the primary 
immunogenic antigen of the influenza virus, and the D1 H1-17/H3-14 antibody based on 
the suppression of UVPD sequence ions. As no crystal structure for this specific antibody-
antigen complex exists, confirmation of the putative epitope regions elevates both the 
UVPD-MS approach and previous literature.  
Aimed at enabling native MS and UVPD for the structural analysis of complex 
biological mixtures in a high-throughput, Chapter 7 demonstrated the application of a 
multistage MS/MS approach to characterize single amino acid variants of BCAT2. 
Disassembly of the homodimer into constituent subunits by IST and subsequent UVPD of 
the monomer afforded significantly higher sequence coverage (increasing from 21% to 
45% for WT BCAT2) as well as enabled confident identification of PLP-bound holo ions. 
Additionally, mapping the origin of observed holo ions along the sequence provided insight 
into the destabilization of interactions with the PLP cofactor resulting from a single point 
mutation (T186R). This study established the utility in incorporating UVPD in a multistage 
MS/MS workflow to improve structural characterization of protein-protein complexes via 
the production of a more diverse set of sequence ions, including assignable holo ions that 
provide insight into ligand interactions.  
The work presented in Chapter 8 harnessed these developments to improve 
structural characterization of ribosomal proteins introduced by on-line CE-MS. Owing to 
the operating principles of CE, this separation method was fully compatible with native 
MS and separated a variety of protein-protein, protein-ligand, and protein-metal complexes 
for subsequent MS analysis. Additionally, tuning the magnesium acetate concentration of 
the BGE yielded substructures of the ribosome (at high concentrations) or disassembled 
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monomers (at low concentrations). UVPD consistently outperformed HCD regarding the 
structural characterization of protein complexes and implementation of the multistage 
MS/MS workflow afforded the highest sequence coverages and allowed tracking of holo 
ions to define ligand interactions. While this work was limited to the analysis of ~50 
proteins, it established an experimental workflow that can be scaled up to more complex 
samples. 
9.2 FUTURE DIRECTIONS 
As the world currently waits at the time of writing this for the development of an 
effective vaccine to end a global pandemic caused by a novel coronavirus (COVID-19), 
the need for rapid, sensitive approaches to identify antigenic epitopes has become 
abundantly clear. Accordingly, further studies are already underway aimed at using the 
UVPD-MS workflow for epitope mapping of a wider variety of antibody-antigen 
complexes. Owing to the adoption of a trimeric structure by the spike proteins on the 
surfaces of most viruses, an important avenue of this future work is determining if the 
antigenic determinants of targets that exist as higher order oligomers can be successfully 
probed. Additionally, it is necessary to establish an ideal antigen size regime or upper limit 
for epitope mapping by UVPD-MS. One anticipated technical hurdle in the analysis of 
more structurally complex antigens is confident assignment of fragment ions in the 
resulting MS/MS spectra. One possible workaround includes using single chain variable 
fragments (scFv) to bind corresponding antigens, as opposed to entire antibodies. These 
fusion proteins retain the specificity of the original antibody but are significantly smaller 
(30 kDa), which could reduce the complexity of resulting UVPD spectra and streamline 
the epitope mapping process.   
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While the use of CE in conjunction with multistage UVPD in Chapter 8 to probe 
ribosomal protein complexes under native MS conditions represents a significant advance, 
much work remains to make this type of analysis routine for complex endogenous samples. 
A logical next step towards this goal would be application of this approach to analyze a 
pre-fractionated lysate for which a workflow is proposed in Figure 9.1. Briefly, lysis of E. 
coli cells and subsequent SEC pre-fractionation would result in 8-10 samples containing 
~200 proteins each for CE-MS analysis. Currently, a major technical challenge with this 
approach is maintaining samples at high enough concentrations during pre-fractionation 
for subsequent CE, owing to the low loading capacity of this electrophoretic separation 
technique. Nevertheless, several pre-concentration methods have been developed including 
field-amplified sample stacking (FASS), transient isotachophoresis (tITP), and dynamic 
pH junction. Although these techniques typically require denaturing solvents, 
developments focused on substituting in native MS solvents could significantly improve 
the CE loading capacity and allow routine injection of less concentrated samples. 
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Figure 9.1: Proposed workflow for the analysis of endogenous protein complexes in E. 
coli cells by CE in conjunction with multistage UVPD-MS. 
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